PF-[ADDRESS_854277] Number: PF-[ADDRESS_854278] Name: [CONTACT_488067] (N/A)
[LOCATION_002] (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:N/A
Protocol Number: C2501001
Phase: 1CCI
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 2Document History
Document Version Date Summary of Changes and Rationale
Amendment 3 05 April 2018 Section 1.3.2: u pdated the preliminary  summary  
of clinical experience with PF-06826647.
Sections 
1.3.2 and [IP_ADDRESS]: d ose rationale updated 
with preliminary  pharmacok inetic (PK) 
parameters and starting dose selection rationale 
for psoriasis cohorts
.
Section 3.1.1 and 3.1.2: introduction of optional 
cohort of Japanese subjects for PK comparability
to support the clinical development plan for 
PF-06826647.  
Section 3.1.2: added text indicating that 
PF
-06826647 dose level may  be adjusted for the 
second psoriasis cohort based on emerging 
clinical data from the planned interim anal ysis, at 
the discretion of the Sponsor .
Figure 1: Study  Schematic updated with planned 
psoriasi s cohort PF
-06826647 dose level (based 
on recent psoriasis dose selection) , dose level for 
the 
optional twice daily  dose regime n cohort 
(BID), and optional Japanese cohort
.
Figure 2: legend updated to add optional Japanese 
cohort .
Section 5.2: edits made t o indicate that psoriasis 
cohorts will be
sponsor -open , in order to allow 
sponsor review interim analysis results to inform 
dose decisions for psoriasis Cohort [ADDRESS_854279] Inclusion Criteria: 
added single criterio n for optional Japanese 
subject eligibility .
Section 6.1: e xpanded the maximum duration of 
the screening period from [ADDRESS_854280] s, in order to accommodate 
potential recruitment delay s in between cohorts, 
while Sponsor reviews result s from the interim 

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 3analysisof psoriasis area and severit y index 
scores .
Section 7, Table 7 : added creatine phosphokinase 
laboratory  test to the chemistry  panel for psoriasis 
subjects, to help ensure adequate safet y 
monitoring for subjects receiving longer duration 
of treatment ( ie,28days). 
Section 9.7: added interim analy sis of key  
secondary  PASI endpoint for the 400 mg 
psoriasis cohort , to be conducted when 
21subjects complete through study  Day28,to 
inform dose selection for subsequent psoriasis 
cohort and to 
support clinical development 
decisions for PF -06826647.
Section 9.7: changed the planned psoriasis 
cohorts from sponsor blind to sponsor- open, in 
order to permit review of interim analy sis results 
by a designated, limited number of sponsor 
colleagues to facilitate dose selection 
adjustment/ decisions for psoriasis C ohort 2. 
Several administrative edits and minor 
clarifications made. 
Amendment 2 20 December 2017 Schedule of Activities: Healthy  Subject Single 
and Multiple Ascending Dose Periods.
Added a blood sample collection on Day 8 of the 
single asending dose period, in order to 
adequatel y characterize the pharmacokinetic (PK) 
profile (terminal half -life) of PF -06826647. 
Removed a PK blood sample on Day 1, [ADDRESS_854281] dose to avoid increasing blood volume 
requirements for subjects. 
Added a stud y visit on Day 17 for extended PK 
sample collection (with corresponding vital sign 
collection and adverse event monitoring) , in order 
to adequatel y characterize the terminal half -life of 
PF
-06826647. Removed the Day [ADDRESS_854282] dose will help to fully characterize the PK profile of PF-06826647. 
Section 1.3.2: Updated the preliminary summary 
of clinical experience.
Section 3.1.[ADDRESS_854283] single 
and multiple ascending dose period: extended the wash-out period between SAD and MAD dosing from 7 days to 14 days, based on preliminary assessment of the potential dose depenedent terminal half-life of PF-06826647.
Section 3.1.1 and 3.2 – added language to the 
dose escalation paradigm to state that the highest dose to be tested in MAD will not exceed the highest dose tested in SAD cohort, and that he highest dose MAD cohort will commence if adequate safety is demonstrated in SAD cohort at the same or higher dose level and the projected exposure at steady state does not exceed NOAEL. 
Amendment 1 06 November 2017 Various administrative changes.
Schedule of activities: removed the Day 28 blood 
collection for viral surveillance from the multiple ascending dose period, added additional blood collection for pharmacokinetic (PK) assessment on Day 1.
Schedule of activities: removed the Day 7 and 
Day 56 blood collection for viral surveillance from the Psoriasis Cohort schedule.
 
 
 
 
 
 CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 5 
 
 
Schedule of activities: added additional 
electrocardiogram (ECG) and vital sign assessment on Day 1 of the multiple ascending dose period, to coincide with the revised Day 1 PK collection.
Section 1.3.2 Preliminary Summary of Clinical 
Experience added to provide rationale for revised PF-06826647 dose levels in the single and multiple ascending dose periods.
Section 1.3.4 Updated Dose Rationale Based on 
Emerging Clinical Data added to provide rationale for revised PF-06826647 dose levels in the single and multiple ascending dose (MAD) periods.
Section 3.1.[ADDRESS_854284] 
amendment 1 PF-06826647 dose levels and addition of optional cohorts to further explore higher PF-06826647 exposure ranges.
Section 4.6.1 Meals and Dietary Requirements, 
updated to specify revised meal requirements for the multiple ascending dose period and psoriasis cohorts (dosing with food based on the emerging PK data from Study C2501001).
Section 5.[ADDRESS_854285] (IRB) request.
Original protocol16 May 2017 N/A
This amendment incorporates all revisions to date, including amendments made at the 
request of country health authorities and institutional review boards (IRBs)/ethics committees (ECs).CCI
PF-[ADDRESS_854286] OF FIGURES .................................................................................................................13
APPENDI CES .........................................................................................................................13
SCHEDUL E OF ACTIVITI ES................................................................................................15
1. INTRODUCTION ...............................................................................................................25
1.1. Mechanism of Action/I ndication .............................................................................25
1.2. Background .............................................................................................................25
1.2.1. Binding to the Pharmacological Target ......................................................25
1.2.2. Cellular Potency  and Selectivity .................................................................26
1.2.3. Non
-Clinical Pharmacokinetics and Metabolism .......................................28
1.2.4. Non
-clinical Safety  Studies ........................................................................29
1.2.5. Biopharmaceutics Properties ......................................................................32
1.3. Rationale ..................................................................................................................32
1.3.1. Study  Rationale ...........................................................................................32
1.3.2. Preliminary  Summary  of Clinical Experience ............................................33
1.3.3. Dose Rationale ............................................................................................34
[IP_ADDRESS]. Dose Selection for FI H Study  (Original Protocol Dose 
Rationale, 16 May  2017)
...................................................................34
1.3.4. Updated Dose Rationale Based on Emerging Clinical Data (Protocol 
Amendment 2, 20 December 2017)
.................................................................38
[IP_ADDRESS]. Dose Selection for Psoriasis Patients
........................................[ADDRESS_854287] Single and Multiple Ascending Dose Periods .................. 45
3.1.2. Psoriasis Multiple Dose Cohorts ................................................................47
3.2. Dose Escalation and Stoppi[INVESTIGATOR_1869] .......................................................................49
3.3. I ndividual Stoppi[INVESTIGATOR_638735] .............................................................................51
3.4. I ndividual Stoppi[INVESTIGATOR_638736] ...................................................52
3.5. Discontinuation/End of Treatment Monitoring for Adverse Events, 
Laborato ry, Vital Signs and ECG Abnormalities ......................................................[ADDRESS_854288] ELIGIBILI TY CRI TERIA .................................................................................54
4.1. I nclusion Criteria: Healthy  Subject Single/Mult iple Ascending Dose Cohorts ......54
4.2. Exclusion Criteria: Health y Subject Single/Multiple Ascending Dose 
Cohorts ......................................................................................................................55
4.3. I nclusion Criteria: Psoriasis Multiple Dose Cohorts ...............................................59
4.4.
Exclusion Criteria: Psoriasis Multiple Dose Cohort ...............................................60
4.5. Randomization Crit eria...........................................................................................65
4.6. L ifesty le Requirements ...........................................................................................66
4.6.1. Meals and Dietary  Requirements ................................................................66
4.6.2. Alcohol, Caffeine, and Tobacco .................................................................68
4.6.3. Activity .......................................................................................................68
[IP_ADDRESS]. Health y Volunteer Single Ascending Dose Per iod...................68
[IP_ADDRESS]. All Subjects ...............................................................................69
4.6.4. Contraception ..............................................................................................69
[IP_ADDRESS]. Females 
– Childbearing Potential .............................................70
4.7. Sponsor’s Qualified Medical Personnel ..................................................................[ADDRESS_854289] Supplies
........................................74
5.8. Concomitant Treatment(s) .......................................................................................74
6. STUDY PROCEDURES
................................ ................................ ................................ .....75
6.1. Screening .................................................................................................................75
6.2. Treatment Period .....................................................................................................75
6.3. Follow -up/End of Study  Procedures .......................................................................[ADDRESS_854290] Withdrawal/Early Termination ..................................................................[ADDRESS_854291] Radiograph........................................................................................837.1.9. Interferon Gamma Release Assay (IGRA) Tests........................................837.1.10. Urine Creatinine and ............83
[IP_ADDRESS]. 24 Hour Urine Creatinine and  in 
Multiple Ascending Dose Period: Day -1 and Day 10 ......................84
[IP_ADDRESS]. 24 Hour Creatinine Clearance Calculation..............................84
7.1.11. Serum Creatinine and Serum Cystatin-C..................................................84
7.1.12. Estimated Glomerular Filtration Rate.......................................................85
7.2. Selection of IndexPlaques and Non-Lesional Skin for Skin Biopsies for 
Psoriasis Subjects ......................................................................................................85
7.3. Skin Biopsies (Psoriasis Subjects only) ..................................................................867.4. Psoriasis Clinical and Histological Assessments ....................................................87
7.4.1. Psoriasis Area and Severity Index (PASI) (Psoriasis subjects only)..........877.4.2. Linear-method Psoriasis Area and Severity Index (L-PASI) .....................88
7.4.6. Target Lesion and Regional Photography (Psoriasis subjects only) ..........89CCI
CCI
CCI
CCI
CCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 107.6. Pharmacokinetics ....................................................................................................91
7.6.1. Plasma for Analysis of PF-06826647.........................................................917.6.2. Urine for Analysis of PF-06826647 ...........................................................927.6.3. Shipment of Pharmacokinetic Samples ......................................................92
 
 
7.10. Blood Volume .......................................................................................................97
7.11. Assessment of Suicidal Ideation and Behavior .....................................................99
7.11.2. Patient Health Questionnaire – 8 items (PHQ-8) ...................................100
7.11.3. Suicidal Behaviors Questionnaire-revised (SBQ-R) ..............................100
7.12. Triggered Requirements......................................................................................100CCI
CCI
CCI
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 117.12.1. Potential Cases of Acute Kidney  Injury .................................................100
7.13. Rater Qualifications
.............................................................................................101
8. ADVERSE EVENT REP ORTI NG....................................................................................101
8.1. Requirements .........................................................................................................101
8.1.1. Additional Detail
s on Recording Adverse Events on the CRF .................103
8.1.2. Eliciting Adverse Event Information ........................................................103
8.1.3. Withdrawal From the Study  Due to Adverse Events (see also the 
Subject Withdrawal/Early Termination section) ...........................................103
8.1.4. Time Period for Collecting AE/SAE I nformation ....................................103
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety .............................................103
[IP_ADDRESS]. Recording Non -serious AEs and SAEs on the CRF ...............104
8.1.5. Causa lity Assessment ...............................................................................104
8.1.6. Sponsor’s Reporting Requirements to Regulatory  Authorities ................[ADDRESS_854292] During Pregnancy  or 
Breastfeeding, and Occupational Exposure
...................................................110
[IP_ADDRESS]. Exposure During Pregnancy ....................................................110
[IP_ADDRESS]. Exposur
e During Breastfeeding ..............................................111
[IP_ADDRESS]. Occupational Exposure ...........................................................111
8.4.3. Medication Errors .....................................................................................112
[IP_ADDRESS]. Medication Errors ....................................................................112
9. DATA ANALYSI S/STA TISTICAL  METHODS .............................................................[ADDRESS_854293] Single Ascending and Multiple Dose .............................113
9.1.2. Psoriasis Multiple Dose
............................................................................113
9.2. Efficacy  Anal ysis..................................................................................................113

PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 129.2.1. Analysis of Sec ondary Endpoints.............................................................113
9.3. Pharmacokinetic Analysis .....................................................................................114
9.3.1. Single and Multiple Dose Periods ............................................................114
9.6. Safety Analysis – Primary.....................................................................................[ADDRESS_854294] KEEPI[INVESTIGATOR_1645] ...........................................................119
11.1. Case Report Forms/Data Collection Tools/Electronic Data Record...................[ZIP_CODE].2. Record Retention.................................................................................................[ADDRESS_854295]/Ethics Committee....................................................[ZIP_CODE].2. Ethical Conduct of the Study ..............................................................................[ZIP_CODE].3. Subject Information and Consent........................................................................[ZIP_CODE].4. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH 
GCP .........................................................................................................................[ADDRESS_854296] OF TABLES
Table 1. Preliminary Summary of Draft Plasma PK Parameters of PF-06826647 
Following Single Oral Dose Administration of PF-06826647 in Healthy Subjects (Fasted)...................................................................................................34
Table 2. Preliminary Summary of Draft Plasma PK Parameters of PF-06826647 
Following Multiple Oral QD Dose Administration of PF-06826647 for 10 Days in Healthy Subjects (Fed-Standard Meal) ..............................................34
Table 3. Predicted Mean Human Total and Free Exposures and Associated Margins 
Following Single Dose Administration of PF-06826647 .....................................36
Table 4. Predicted Mean Human Total and Free Exposures and Associated Margins 
Following Once Daily Dosing of PF-06826647 for 10 Days...............................37
 
Table 7. Laboratory Tests ...................................................................................................79
Table 8. Blood Volume: Single Ascending Dose Period....................................................97Table 9. Blood Volume: Multiple Ascending Dose Period................................................98Table 10. Blood Volume: Psoriasis Multiple Dose Period...................................................[ADDRESS_854297] OF FIGURES
Figure 1. Study  Schema .......................................................................................................48
Figure 2. Legend for Figure 1 ..............................................................................................49
APPENDICES
Appendix 1. Abbreviations ....................................................................................................125
Appendix 2. Cockcroft-Gault Calculation .............................................................................132Appendix 3. Prohibited Concomitant Medications................................................................133Appendix 4. Estimated Glomerular Filtration Rate ...............................................................135
CCICCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 14Appendix 8. Patient Global Assessment of Psoriasis ............................................................139
Appendix 10. Suicidal Behaviors Questionnaire-Revised (SBQ-R) .....................................146
Appendix 11. Patient Health Questionnaire – 8 items (PHQ-8)............................................148CCI
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 15SCHEDULE OF ACTIVITI ES
The schedule of activities table provides an overview of the protocol visits and procedures.  Refer to the STUDY PROCEDURES and 
ASSESSMENTS sections of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed in the schedule of activities table, in order to condu ct 
evaluations or assessments required to protect the well-being of the subject. 
SCHEDULE OF ACTIVITIES Single Ascending Dose - Period 1: Healthy Subject Cohorts
Study Day Screen ing
-28 to -2Day
-1Day 1 Day 
2Day 
3Day 
4Day 8a
Follow -up
/ET*
Hours Post Dose
Protocol Activity0 0.5 1 2 4 6 8 12 16 24 36 48 72 168
Randomization X
Informed Consent X
Admission to CRU X
Discharge from CRU X
Outpatient VisitbX X
Inclusion/Exclusion Criteria X X
Drug/Alcohol/Tobacco History X X
Medical History X X
Physical ExaminationcX X X
Demography X
Body weight X X X
Height X
Interferon Gamma Release Assay 
(IGRA)X
HIV, HepBsAg, HepBcAb, HCVAb X
Blood Safety Labs 
(hematology & chemistry) (fasting)dX X X X X
Fibrinogen X X
Lipid Panel (fasting)eX X X X
Urinalysis X X X X X X
FSHfX

PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 16Study Day Screening
-28 to -2Day
-1Day 1 Day 
2Day 
3Day 
4Day 8a
Follow-up
/ET*
Hours Post Dose
Protocol Activity0 [ADDRESS_854298] X X
ECGh(12-lead) X X X X X X X X X X X X X X X
Continous cardiac monitoring by 
[CONTACT_638767] [ADDRESS_854299] dose
Vital signs: Supi[INVESTIGATOR_638737], BP, 
and Oral TemperatureX X XXXX X X X X X X X X X
Viral Surveillance:
 
 
Study Treatment Administration X
PK Blood Sampling X X X X X X X X X X X X X
Serious and non-serious adverse event 
monitoringX→→→→→ →→→ → → → → X
Prior/Concomitant treatments X X →→→→→ →→→ → → → → X
Blood for mRNA analysis X X X X X X X X X
Abbreviations: →= ongoing/continuous event; BP = blood pressure; ;CRU = clinical research unit; ECG = electrocardiogram; 
FSH = follicle-stimulating hormone; ; HepBcAb = hepatitis B core 
antibody; HepBsAg = hepatitis B surface antigen; HCVAb = hepatitis C antibody; HIV = human immunodeficiency virus; ; PK = Pharma cokinetics; 
PR = pulse rate; .
a. End of study visit ( ±1 day).
b. Subjects will reside in the clinical research unit until the morning of Day 4 and return on Day 8 ±1 day for the end of the single dose period visit.
c. A full physical examination may be done at screening or may be differed to Day -1 (prior to randomization) of Period 1 at the discretion of the investigator.  A limited 
physical exam may be completed on Day 8 (instead of a full exam) at the discretion of the investigator. 
d. Chemistry and hematology labs are collected following fasting period of at least 8 hours (on Day 1, fasting applies to hour 0 lab s only).
e. Lipid Panel (Cholesterol, Triglycerides, HDL, and LDLc): Fasting requirement of at least [ADDRESS_854300] 12 consecut ive months.
g. See protocol Section 4.6.4 (Contraception).  Investigator will discuss appropriate contraception methods with male subjects.
h. ECGs will be collected in triplicate approximately 2-[ADDRESS_854301] dose period.
 
* ET: early termination – refer to Section 6.[ADDRESS_854302] is withdrawn due to an adverse event, in addition to the early termination assessments 
included in the schedule of activities , a final PK sample should be collected when possible. 
Note: Time 0 on Day 1 is pre-dose. All assessments/samples at time 0 occur pre-dose, including PK sample collection. C
CI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 18SCHEDULE OF ACTIVITIES Multiple Ascending Dose - Periods 2: Healthy Subject QD and Optional BID and Japanese 
Subject Cohorts
The Schedule of Activities table provides an overview of the protocol visits and procedures.
Note: The below schedule assumes healthy subjects entering the multiple ascending dose (MAD) period have completed the single 
ascending dose period (SAD).  Prior to entering the MAD period, any subjects that have not completed the SAD period must comple te 
the screening assessments listed in the SAD Schedule of Activities (including sample collection for Pharmacogenomic Sample Prep D1), and must meet eligibility requirements for healthy subjects outlined in the Inclusion Criteria: Healthy Subject 
Single/Multiple Ascending Dose Cohorts . 
Study Day Day
-1Day
1Day
2Day
3Day 
4Day 
5Day 
6Day
7Day 
8Day
9Day 10 Day 
11Day 
12Day 
13Day 
14Day 
17Day 28a
Follow-up
/ET*
Hours Post Dose
Protocol Activity0 0 . 5 [ZIP_CODE] 1 2 1 6 2 4 0 0 . 5 1 2 4 6 8 1 2 1 6 2 4 4 8 7 2 9 6 1 6 8
Confirm key eligibility 
criteria are met (safety labs, vitals, ECG)
bX
Contraception CheckcX
Urine pregnancy test for femalesX
Admission to CRU X
Discharge from CRUdX
Outpatient visit XX
Physical ExaminationeX X
Body weight X X
Blood Safety Labs 
(hematology & chemistry)(fasting)
fXmXX X X X X X
Fibrinogen X X
Immunoglobulins: IgA, CCI
C
CI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 19Study Day Day
-1Day
1Day
2Day
3Day 
4Day 
5Day 
6Day
7Day 
8Day
9Day 10 Day 
11Day 
12Day 
13Day 
14Day 
17Day 28a
Follow-up
/ET*
Hours Post Dose
Protocol Activity0 0 . 5 [ZIP_CODE] 1 2 1 6 2 4 0 0 . 5 1 2 4 6 8 1 2 1 6 2 4 4 8 7 2 9 6 1 6 8
Lipid Panel (fasting)gX XX X X
Urinalysis X X X X X X X X X X X
Urine Drug Test X
ECGhX X XXXX X XXX X XX X X X X X X X X XXXXX X
Vital signs: Supi[INVESTIGATOR_638738], BP and Oral Temperature
iX X XXXX X XXXXXXXX X X X X X X X X X XXXX X X
24 hr Urine Collection for 
measurement, 
Creatinine Clearance, 
6-β-Hydroxycortisol/cortis
ol ratio and Urine PKj0-24 
hr0-24 hr
Study Treatment 
AdministrationX XXXXXXXX X
PK Blood SamplingkX XXXXXXX X X X X X X X X X X X X XXXX X
 
 
Serious and non-serious 
adverse event monitoringXX →→→→→→→→ →→→→→→→→→ → → → → → X
Prior/Concomitant 
treatmentX→ →→→→→→→→ → →→→→ → X
 
Abbreviations: →= ongoing/continuous event; BP = blood pressure; ; CRU = clinical research unit; ; ECG = electrocardiogram; 
; PK = Pharmacokinetics; 
PR = pulse rate; CCI
CCI
CCI
CCI CCI
CCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 20a. End of study procedures ( ±3 day).
b. Prior to dosing on Day 1, confirm that safety labs, ECG, and vital sign results, contraception check and prior/concomitant tre atments from Day -1 (or from Day 8 of SAD if 
obtained within 48 hours of MAD Day -1) meet eligibility requirements outlined in Section 4.[ADDRESS_854303] will not continue into the MAD period. 
c. See protocol Section 4.6.4 (Contraception).  Investigator will discuss appropriate contraception methods with male subjects. 
d. Subjects will reside in the clinical research unit until the morning of Day 14, returning on the morning of Day 28 ±3 days for the end of study procedures visit.
e. Limited physical examination (at the discretion of the principle investigator, exam may be limited or full).
f. Chemistry and hematology labs are collected following fasting period of at least 8 hours (on Day 10, fasting applies to hour 0 la bs only).
g. Lipid panel (Cholesterol, Triglycerides, HDL, and LDLc):Fasting requirement of at least [ADDRESS_854304]-dose; vitals taken on Days 2-[ADDRESS_854305]-dose; 
vitals taken on Days 12, 13, 14 will be performed in the morning.  Vital signs will also be collected at the Day 17 and Day 28 (fo llow up/ET) visit.
j. An aliquot (urine blank) from the 0-24 hour period will be obtained from the urine collection for creatinine clearance on Day  -1 for both the QD cohort and the BID cohort.
On Day 10, urine will be collected for the BID cohort over 2 time intervals: 0-12 hours and 12-24 hours. The Day 10 PK sample will be  obtained from the 0-12 hour interval. 
k. Blood samples collected for PK pre-dose on Days 1, 2, 4, 6, 8 and 10, and on the morning of Days 11-14 (following at least a [ADDRESS_854306]) and on 
study Day 17.
 
* ET: early termination – refer to Section 6.[ADDRESS_854307] is withdrawn due to an adverse event, in addition to the early termination assessments 
included in the schedule of activities , a final PK sample should be collected when possible.
Note: An optional BID cohort may be included based on emerging PK data.  Subjects participating in the BID cohort will follow the  above schedule. 
Administration of blinded study medication occurs on study Days [ADDRESS_854308] dose, obtain vital signs including supi[INVESTIGATOR_9204], pulse rate (after at least [ADDRESS_854309]), and oral te mperature.  Assess symptoms by [CONTACT_638768] a non-leading question such as “How do you feel?”.  On study Day 10, the assessment time course depi[INVESTIGATOR_638739].  Assessments on Day 10, hour 0, occur pre-dose. C
CI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 21SCHEDULE OF ACTIVITIES: Psoriasis Cohorts 
Study Day Screen
ing
-28 to 
-2D 
-1D 1 D2 D 3 D 4 D 5 D 
6D 
7D 8 D 9 D 
10D 
11D 
12D 
13D 14 D 21 D
28Day 
29D 
35D
42D 56/ETaD [ADDRESS_854310] Dose
Protocol Activity0 0 . 5124681 2 1 62 4
Informed Consent X
Drug/Alcohol/Tobacco 
HistoryX
Demography X
Medical History X
Prior/Concomitant 
treatmentXX→ → →→→→ →→→→→→→→ → → →→ →→→→→ →→→→ → X
FSHbX
Urine pregnancy test for 
femalesX X
Contraception CheckcXX XX X
Inclusion/Exclusion 
CriteriaX
Admission to CRU X
Randomization X
Discharge from CRU X
Interferon Gamma 
Release Assay (IGRA)X
Chest X-raydX
HIV, HepBsAg,
HepBcAb, HCVAbX
 
Non lesional biopsy X
Lesional biopsy of index 
lesion XX XCCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 22Study Day Screen
ing
-28 to 
-2D 
-1D 1 D2 D 3 D 4 D 5 D 
6D 
7D 8 D 9 D 
10D 
11D 
12D 
13D 14 D 21 D
28Day 
29D 
35D
42D 56/ETaD [ADDRESS_854311] Dose
Protocol Activity0 0 . 5124681 2 1 62 4
Clinical Evaluation: 
Plaque Lesion Photography
fXX X X X X X
Outpatient visit XX X X
Physical ExaminationgXX X X X X
Body weight X X X
Height X
 
Blood Safety Labs 
(chemistry and 
hematology) (fasting)hXX X X X X XXX X X X X
 
Lipid Panel (fasting)iXX X XXX X
Urinalysis X X X X X X X X X X X X X
Urine Drug Test X X
ECGjXX X X X X X X X X X X X X
Vital signs: Supi[INVESTIGATOR_638737], BP and Oral 
TemperaturekX X X X X X XX X XXXXXX X X X X X XXXX X X X X X X
Study Treatment 
AdministrationlX X X X XX X XXXXXX X X X
PK Blood SamplingmX X X X X X XXXXX X X X X
 
 
 CCI
CCI
CCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 23Study Day Screen
ing
-28 to 
-2D 
-1D 1 D2 D 3 D 4 D 5 D 
6D 
7D 8 D 9 D 
10D 
11D 
12D 
13D 14 D 21 D
28Day 
29D 
35D
42D 56/ETaD [ADDRESS_854312] Dose
Protocol Activity0 0 . 5124681 2 1 62 4
Serious and non-serious 
adverse event monitoringX→ → →→→→ →→→→→→→→ → → →→ →→→→→ →→→→ → X
 
 
 
 
Patient Global 
AssessmentXX X X X X X
PHQ-8oX
SBQ-RoX
Abbreviations: →= ongoing/continuous event; ; BP = blood pressure; ; CRU = clinical research unit; D=Day;  
; ECG = electrocardiogram; ; FSH = follicle stimulating hormone; HepBcAb = hepatitis B 
core antibody; HepBsAg = hepatitis B surface antigen; HCVAb = hepatitis C antibody; HIV = human immunodeficiency virus;  
; IGRA = interferon gamma release assay;  
 PK = Pharmacokinetics; PR = pulse rate; 
a. End of study procedures ( ±3 days).  Note: the visit window ( ±3 days ) applies to outpatient visits on study Da ys 35, 42, 56, and 84. ET: early termination – refer to 
Section 6.[ADDRESS_854313] 12 consecut ive months.
c. See protocol Section 4.6.4 (Contraception).  Investigator will discuss appropriate contraception methods with male subjects.
d. Only required for psoriasis subjects with history of previously (adequately) treated TB, as described in the protocol eligibi lity criteria (see protocol Section 4.3 ).  Chest x-ray 
taken within 3 months of screening visit can be used to assess eligibility if available.CCI
CCI
CCI
CCI
CCI
CCI CCI CCI
CCI
CCI
CCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 24 
f. Target lesion and regional photography.
g. A full physical examination may be done at screening or may be differed to Day -1 (prior to randomization) at the discretion of the investigator.  A full physical exam should 
also be performed at Day 28.  A limited physical exam can be performed at all other times if no findings during previous examina tion or new/open AE, at the discretion of the 
investigator.
h. Safety labs (chemistry and hematology) are collected following at least 8 hours of fasting (on Day 28, fasting requirement applies  to hour 0 only).
i. Lipid panel (Cholesterol, Triglycerides, HDL, and LDLc): Fasting requirement of at least 8 hours.
j. Triplicate ECGs will be collected on Day 1, Day 28, and Day 29.  Single ECGs will be collected at all other time points/visits.k. Vitals taken on Days 1-[ADDRESS_854314]-dose; vitals will also be taken on Day 29, 35, 42 and 56/ET (follow-up) visits.
l. Study treatment administration occurs once daily for 28 days, starting on Day 1 and ending on Day 28.
m. Blood samples collected for PK predose on Days 1, 7, 14, 21, and 28 (time 0), and on the morning of Day [ADDRESS_854315] recent or active suicidal ideation or behavior will be excluded from the study (refer to Section 4.4 ).
 
Administration of blinded study medication occurs on study Days [ADDRESS_854316] dose, obtain vital signs including supi[INVESTIGATOR_9204], pulse rate (after at least [ADDRESS_854317]), and oral temperature.  Assess 
symptoms by [CONTACT_104567] a non-leading question such as “Ho w do you feel?”.  On study Day 28, the 
assessment time course depi[INVESTIGATOR_638740].  Assessments on Day 28, hour 0, occur pre-dose. C
C
C
C
C
C
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 251.INTRODUCTION
The Janus kinase (JAK) family, including JAK1, JAK2, JAK3 and Tyrosine kinase 2 
(TYK2), is a group of cy toplasmic ty rosine kinases that mediate signal transduction via 
interactions with Ty pe1 and Ty pe2 cytokine receptors critical for leukocy te activation, 
prolif eration, survival and function .5,6
PF
-06826647 is a potent TYK2 inhibitor with a good selectivity  profile over other human 
kinases.  Based on its cy tokine inhibition profile, PF-06826647 is expected to target the
T-helper 1 (Th1) and T - helper 17 (Th17) pathway s, and Ty pesI and II interferon signaling, 
directly  by [CONTACT_488040]2, and to provide therapeutic be
nefit in the treatment of 
inflammatory  conditions driven by  [CONTACT_78443]1/Th17 and interferon immune responses . 
This single -and multiple -ascending dose study  is the first evaluation of PF-06826647 in 
humans.  The goal is to assess the safet y, tolerability , pharmac okinetics (PK) and 
pharmacod ynamics (PD) in healthy  subjects and subjects with plaque psoriasis.  The 
inclusion of a psoriasis cohort will facilitate optimal assessment of TYK2 modulation in 
vivo, given that Th1 
and Th17 pathway s are not up regulated in th e absence of inflammation.  
1.1. Mechanism of Action/ Indication
PF-06826647 is a TYK2 inhibitor that is currently  being developed for the treatment of
psoriasis and Crohn’s disease (CD).
TYK2 pairs with JAK1 to mediate ty peI interferon (I FN) signaling and wit h JAK2 to 
transmit interleukin ( IL-12)and IL -23 signaling.  Additionally JAK1 pairs with JAK3 to 
mediate -common cy tokine signaling and also with JAK2 and/ or TYK2 to transmit the 
signals of additional cy tokines important in inflammation and immune responses including 
IL-6,andIFN, JAK2 homodimers are critical for the signaling of hematopoietic cy tokines 
and hormones including erythropoietin (EPO), IL -3,granulocy te-macrophage 
colony -stimulating factor (GM -CSF) and prolactin.  Key  cytokines implicated in the 
pathophy siology  of both Crohn’s disease and plaque psoriasis, such as IL -12 and IL -23, 
requir e TYK2 for signal transduction , indicating that inhibition of TYK2 mediated signaling
could be efficac ious in the treatment of these inflammatory  conditions.
1.2.Background 
1.2.1. Binding to the Pharmacological Target
PF-06826647 is an inhibitor of human TYK2.  The inhibitory  potency  of PF -06826647 on 
human TYK2 was determined by  [CONTACT_2329] a mobility
 shift microfluidic assay to monitor 
phosphory lation of a s ynthetic peptide by  [CONTACT_638769]2.  When the assay  was
performed under 1 mM adenosine 
triphosphate (ATP), PF-06826647 showed IC50(half 
maximal inhibitory  concentration) of 14.[ADDRESS_854318] human JAK1, JAK2 and JAK3, with I C50sof 383, 74.2 and >10,[ADDRESS_854319] mouse TYK2 in the kinase assays.  Sequence alignment of the TYK2 enzy me reveals 
that, within the ATP binding pocket, human TYK2 has an isoleucine at amino acid 960, 

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 26while other species with known sequences bear a valine at the equivalent position, except in 
chimpanzee.  Mouse TYK2 and human TYK2 I960V mutant kinase domains were prepared 
to gain an understanding of species s electivity , relative t o the wild -type human protein .  The 
IC50of PF -06826647 measured in this assay  at 1 mM ATP was 385 nM for mouse TYK2, 
and 344 nM for human TYK2 I960V mutant.  The results indicate that PF -06826647 binds 
more strongly  to TYK2 with isol eucine at amino acid 960 than valine, and resulting in 
relativel y lower potency in preclinical species when compared to human.
1.2.2. Cellular Potency and Selectivity 
The JAK family  kinases mediate signal transduction via interactions with ty peI (eg, IL-
2, 
IL-6, IL -23, GM -CSF) and ty pe II (eg, ty peI IFNs, IL -10) cytokine receptors.  The JAK 
signaling pathway s involves various hetero -or homodimer combinations (TYK2/JAK2, 
JAK1/JAK3, JAK1/JAK2, TYK2/JA K1, or JAK2/JAK2).  Upon binding of the cy tokine to 
its recept or, the associated JAKs are activated, and phosphory late each other and the 
receptor.  The phosphorylated receptors serve as docking sites for the signal transducer and 
activator of t ranscription (STAT )famil y (STAT1, STAT2, STAT3, STAT4, STAT5a, 
STAT5b, a nd STAT6) of transcription factors.  The STATs are then phosphory lated by  [CONTACT_42020]-localized JAKs, which stabilizes homo -or heterodimeric STAT complexes that 
translocate to the nucleus where they  bind to specific gene promoters and modulate 
transcription of a range of target genes. 
The cellular potency  and selectivity  of PF -06826647 was mainly  evaluated using human 
whole blood (HWB).  HWB was pretreated with PF- 06826647 and challenged with various 
cytokines to stimulate phosphory lation of STATs.  I nhibition of STAT phosphory lation by  
[INVESTIGATOR_16335]-06826647 was measured by [CONTACT_638770]- STAT antibodies.
IL-12 and IL -23, both signaling through JAK2/TYK2, are important for the differentiation of 
Th1 and Th17, respectiv ely.  Treatment of HWB with PF - 06826647 led to inhibition of 
IL-12 induced STAT4 phosphory lation with an IC 50of 53 nM and IL -23 induced STAT3 
phosphory lation with an IC 50of 112 nM.  I n human peripheral blood mononuclear cell s
(PBMCs ), PF-06826647 potently inhibited IL -12 induced pSTAT4 with an IC 50of 20 nM.
Treatment of HWB or human PBMCs with PF -06826647 resulted in inhibition of I FN
stimulated STAT3 phosphory lation (mediated via TYK2/JAK1) with an I C50of 66 nM and 
23nM, respectivel y.  Although IL -10signaling is also mediated via the TYK2/JAK1 pair, 
PF-[ADDRESS_854320] IL- 10 induced STAT3 phosphory lation with an I C50of 
427nM in HWB.  Signaling of the ty pe II interferon, I FN, is controlled by  [CONTACT_166527]1/JAK2.  
PF-06826647 was shown to block I FNinduced pSTAT1 with an I C50of 2,220 nM in HWB.
The common  chain cy tokines, such as IL -15 and IL -21, are dependent on JAK1 and JAK3 
to initiate signaling upon binding of their receptors.  PF -06826647 pre -incubation in human 
whole blood resulted i n an inhibition of STAT5 phosphory lation induced by [CONTACT_8668] -15 with an 
IC50of 4,840 nM and an inhibition of STAT3 phosphory lation induced by  [CONTACT_8668]-21 with an 
IC50of 4,890 nM in ly mphocy tes.

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 27IL-6 signaling is thought to be dependent on JAK1/JAK2/TYK2.  The I C50values in the IL - 6 
assay s were dependent on the STAT phosphory lated.  For example, IL -6 stimulated STAT1 
phosphory lation (I C50= 566 nM) was more readily  inhibited than STAT3 phosphory lation 
(IC50= 4,370 nM) b y PF-06826647 in CD3+lymphocy tes of human whol e blood.  IL -27 
signaling is also mediated by [CONTACT_638771] -6.  PF -06826647 suppressed 
IL-27 induced pSTAT3 with an I C50of 201 nM.
IL-4 initiates signal transduction through one of two different receptor complexes, a ty peI 
receptor expressed on hematopoietic cells or a t ypeII receptor expressed mainly  on 
non-hematopoietic cells.  The ty peI receptor is a heterodimer of IL-4 receptor (IL - 4R) and 
the  c chain, and the t ypeII receptor is a heterodimer of IL -4Rand IL -13 receptor (IL -13R) 
1.  IL - 13 onl y activates the type II IL-4R.  Following cy tokine binding, the ty peI receptor 
(IL-4Rand the  c chain) activates JAK1 and JAK3, while the ty peII receptor (IL -4Rand 
IL-13R1) stimulates mainly  JAK1 .  Activation of either ty peI or t ypeII receptors leads to 
phosphory lation of STAT6.  I n CD20+B and CD3+Tcells, IL -4-induced pSTAT6, mediated 
via JAK1 and JAK3, was inhibited by  [INVESTIGATOR_16335]-06826647 with I C50values of 3,413
nM and 
1,227 nM, respectivel y.  In CD14+monocy tes, PF -[ADDRESS_854321] IL -4 induced pSTAT6, which is controlled mainly  by [CONTACT_166527]1.  I n HWB, IL -13 
induced pSTAT6 was detected in CD14+monocy tes and CD20+Bcells, but not in CD3+
Tcells.  PF -06826647 pre -incubation in human whole blood resulted in an inh ibition of 
STAT6 phosphory lation induced by  [CONTACT_8668]-13 with I C50values of 807 nM and 393 nM detected 
in CD14+monocy tes and CD20+Bcells, respectively.
Inhibition of JAK2/JAK2 homodimer was assessed through erythropoietin (EPO )induced 
STAT5 phosphory lation w ith an I C50of 547 nM in human bone marrow CD34+progenitor 
cells spi[INVESTIGATOR_638741].  PF- 06826647 maintains a 10 -fold selectivity  over 
JAK2 as determined by [CONTACT_638772]2 dependent EPO signaling in bone 
marrow CD34+progenitor ce lls to the TYK2/JAK1dependent human whole blood I FN
assay .  These results demonstrate that PF -[ADDRESS_854322] suppression of the JAK2/JAK2 driven pathway .
PF-06826647 was also assessed for its cellular activity  in various cell ty pes and settings.  
IL-12 is a critical cy tokine that is required for the promotion of Th1 development as well as 
IFNproduction .  IL-12 sy nergizes with IL -18 in inducing I FNproduction.  IL -12 and 
IL-
18 activate different transcriptional factors: the former activates STAT4, and the latter 
activates NF -κB and AP -1, which signaling is independent of the JAK family  kinases.  IL-
12 
upregulates expression of the IL -18 recept or to promote IL -18-driven signaling, and 
IL-
12-activated STAT4 enhances the binding activity  of IL - 18-induced AP -1 to I FN
promoter. 

PF-[ADDRESS_854323] I FNproduction which was 
triggered b y a combination of IL -12 and IL-18 in human CD4+T, CD8+T, and CD56+NK 
cells.  IL -12 signals via TYK2 and JAK2.  As expected, PF -06826647 abrogated I FN
produc tion by  [CONTACT_638773] -12 signaling that was necessary  for the s ynergy of IL -12 and 
IL-18.  The inhibition by  [INVESTIGATOR_16335]-06826647 was dose dependent with IC 50values of 177, 123, and 
217nM in human CD4+T, CD8+T, and CD56+NKcells, respectivel y. 
TypeI IFNs h ave been shown to contribute to the progression of man y autoimmune diseases.  
Numerous gene expression profiling studies have shown up- regulation of int erferon induced 
genes .  In vitro, t ypeI IFN release and the resulting gene expression pattern can be in duced 
in PBMC using immune complexes constructed artificially  by [CONTACT_638774] 
G (IgG)purified from systemic lupus ery thematosus patients with apoptotic cellular debris 
from U937 cells as a source of nuclear antigens .  The in vitro activity  of PF-06826647 
inhibiting ty peI IFN induced genes in normal human PBMC stimulated with immune 
complexes was assessed .
IC50curves were generated in PBMCs from 3 human volunteer blood donors for IFN induced 
genes quantified b y quantitative reverse transcripta se poly merase chain reaction (qRT -PCR).  
PF-06826647 potently  blocked immune complex induced expression of 3 IFN induced genes, 
radical S -adenos yl methionine domain -containing protein 2 (RSAD2), ubiquitin specific 
peptidase 18 (USP18) and guany late binding protein 1 (GBP1) with IC50s of 36.7, 44.1, and 
43.8 nM, respectivel y.
In summary , PF-06826647 potently  inhibited TYK2 -dependent cy tokine receptors, such as 
receptors for IFN , IL-[ADDRESS_854324] receptors that do not signal 
through TYK2, like receptors for IL- 15 (signaling through JAK1/JAK3), IFN (signaling 
through JAK1/JAK2) or EPO (signaling through JAK2/JAK2).
1.2.3. Non-Clinical Pharmacokinetics and Metabolism
Single dose pharmacokinetic studies with PF -06826647 were conducted after oral and IV 
administration to mice and rats.  PF- 06826647 had moderate oral bioavailability  (26% to 
51%) utilizing a spray ed-dried dispersion (SDD) formulation versus 0.5% methy l cellulose 
(<1% to 12%).  After IV administration, PF
-[ADDRESS_854325] eady  state volume of 
distribution (Vss) of approximately  0.9 to 1.4 L/kg and a low plasma clearance (CL [10 to 
18mL/min/kg]), relative to mouse and rat liver blood flows.  Sy stemic exposures (maximum 
observed concentrations [C max] and area under the conce ntration time curve [AUC]) of 
PF-06826647 after repeat oral dosing in the pi[INVESTIGATOR_638742] (up to 500 mg/kg/day ) and monkey s (up to 300 mg/kg/day ) in a less than 
dose-proportional manner.  No sex- related diffe rences in exposure and no accumulation of 
PF-06826647 were observed over the dosing period in either species.  In vitro, PF -06826647 
showed high apparent passive permeability  and may  be a substrate for P gly coprotein (P -gp).  
PF-06826647 binding to plasma proteins ranged between 62% to 82%, and PF -[ADDRESS_854326]  for PF -
06826647 is expected to be CYP450 mediated 
metabolism through CYP1A2, 2
D6and3A.  PF- 06826647 did not inhibit the major 
cytochrome CYP450 or UGT enzy mes (I C50>25M).  
PF-06826647 induced CYP3A4 
messenger Riboneucleic acid ( mRNA )expression in 1 of 3 lotsof hepatocytes ( 4.7-fold 
increase at 10M),but no corresponding induction was seen in CYP3A4 enzy matic 
activity .  Induction of CYP1A2 enzy me activity  occurred in 2 lots of hepatocy tes 
(approximatel y 2-fold at 10M), and PF- 06826647 did not induce CYP2B6 mRNA levels 
or enzymatic activity .  Based on its in vitro profile, the potential for PF- 06826647 mediated 
CYP450 or UGT drug interactions is low at clinically  relevant concentrations (C max355nM; 
Cmax,u 135
nM).
PF-06826647 showed little to no inhibition of the multidrug and toxin extrusion protein 
(MATE1), multidrug resistant protein 1 (MDR1), multidrug resistance -associated protein 
(MRP2), MRP3, sodi um/taurocholate co -transporting poly peptide (NTCP), organic anion 
transporting poly peptide (OATP) 1B1, OATP1B3 and organic cation transporter (OCT) 2.  
However, PF -06826647 did inhibit MATE2K with an estimated IC 50value of 0.53 M
. 
Human pharmacokinetics of PF -06826647 were predicted using ph ysiologically  based 
pharmacokinetic modeling, scaling intrinsic clearance from human liver microsomes and 
hepatocy tes.  Human blood clearance is predicted to be ~2mL/min/kg, volume of 
distribution 1.3 L/kg, half -life6hours ,and oral bioavailability  of ~90%.  The once daily  
clinical dose predicted to achieve the average concentration resulting in approximately  
80% inhibitory  effect ( Cav80,ss)on IL -12 is 20 mg.  The target unbound AUC 24,ssto achieve 
an 80% average d ail
y inhibition of IL -12 (TYK2/JAK2) is approximatel y 587 ng*h/mL .  The 
corresponding PF -06826647 unbound C maxis approximately  52ng/mL (135 nM).
1.2.4. Non-clinical Safety S tudies
PF-[ADDRESS_854327] ivity over 
JAK1, JAK2 and JAK3 of 5x, as well as good specificit y profi le over the broader kinome.  
PF
-06826647 blocked various TYK2- dependent cellular functions in vitro, including 
phosphorylation of STAT induced by  [CONTACT_488043]2 -dependent cy tokines such as IFN ,IL-[ADDRESS_854328] TYK2 -independent cy tokines like IL -15 (JAK1/JAK3 
dependent), IFN(JAK1/JAK2 dependent) or EPO (JAK2/JAK2 dependent) in HWB, 
IL-12-induced IFN production in human T and NK cells, and t ypeI IFN gene signature 
[CONTACT_491203] b y immune complexes in human PBMCs.  Treatment with PF
-[ADDRESS_854329] panel of receptors, kinases, transporters, 
ion channels, enzyme targets (at 10,000 nM), and phosphodiesterases (at 30,000 nM).  A 
50% inhibition was observed against Abl, AurA/Aur2, KDR (VEGFR2), and Src kinases 
with I C50values of 1300, 710, 160, and 4300 nM, respectivel y.  These IC 50values 
correspond to approximately  9.6x, 5.3x, 1.2x, and 32x, respectivel y, the predicted human 
efficacious unbound C max.  In a functional cell -based assay , PF-06826647 inhibited Abl and 
VEGFR2 kinase less potently  with IC 50values of ˃30,000 nM and 18,000 nM which are 
˃222x and 133x the projected human efficacious unbound C max, respectively . These results 
indicate that PF-[ADDRESS_854330] dose tested (500 mg/kg).  The unbound C maxat 
500mg/kg is [ADDRESS_854331] dose tested (300 mg/kg), corresponding to 
approximatel y 28x the projected human efficacious unbound C max.  In an exploratory  
cardiovascular safet y pharmacolog y study in rats, PF -
06826647-related increased diastolic 
and mean blood pressure (each +3 mmHg) from 0
-2hours postdose ,and increased heart rate 
(+18 to +13 bpm) from 2-12 hours postdose ,were observed at 500 mg/kg (the highest dose 
tested).  No PF -06826647- related effects were observ ed in an y parameter measured at 
50
mg/kg, corresponding to 6.5x the predicted human efficacious unbound C max.
The hERG IC 50for PF -06826647 was >10,000 nM, which is >74x the predicted human 
efficacious unbound C max.
PF-06826647 was negative for mutagenicity  in the GL P bacterial reverse mutation assay .  
Although 
PF-06826647 was positive in the invitro micronucleus assay  in TK6 cells by [CONTACT_638775], it did not induce micronuclei in vivo in reticulocy tes in the 1 -month 
study  in rats (at exposures 41x the predicted human unbound efficacious C maxand AUC 24).
PF-06826647 absorb s intheultraviolet A (UVA) andultraviolet B (UVB)range and could 
present potential risk for phototoxicity .  Therefore, PF-06826647 will be evaluated for 
phototoxicity  prior 
to enrollment in large clinical trials .
PF-06826647 was evaluated in rats and c ynomolgus monkey s in singl e-and repeat -dose
toxicity and/or toxicokinetic studies up to 1 month in duration.  The high dose selection in the 
1-month pi[INVESTIGATOR_638743] .  Target 
organs and s ystems identified with PF-06826647 administration in rats and monkey s include 
the immune and hemol ymphatic systems (thymus, spleen, ly mph nodes, bone marrow, 
erythron, and leukon), bone, and liver. In addition, other PF-06826647- related findings 
occurred in clinical observations, body  weights, and/or clinical pathology  parameters
.  In the 
immune and hemoly mphatic sy stem, decreased l ymphoid cellularity within the ly mphoid 
follicles of the thymus and spleen was observed in rats 30mg/kg/day , and in the thy mus, 

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 31spleen, and l ymph node (mesenteric) in monkey s at 150mg/kg/day .  This finding was 
associated with nondose -related lower or decreased lymphocy te,white blood count ( WBC ), 
and/or eos inophil counts in rats and monkey s at  30mg/kg/day .  Additionally , lower 
reticulocy te numbers were observed in rats at 30(15twice a day  (BID) mg/kg/day  and not 
associated with an y adverse effects in red blood cell ( RBC) mass parameters.  Further 
observ ations included lower numbers of T cells, Bcells, NKcells, and absolute ly mphocy te 
counts inperipheral blood and/or spleen ofrats at 30(15BID)mg/kg/day for cy totoxic 
Tcells and NK cells in spleen or 200(100 BID)mg/kg/day  for all other 
PF-06826647- related immunophenoty pi[INVESTIGATOR_128007] .  In monkey s, decreased numbers of 
T cells in peripheral blood and NK cellsin peripheral blood and spleen occurred at 
30mg/kg/day ,and decreased number of T cells, B cells, and absolute ly mphocy tes occurred
in the spleen at 300mg/kg/day . Minimal decreased cellularity  in all cell lineages was 
observed in the bone marrow (sternum) of monkey s at 150mg/kg/day  and corresponded 
with decreased RBC mass parameters ( red blood cell ( RBC
),hemoglobin (HGB ), and 
hematocrit (HCT )),reticulocy tes,and WBC counts at  30mg/kg/day .  The findings in the 
thymus, spleen, l ymph nodes, bone marrow, erythron, and leukon observed in rats and 
monkey s are consistent with the pharmacological activity
 of PF -06826647 , and were not 
adverse due to their low magnitude/severit y of the effects and/or because they were not 
associated with an y clinical or microscopic evidence suggestive of PF-06826647 -related 
infections in these animals.
PF-06826647- related higher or increased a lanine transaminase ( ALT), aspartate 
aminotransferase ( AST ), alkaline phosphatase (ALP ), and/or trigly cerides were observed in 
rats at  30(15BID)mg/kg/day  and in monkey s at 30mg/kg/day .  Additionally , higher 
cholesterol was observed in rats at 500 (250 BID)mg/kg/day . None of these alterations were 
adverse due to their minor magnitude and the absence of correlating microscopic findings.
PF-06826647- related nonadverse minimall yhighe rfemora lmetaph yseal medullary
trabecular bone thickness was observed in the bone of th
e stifle joint in rats at 500 mg/kg/day  
after [ADDRESS_854332] on bone was not 
observed in monkey s.
Other nonadverse PF- 06826647 -related findings included clinical observations, body  
weights, and/or clinical pathology  parameters that lacked in -life or post -mortem correlates 
and/or were m inor in magnitude.  These included higher mean fibrinogen in rats at 
200(100 BID)mg/kg/day ; higher mean total protein, consisting of both higher mean 
albumin and globulin, in rats at 500 (250 BID)mg/kg/day ; dose -dependent, lower mean bod y 
weight gain a nd mean absolute body  weight in rats at 30(15BID)mg/kg/day ; decreased 
phosphorus in monkey s at 30mg/kg/day ; and pale/white discolored feces in monkey s at 
100mg/kg/day .

PF-[ADDRESS_854333]-level (NOAELs) in the 1-month pi[INVESTIGATOR_638744] 500 (250 BID) mg/kg/day in rats (unbound C max= 1870 ng/mL and 
AUC 24= 16,600 ng•h/mL) and 300 mg/kg/day in cynomolgus monkeys (unbound 
Cmax= 1790 ng/mL and AUC 24= 19,900 ng•h/mL).  Exposures  at these doses were 
28x to 36x the predicted human efficacious unbound exposures (C maxand AUC 24).
The nonclinical safety profile of PF-[ADDRESS_854334] in human (FIH) study using a suspension or immediate release (IR) tablet of the spray dried dispersion.
Additional information for this compound may be found in the single reference safety 
document (SRSD), which for this study is the Investigators Brochure (IB). 
1.3. Rationale 
1.3.1. Study Rationale 
This Phase [ADDRESS_854335]-in-human (FIH) study will evaluate safety, tolerability, PK and  of 
PF-06826647 in healthy subjects and in subjects with plaque psoriasis.  The combined single ascending dose (SAD) and multiple ascending dose (MAD) design was selected because it provides the opportunity to shorten the time between completion of the SAD and MAD phases of early drug development, without compromising the safety of the subjects.  In addition, the dosing in MAD period will be done under fed condition and PK on Day [ADDRESS_854336] 
the potential to inhibit renal transport of creatinine.  In order to provide an additional assessment of renal function during this trial, serum cystatin C will be collected in order to estimate glomerular filtration rate (GFR).  Cystatin C is produced by [CONTACT_638776] a CC
I
CCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 33constant rate and is 100% eliminated by [CONTACT_575225], without influence of renal 
transporters.  The blood concentration of cystatin C is not substantially affected by [CONTACT_17977], nutritional status or inflammatory disease.  Therefore, serum cystatin C will serve as a nonbiased biomarker of GFR in addition to  
 
 
 
 
 
 
 
 
 sites and subjects, unless 
prohibited by [CONTACT_168047] (EC) decision.
1.3.2. Preliminary Summary of Clinical Experience
As of March 25, 2018, the one, on-going
clinical trial is the current study, C2501001.  In this 
study, dosing of six single ascending dose cohorts and three multiple ascending dose cohorts  has been completed, with [ADDRESS_854337] been no serious adverse events (including death) reported.  Based on preliminary 
review of data, all reported adverse events (AEs) have been of mild intensity. 
Preliminary pharmacokinetic data from the 3, 10, 30, 100, 400, and 1600 mg dose levels in 
SAD are summarized in Table 1 . The results indicate that exposure (AUC and C
max) is lower 
than predicted by [CONTACT_638777] [ADDRESS_854338] longer terminal half-life at higher dose, possibly due to the biphasic c oncentration time profile and increased ability to 
measure the concentration for longer period at higher dose. The terminal half-life at 10 mg was approximately 6 hours whereas at 400 mg it was approximately 15 hours. CCI
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 34Table 1. Preliminary Summary of Draft Plasma PK Parameters of PF - 06826647 
Following Single Oral Dose Administration of PF -06826647 in Healthy 
Subjects (Fasted)
Single 
Dose
(mg)Cmax(ng/mL) AUC 24(ng.hr/mL) AUC last(ng.hr/mL) t½
hr
3 8 (38) 40 (56) 40 (56) NR
10 47 (35) 346 (64) 355 (67) 6 (33)
30 78 (34) 543 (49) 639 (58 ) NR
100 167 (55) 1160 (55) 1378 (53 ) NR
400 329 (28) 1933 (28) 2135 (26) 15 (33)
1600 1218 (25) 9321 (34) 9796 (34) 13 (56)
Geometric mean (%CV) for all except arithmetic mean (%CV) for t ½, Abbreviations: %CV = percent coefficient of 
variation; NR = No t Reportable ;AUC 24= Area under the concentration -time curve from time zero to [ADDRESS_854339] single 
dose; C max=Peak plasma concentration .
Preliminary pharmacokinetic data on Day [ADDRESS_854340] meal at 30, 100 and 400 mg once dail y (QD)
are summarized in Table 2.  By  [CONTACT_638778] 1, single 
dose a dministration with standard meal modestl y increased the ex
posure of PF -[ADDRESS_854341] accumulation (1.3 and 1.2 fold for 
AUC and C maxat 400 mg, respectivel y). 
Table 2. Preliminary Summary of Draft Plasma PK Parameters of PF- 06826647 
Following Multiple Oral QD Dose Administration of PF- 06826647 for 
10Days i n Healthy Subjects (
Fed-Standard Meal )
Day 1 Day 10
Dose
(mg)Cmax(ng/mL) AUC 24(ng.hr/mL) Cmax(ng/mL) AUC 24(ng.hr/mL) t½
hr
30 84 (24) 664 (25) 85 (27) 752 (32) 9 (67)
100 267 (20) 1811 (23) 263 (30) 1950 (34) 7 (38)
400* 520 (30) 3488 (58) 689 (1 4) 4919 (32) 4(13)
Geometric mean (%CV) for all except arithmetic mean (%CV) for t ½;Abbreviations: %CV = percent coefficient of 
variation; NR = Not Reportable . AUC 24= Area under the concentration -time curve from time zero to [ADDRESS_854342] single 
dose; C max=Peak plasma concentration; *Partial d ata (only 4 subjects up to Day 11).
1.3.3. Dose Rationale
[IP_ADDRESS]. Dose Selection for FIH Study (Original Protocol Dose Rationale, 16 May 2017)
The data from in vitro pharmacologic and toxicologic studies on PF- [ADDRESS_854343] -in-human study .
The efficacious concentration (C eff) for PF -06826647 was derived as a concentration that is 
expected to achieve approximately  80% average daily  inhibition of IL -
12.  Based on the
unbound IC50value of IL -12 ( Unbound IC 50=14 nM calculated based on total I C50=53nM, 
fraction unbound in human of 0.38 and RBC partition ratio of 1.4) determined by  [CONTACT_638779]-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 35(phosphory lated signal transducer and activator of transcription proteins )modulation in 
in-vitro human whole blood and assuming Hill coefficient of 1, the calculated C effis56nM.  
The predicted C av,24 hat a dose of 20 mg QDas SDD formulation is expected to produce 
approximatel y 80% daily averag e inhibition of IL12, therefore, 20 mg is a projected 
efficacious dose.
The human PK of PF -06826647 was predicted using GastroPlus phy siologically  based 
pharmacokinetic modeling by  [CONTACT_638780] ( HLM) and human hepatocy tes (HEP).  HLM predicted a human clearance of 
2.3mL/min/kg, while that by  [CONTACT_638781] 1.5 mL/min/kg.  Given the confidence in CYP450s 
mediated metabolism as primary  clearance mechanism and similarity  between scaled 
clearance sby [CONTACT_638782]
d HEP, 2 mL/min/kg was used for simulation sof human PK 
concentrations .  GastroPlus predicted dose dependent bioavailability  with SDD formulation, 
which was used to improve the solubility  and bioavailability  of PF -
06826647. At lower 
doses (~ <100 mg), the predicted bioavailability  is expected to be >80% (see Table 3below) 
but it is expected to decrease considerabl y at higher doses (~ >100 mg).
The nonclinical safet y profile of PF
-06826647 has been adequatel y characterized in rats and 
cynomolgus monkey s to support progression into human clinical studies up to 1 month in 
duration ( Section 1.2.4 Non clinical safet y studies).   In cynomolgus monkeys, no observed 
adverse e ffect level ( NOAEL )
was established at 300 mg/kg/day  while in rats, the NOAEL 
was established at 500mg/kg/day  and were the highest doses tested in both species.  The 
resulting combined male and female mean NOAEL exposures in rats based on freedrug were 
[ZIP_CODE] ng.hr/mL  and 1870 ng/mL  for the AUC 24,ssand C max, respectivel y.  The corresponding 
values for the monkey  were [ZIP_CODE] ng.h/mL and 1790 ng/mL for AUC and C max, respectivel y.  
No clear differences in the species sensitivity  were noted .  Since rat had lowe r free AUC 24,ss, 
exposure limits were based on the NOAEL exposures observed in rats 
(AUC 24,ss=
[ZIP_CODE] ng.hr/mL and C max=1870 ng/mL ). 
Human PK parameter estimates for PF-[ADDRESS_854344] based on in vitro inhibition of cy tokines (IL12, IL23 and I FN-) were 
used to estimate the starting dose in this study .  Based on the predicted average 
concentrations over dosing interval (
Cav,24 h) and in vitro I C50in whole human blood (after 
accounting for fract ion unbound of 0.38 and RBC partitioning of 1.4) , the projected percent 
inhibitions of cy tokines IL -12, IL -23 and I FN-(IL-12:Total I C50=53nM,Unbound 
IC50=14nM; IL-23:Total I C50=112 nM,Unbound IC 50=30 nM ; IFN:Total 
IC50=66nM,Unbound I C50=18 nM; Unbound IC 50calculated based onfraction unbound in 
human 0.38 and RBC partition ratio=1.4 ) atthe proposed starting single dose of
3mgare 
approximatel y 43, 27 and 38%, respectively .  In the FIH study  with TYK2/JAK1 inhibitor 
(PF-06700841) as a single dose of 200mg, these cy tokines were inhibited up to 
>95% without any  safety concern.   The planned starting single dose of 3mg is predicted to 
provide, relative to the exposures (based on free concentrations) on Day 29observed from 
the highest dose ( 500mg/kg/d ay) administered to rats, exposure margins 
of 260 -fold for C max
and 185-fold for AUC 24.  The maximum recommended starting dose based on human 
equivalent dose ( HED )approach with safet y factor of 10 is 225 mg.  The proposed starting 
dose of 3
mg is approxim ately  1/1880thof the HED based on the highest dose 

PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 36(500 mg/kg/day) administered to rats.  The expected levels of inhibition of these cytokines 
will provide minimal pharmacological activity and no safety concerns at the starting dose of 3m g .
The proposed single ascending (SAD) doses for this study are 3, 10, 30, 100, 200 and 400 mg
to identify the expected clinically efficacious dose range in humans and to provide safety coverage for the expected clinically-relevant dose range. The margins for the highestproposed single dose (400 mg) established on the free exposures in rat are projected to be approximately 4- fold for C
maxand 3- fold for AUC 24which are well within the NOAEL 
exposure.
The resulting mean total and free exposures and associated margins following the proposed 
single doses of PF-06826647 during the single ascending dose period are provided inTable 3.
Table 3. Predicted Mean Human Total and Free Exposures and Associated Margins 
Following Single Dose Administration of PF-06826647
Dosea
(mg)Predicted 
Bioavailabilityb
(%)Predicted Human Exposure of plasma 
PF-06826647bPredicted Safety 
Margin based on 
freeplasma 
PF-06826647d
Free Cmax
(ng/mL)Total Cmaxc
(ng/mL)Free AUC 0-24
(ng•h/mL)Total AUC 0-24c
(ng•h/mL)CmaxeAUC 0-24f
3 88 7 19 90 237 260 185
10 87 23 61 296 778 80 56
30 84 66 [PHONE_13289] 28 20
100 69 [PHONE_13290] 6017 10 7
200 56 [PHONE_13291] 9701 6 5
400 41 444 1168 5409 [ZIP_CODE] 4 3
AUC 0-24= Area under the concentration time curve from time zero to 24 hours after single dose; CL = Clearance; 
Cmax= Peak plasma concentration; NOAEL = No observed adverse effects level.
a. Depending on the available safety and PK data, dose escalation may be adjusted to doses other than those 
outlined above with intermediate doses evaluated instead of or in addition to the planned dose levels while following dose escalation and stoppi[INVESTIGATOR_213850] 3.2 .
b. GastroPlus predicted. Exposure prediction was based on scaled clearance (CL = ~2 mL/min/kg) from human 
liver microsome and human hepatocytes.
c. Calculated using unbound values correcting for protein binding in humans (Human unbound fraction=0.38).d. Derived using Day 29 exposure of PF-6826647 at NOAEL (500 mg/kg/day) from 1 month rat toxicity study. 
Exposure on Day 29 in rats at 500 mg/kg/day (NOAEL): Total AUC
24=92,100 ng.h/mL, free 
AUC 24=16,600 ng.h/mL, Total C max=10,400 ng/mL,  free C max= 1870 ng/mL; rat unbound fraction = 0.18.
e. C maxMargins=C maxin Rat on Day 29/Predicted C maxin human post single dose.
f. AUC margins = AUC 24in Rat on Day 29/Predicted AUC 0-24in human post single dose.
The multiple dose period is planned to be initiated at the 10 mg QD dose level; however, the 
starting dose in MAD may be adjusted based on available PK, and safety data from the SAD cohorts.  Based on the predicted steady state exposures (C
max,ss and AUC 24,ss), 
10 mg QD is expected to provide margins of 71-fold for C max,ss and 50-fold for AUC 24,ss
relative to the free exposure in rat on Day 29.  The proposed doses for the multiple ascending dose (MAD) period are 10, 30, [ADDRESS_854345] margins of 5-fold and 4-fold for C max,ss and AUC 24,ss, respectively.
Listed in Table 4 are the mean exposure (total and free) and associated margins following the 
proposed QD dosing regimen for 10 days.
Table 4. Predicted Mean Human Total and Free Exposures and Associated Margins 
Following Once Daily Dosing of PF-06826647 for 10 Days
Dosea
(mg)
QDPredicted 
Bioavailabilityb
(%)Predicted Human Exposure of plasma 
PF-06826647bPredicted Safety 
Margin based on 
freeplasma 
PF-06826647d
Free Cmax
(ng/mL)Total Cmaxc
(ng/mL)Free
AUC 24,ss
(ng.h/mL)Total AUC 24,ssc
(ng.h/mL)CmaxeAUC 0-24f
10 87 26 69 332 874 71 50
30 84 76 [PHONE_13292] 25 17
100 69 [PHONE_13293] 7010 9 6
200 56 [PHONE_13294] [ZIP_CODE] 5 4
AUC 24,ss= Area under the concentration-time curve from zero to [ADDRESS_854346] dose at steady state; CL = Clearance; 
Cmax= Peak plasma concentration; C max,ss = Maximum concentration at steady state ; QD = Once daily
a. Depending on the available safety and PK data, dose escalation may be adjusted to doses other than those 
outlined above with intermediate doses evaluated instead of or in addition to the planned dose levels while 
following dose escalation and stoppi[INVESTIGATOR_213850] 3.2 .
b. GastroPlus predicted. Exposure prediction was based on scaled clearance (CL =~ 2 mL/min/kg) from human 
liver microsome and human hepatocytes.
c. Calculated using unbound values correcting for protein binding in humans (Human unbound fraction=0.38).
d. Derived using Day 29 exposure of PF-6826647 at NOAEL (500 mg/kg/day) from 1 month rat toxicity study. 
Exposure on Day 29 in rats at 500 mg/kg/day (NOAEL): Total AUC 24=92,100 ng.h/mL, free 
AUC 24=16,600 ng.h/mL, Total C max=10,400 ng/mL,  free C max= 1870 ng/mL; rat unbound fraction = 0.18.
e. C maxMargins=C maxin Rat on Day 29/Predicted C maxin human post single dose.
f. AUC margins = AUC 24in Rat on Day 29/Predicted AUC 0-24in human post single dose.
All the doses in SAD or MAD cohorts except starting dose of 3 mg in SAD cohort are 
nominal and may be adjusted, as the study progresses depending upon emerging PK,safety, and tolerability data.  Other intermediate doses or lower doses may be administered instead of the planned doses, or changes in dosing frequency or titration schemes may be proposed for MAD cohorts if safety/tolerability issues become apparent, if evidence of nonlinear PK dictates the need to escalate more slowly, or if subsequent doses are predicted to result in exposures that exceed the target limits.  However, the projected exposure for the modified doses or additional cohorts will be equal to or less than a free AUC of [ZIP_CODE] ng.h/mL or free C
maxof 1870 ng/mL following either single dose or multiple dose 
administration to ensure that the projected exposure of the altered planned dose scheme does not exceed the exposure limit.CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 381.3.4. Updated Dose Rationale Based on Emerging Clinical Data (Protocol 
Amendment 2, 20 December 2017)
Based on the evaluation of the emerging human PK data, the observed exposure was lower 
than predicted and the increase in exposure appears to be less than dose proportional except at 3 mg SAD (dosed as suspension). Protocol amendment 1 updates the initially proposed dose levels with the aim to achieve exposure that will allow a full exploration of the clinical efficacy in future clinical studies. Also, the MAD cohort will be dosed under fed conditionin a hope to improve the bioavailability of PF-06826647
Under protocol amendment 1, the proposed dose of SAD Cohort 5 will be 400 mg. 
Accounting for the less than dose proportional increase in AUC
24and C maxobserved at 
100 mg, 400 mg is predicted to provide approx imately ~2 fold higher expos ure than 100 mg.  
The doses of Cohort 6 and two optional SAD cohorts (Cohort 7 and Cohort 8) will be based on the emerging PK,  and Safety data but in all cases will be selected to provide a projected exposure of no more than approximatelly [ADDRESS_854347] dose cohort exposure and less or equal to the PK stoppi[INVESTIGATOR_227505]. All dose levels listed in Table 5 are 
nominal and any of the listed or intermediate doses may be used based on emerging PK,  and safety data. However, the maximum dose tested will not exceed 1600 mg (16 × 100 mg Tablets), based on practical limitations. The projected safety margin for AUC
24and C maxat 1600 mg SAD is approximately 8 and 7 fold, respectively ( Table 5 ). 
The projected PK parameters in Table 5 are based on preliminary exploratory population PK 
model from draft human PK data up to SAD Cohort 4, assuming nonlinear decrease in bioavailability with increase in dose. The projected geometric mean total and free exposures and the associated projected margins for doses (up to 1600 mg) are provided in Table 5 .CC
I
CC
ICCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 39 
 
  
 
 
 
 
 
 
 
 
 
 
   
 
  
 
 
 
 
 
 
 
 
  CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 40 
 
  
 
 
  
   
 
 
 
 
   
 
  
[IP_ADDRESS]. Dose Selection for Psoriasis Patients
Two cohorts of subjects with moderate to severe plaque psoriasis are proposed to be studied 
at two dose levels to be administered PF-06826647/placebo QD for 28 days. The initial psoriasis cohort will commence at 400 mg PF-06826647 (or placebo). The nominal dose for second psoriasis cohort dose level is planned to be 100 mg PF-06826647 (or placebo), whichmay be adjusted based on results from the 400 mg psoriasis cohort. These dose levels areselected based on preliminary PK, safety and tolerability data up to 1600 mg single dose in SAD Period and up to 400 mg QD for 10 days in MAD Period in healthy subjects.
Dose selection for this part of the study is based on the observed PF-06826647 exposure in 
healthy subjects and in vitro potency data aiming to achieve high inhibition of TYK2 dependent cytokines while maintaining selectivity over other JAK enzymes and modulation of associated genes. The C
av,24at steady state at 100 and 400 mg dose in healthy subjects 
was approximately 81 and 205 ng/mL, respectively. Based on the IC 50value of IL-12 (total 
IC50=53 nM) determined by [CONTACT_638783], RBC 
partition ratio of 1.4 and assuming Hill coefficient of 1, the average daily inhibition of IL-12 at 100 and 400 mg will be approximately 85 and 93%, respectiv ely. Similarly, IFN α (total 
IC
50= 66 nM) will have average daily inhibition of approximately 82 and 92% while the 
average inhibition of IL-23 (total IC 50= 112 nM) will be approximately 73 and 87% at CCI
CCI
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 41100and 400 mg,respectively .These two doses are also supported by  [CONTACT_638784]2 pharmacology  modulation of Ty pe-IIFNgene s.
In addition, based on data observed to date in healthy  subjects ( see Section 1.3.2 )these doses 
are expected to be safe and well tolerated. Although, based on in vitro data, the average 
inhibition of EPO (total IC 50= 547 nM) is expected to be approximatel y 35% and 58% at 
100and 400mg respectively , no clinicially  significant changes in hemoglobin w ereobserved
in healthy  subjects at the same dose. Based on the observed steady  state free exposures 
(Cmax,ss and AUC 24,ss), 400mgQDis expected to provide margins of about 7-fold for C max,ss
and about 
9-fold for AUC 24,ssrelative to the free exposure in rat on Day 29(NOAEL) . 
The initial psoriasis cohort will commence at 400 mg QD PF-06826647 for 28 days. Dosing 
of the second psoriasis cohort will occur after completion of 400 mg psoriasis C ohort 28 day  
dosing, while the follow up periods of the two cohorts may  be parallel or staggered based on 
operational considerations.  Following interim analy sis review of efficacy  data from 
21subjects (14active and 7 placebo) completing through study  Day28 in the [ADDRESS_854348] meal in order to achieve higher exposure.
2. STUDY OBJECTIVES AND ENDPOINTS
Objectives and Endpoints : Healthy Su bject Single and Multiple Ascending Dose Cohorts
Prim ary Objective (s): Prim ary Endpoint (s) - Safety : 
To determine the safety and tolerability of 
escalating single a nd multiple doses of 
PF-06826647 administered to healthy subjects.Vital signs (blood pr essure, pulse rate, oral 
temperature) .
Physical examination findings over time.
12-lead ECG parameters.
Incidence and severity of treatment emergent 
adverse events and withdrawals due to treatment 
emergent adverse events.
Incidence and magnitude of treatm ent emergent 
clinical laboratory abnormalities including 
hematology (with differentials ), fibrinogen,
chemistry, fasting glucose, lipi[INVESTIGATOR_805], urinalysis.
Change in 24hour creatinine clearance 
from 
Day -1and Day 10(MAD only).
Secondary Objective(s) : Second ary Endpoint (s): 
To characterize the PK of PF -06826647 in plasma 
and urine (urine PK in multiple ascending dose 
period only) following oral administration of Systemic pharmacokinetics parame ters(defined 
in Section 9.3.1 )will include :

PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 42escalating single and multiple oral doses to 
healthy subjects.•Single Dose: Cmax, Tmax, AUC inf, AUC last,
AUC 24,Cmax(dn), AUC inf(dn), AUC last(dn) , 
t½, MRT, V z/F, and CL/F (if data permit).
•Multiple Dose:
•Day 1: C max, Tmax, AUC tau (tau=12 or 
24 hours), C max(dn), AUC tau(dn).
•Day 10: C max, Tmax, AUC tau (tau=12 or 
24 hours), C max(dn), AUC tau(dn), t½, C min,
Cav,Rac, Rac,Cmax ,P T R ,  M R T ,  V z/F,CL/F (if 
data permit).
•Urinary Pharmacokinetics (defined in 
Section 9.3.1 ;for healthy subjects, multiple 
ascending dose period only): Ae tauand Ae tau%, 
CLr (if data permit).
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 43Objectives and Endpoints: Psoriasis Multiple Dose Cohorts
Primary Objectives - Safety Primary Endpoints - Safety
•To determine the safety and tolerability of 
multiple dose administration of PF-06826647 in 
psoriasis subjects.•Vital signs (blood pressure, pulse rate, and oral 
temperature).
•Physical examinations fndings over time.
•12-lead ECG parameters.
•Incidence and severity of treatment emergent 
adverse events and withdrawals due to treatment emergent adverse events.
•Incidence and magnitude of treatment emergent 
clinical laboratory abnormalities including hematology (with differentials) chemistry, fasting glucose, lipi[INVESTIGATOR_805], urinalysis.
Secondary Objectives Secondary Endpoints
•To characterize the PK of PF-06826647 in plasma 
following oral administration of multiple oral doses to plaque psoriasis subjects.
•To evaluate the efficacy of PF-06826647 in 
moderate to severe plaque psoriasis.•Multiple Dose
(defined in Section 9.3.1 ): C max, 
Tmax, AUC tau, C max(dn), AUC tau(dn), t ½, PTR, 
Cmin, Cav, MRT, V z/F and CL/F (if data permit).
•Change from baseline in psoriasis area and severity 
index (PASI) score at Day 28.
 
 
  
 
 
 
 
 
 
 
 
  
 
 CCI
CCI
PF-[ADDRESS_854349] Single and Multiple Ascending Dose Periods
In the combined single ascending and multiple ascending dose (SAD/MAD) healthy subject 
cohorts there will be approximately 8 subjects per dose level; 6 subjects will receive PF-06826647 and 2 subjects will receive placebo per the randomization code. 
Healthy subjects will be randomized (once) into the SAD period, at which time, they will 
receive treatment assignment (active PF-06826647 dose level or placebo) for both the SAD and MAD periods.  Subjects will receive the same blinded treatment assignment (ie, the same dose level of active PF-06826647 or placebo) throughout in both the SAD (Period 1) and MAD (Period 2) periods. 
During the single ascending dose (SAD) period, healthy subjects in Cohort 1 to Cohort 6 will 
receive single doses of 3, 10, 30, 100, 400, or 1600 mg of PF-06826647 or placebo in a dose escalation format as shown in the Study Schema ( Figure 1 ).  The doses and meal condition of
optional cohorts (Cohort 7 and Cohort 8) will be decided on emerging PK, and safety data from prior SAD and MAD cohorts. Dose escalation to subsequent cohorts will be based on a minimum of 3 days of safety data and PK over 24 hours in a minimum of 6 subjects enrolled in a cohort.  Subjects will reside in the clinical research unit (CRU) for the single ascending dose phase from Day -1 until completion of protocol assessments on 
Day 4.  Dosing occurs on Day 1.  Subjects will return to the unit on Day 8 ( ±1) day for the 
end of single dose period assessment and PK sample.
At least 14 days (minimum wash-out period) will separate the beginning of the single and 
multiple dose periods (ie, at least [ADDRESS_854350] QD dose in the MAD); however, the minimum wash-out period may be adjusted based on emerging PK data.  Based on the PK predictions and emerging PK data from this study, the currently planned starting dose in the MAD period is 30 mg (previously, a PF-06826647 starting dose of 10 mg was planned for the MAD period under the original protocol) is not expected to provide pharmacologically relevant exposure.  In the multiple ascending dose (MAD) period, healthy subjects in Cohort 3 to Cohort 6 in Period 2 will receive doses of 30, 100, 400, or 1200 mg QD of PF-06826647 or placebo for 10 days (Day 1 through Day 10) with standard meal. The dose of Cohort 6 in MAD (Period 2) may be adjusted based on emerging data from earlier MAD cohorts in the trial. Subjects will be housed for the duration of the multiple dosing period, discharged on the morning of Day 14. Subjects will return for outpatient visits on morning of Day 17 for PK sample collection and 
Day 28 ( ±3 days) for end of study procedures. Based on emerging PK data, subject may be 
asked to return between Day 17 and Day 28 for an additional outpatient visit for PK sample CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 46collection. The additional PK sample will allow characterization of terminal half-lives at 
higher dose cohorts. 
The multiple ascending dose study is planned to be initiated in the same subjects who 
previously participated in the single dose period at the same dose level, when possible(except for the optional twice daily, BID cohort and optional Japanese cohort).  The highest dose to be tested in MAD will not exceed the highest dose tested in SAD cohort. Except the highest dose cohort, dosing in the MAD period will commence at the intended dose level(eg, 30 mg QD) if adequate single dose safety is demonstrated for next dose level (eg, 100 mg SAD). Subsequent MAD cohorts at higher dose levels (eg, 100 mg QD) will not be initiated until the single dose safety/tolerability has been established up to next dose level (eg, 400 mg), and a minimum of 10 days of safety and PK data from the preceeding multiple dose cohort (eg, 10 mg QD) from at least 6 subjects (with at least one subject on placebo) has been reviewed.  The remainder of the cohorts (except highest dose cohort) will follow a similar escalation paradigm.  Dosing in highest dose MAD cohort will commence if adequate safety is demonstrated in SAD cohort at the same or higher dose level and the projected exposure at steady state does not exceed NOAEL. 
Twice daily (BID) dosing (for 10 days) may be evaluated as a separate cohort based on 
emerging PK data from this FIH study. Dosing in the BID cohort will not commence until review of safety data from the equivalent QD MAD cohort (minimum review of [ADDRESS_854351] on placebo).
An optional Japanese cohort may also be included. If conducted, the dose administered will 
be equal to or less than the maximum PF-06826647 dose level administered in the healthy volunteer MAD period.  Up to 8 subjects (including subjects on placebo) may be included in the optional Japanese cohort. 
Administration of investigational product will be in fasted state in the SAD period and under 
standard meal conditions in MAD and in psoriasis cohorts. Based on the emerging PK,  
and safety data, the meal condition requirement in SAD, MAD and psoriasis 
cohorts may be changed. 
During the single and multiple ascending dose periods the dose increments and planned 
doses may be adjusted, as the study progresses dependent upon emerging PK, safety, and tolerability data.  Other intermediate doses or lower doses may be administered instead of the 
planned doses, or changes in dosing frequency or titration schemes may be proposed for 
MAD cohorts if safety/tolerability issues become apparent, if evidence of nonlinear PK dictates the need to escalate more slowly, or if subsequent doses are predicted to result in exposures that exceed the target limits.  Any potential altered dose scheme will be equal to or less than a projected 3-fold increase in exposure from the previous highest dose if a higher dose is warranted to achieve exposure. The projected exposure will be equal to or less than a free AUC of [ZIP_CODE] ng.h/mL or free C
maxof 1870 ng/mL following either single dose or 
multiple dose administration to ensure that the projected exposure of the altered planned dose scheme does not exceed the exposure limit.CCI
PF-[ADDRESS_854352] cohorts, approximately 42 subjects will be enrolled 
with approximately 14 subjects receiving placebo, and approximately 28 subjects receiving one of two possible PF-06826647 dose levels, for 28 days.  PF-06826647 dose range for the psoriasis cohorts will be selected based on emerging PK,  and safety data from the healthy subjects SAD/MAD periods. Refer to Protocol Section [IP_ADDRESS] for psoriasis dose 
selection rationale. QD dosing is planned for psoriasis subjects, however, daily dosing regimen (eg, QD, BID) may be adjusted based on emerging PK data from the SAD/MAD periods. Psoriasis subjects who discontinue early from the trial may be replaced at the discretion of the sponsor. PF-[ADDRESS_854353] MAD period.  Psoriasis subjects enrolled into the multiple dosing period will receive PF-06826647 or placebo (QD) for [ADDRESS_854354] dose.  Doses will be selected based on emerging PK, PD and safety data from the study (notto exceed C
maxand AUC 0-24limits of 1870 ng/mL and 16,600 ng·h/mL, resp ectively).  
Dosing in psoriasis subjects will commence if adequate safety is demonstrated in healthy subjects participating in the MAD period at the equivalent dose level. At a minimum, [ADDRESS_854355] 6 healthy subjects (with at least one subject on placebo) receiving the equivalent QD dose level will be reviewed to confirm that a given PF-06826647 dose is safe and well tolerated before administering PF-06826647 to psoriasis subjects. Subjects will be housed through Day 28 of the multiple dosing period, discharged 
on Day 28, to return for outpatient visits on the mornings of Days 35 ( ±3 days), 42 ( ±3 days), 
56 (±3 days) and 84 ( ±3 days)(end of study). The 28 day treatment duration is supported by 
[CONTACT_638785] , as well as assessment of clinical endpoints (eg, PASI). CCI
CC
I
CCI
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 48Figure 1.Study Schema
Numbers 1 –
8refer to subject cohorts.  Subjects completing the SAD period w ill continue into the MAD period
when applicable, after protocol defined washout and follow up. 
*Cohorts 7 and 8 are optional single dose cohorts that may be conducted at discretion of Sponsor and based on 
emerging PK data. If conducted, the dose and meal condition will be decided based on emerging PK, PD, and 
safety data from the multiple ascendi ng dose period of the trial.
**Cohort 9 is an optional cohort for assessment of twice daily (BID) PF -06826647 dosing. BID dose level will 
be determined based on emerging PK, PD, safety and tolerability data. The planned PF -06826647 dose level to 
be adm inistered in the BID cohort is 200 mg twice daily (total daily dose of 400 mg).
*** B ased on interim analysis results from 400mg psoriasis cohort, thePF-[ADDRESS_854356] MAD period.
HVs = healthy volunteers
All cohorts are placebo controlled .
Note on optional Japanese subject cohort : if conducted, administration of PF -06826647 (or matching placebo) 
to Japanese subjects will occur once daily for 10 day duration , and subjects w ill follow the MAD period 
schedule of activities . 

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 49Figure 2. Legend for Figure 1
SAD = Single ascending dose Period 1                 QD = once daily 
MAD=multiple ascending dose Period 2              BID=twice daily 
3.2.Dose Escalation and Stoppi[INVESTIGATOR_638745] d ose escalation rules appl y to the single and multiple ascending dose healthy 
subject cohorts.  Individual stoppi[INVESTIGATOR_638746] (SAD/MAD) and psoriasis 
subjects are also outlined below.
Dose -escalation stoppi[INVESTIGATOR_638747] e whether the maximal tolerated dose 
has been attained.  Dose escalation may  be stopped if it is determined that the limits of safety  
and/or tolerability  have been reached.  This decision will be made after a discussion takes 
place between the sponsor stud y team and the investigator.  The sponsor study team may not 
overrule the investigator’s decision to stop dose escalation.  If dose escalation is stopped 
because of an y of these criteria, additional cohorts may receive the same or lower doses of 
the invest igational product.
The dose escalation will be terminated based on the following criteria:
If 50% or more of the subjects receiving active drug at a given dose level (but not 
subjects receiving placebo) develop similar clinically  significant laboratory , 
electrocardiogram (ECG), or vital sign abnormalities as described below in 
Section 3.3), or severe adverse events (AEs) in the same organ class, indicating 
dose-limiting intolerance.
Dosing will be paused for an y serious adverse event (SAE) that occurs in a subject 
receiving active treatment until causality  is fully  assessed by  [CONTACT_458] 
(PI) and sponsor.  Dosing may
 resume if the SAE is determined to be not drug -related 

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 50by [CONTACT_941] P I and sponsor.  If the SAE is determined to be either drug -related or 
unknown, either dosing will cease or the SAE will be evaluated b y the sponsor’s 
protocol review committee (or similar review group), which is independent of the 
study  team and investigat ors.  If the protocol review committee determines that 
dosing may  resume, a plan that mitigates risks to subjects with the resumption of 
dosing will be implemented.  Such a plan could include a revision of 
inclusion/exclusion criteria, repeating or reducin g the dose, or adding appropriate 
safet y monitoring.
It is determined that the limit of safety  and/or tolerability  has been reached.  This 
decision will be made following discussions between the study  team and the 
investigator.
Other findings that, at the discretion of the stud y team and investigator, indicate that 
dose escalation should be halted.
If, at an y dose level, the average exposure reaches or exceeds the pharmacokinetic 
(PK) stoppi[INVESTIGATOR_638748] C maxand AUC 0
-24values of 1870 ng/mL  and 
16,600 ng.h/mL , respectively .
If, based on the observed
data, the group mean maximum observed concentration 
(Cmax) or area under the curve (AUC) (based on total plasma concentration) of the 
next planned dose is projected to exceed the escalation limits, tha t dose will not be 
explored.  Modified doses may be explored if they are not expected to exceed PK 
stoppi[INVESTIGATOR_3418].
Progression to the next single dose level will occur if the last dose was well tolerated and 
after satisfactory  review of the available sa fety and PK data.  Minimum data required for 
dose escalation review includes 24 hour PK data, adverse event/serious adverse events, vital 
sign and ECG data, urinaly sis, chemistry  and hematology  laboratory  results through Day [ADDRESS_854357] 6subjects (with at least one subject on placebo) within a given dose cohort .
Initiation of the multiple ascending dose stud y will commence at the 10 mg dose level if 
adequate safet y is demonstrated for single doses up to 30 mg. Similarly , the 30 mgdose 
level will not be initiated until the safety /tolerability  has been established up to100 mg single 
dose and a minimum of 10days of safety  data (vital sign and ECG data, urinaly sis, 
chemistry , hematology , adverse event data) and 10day PK data from the preceding multiple
dose cohort from at least 6subjects (with at least one subject on placebo). The remainder of 
the cohorts will follow a similar escalation paradigm (except for the highest MAD cohort 
dose level, which will be equal to or less than the maximum SAD dose level tested) .Dosing 
in highest dose MAD cohort will commence if adequate safet y is demonstrated in SAD 
cohort at the same or higher dose level and the projected exposure at steady state does not 
exceed NOAEL. Dose l evels may  be adjusted based on emerging PK data from this study , 
however, this escalation paradigm will still apply . 

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 513.3.Individual Stoppi[INVESTIGATOR_638749]:
Dosing will be discontinued for an y treatment emergent serio us adverse event (SAE) 
that occurs in a subject receiving active treatment unless the SAE is clearl y unrelated 
to study  drug (eg, subject is the victim of a motor vehicle accident).
Serious infections, defined as an y infection (viral, bacterial, and fungal ) requiring 
parenteral antimicrobial therap y or hospi[INVESTIGATOR_059] .
Laboratory, Vital Sign, and ECG Abnormalities:
Individual stoppi[INVESTIGATOR_638750] (single repeat preferabl y 
performed within 24 hours of initial result) of the para meters outlined below. 
Grade 3 lymphopenia (<500 cells/mm3).
Grade 3 neutropenia (<1000 cells/mm3).
Grade 3 ALT/AST (>5x upper limit of normal (ULN) when not accompanied by  [CONTACT_638786]).
Grade 3 bilirubin (>2.[ADDRESS_854358] when not accompanied by  [CONTACT_638787]/AST).
Changes in liver function tests that meet Hy ’s Law criteria.
Serum creatinine 1.[ADDRESS_854359]. 
Note : An increase of  0.3mg/dL  (or 26.5mol/L) in serum creatinine relative to 
subjects’ own baseline measurement should trigger another a ssessment of SCr within 
24-hours from awareness.   See Potential Cases of Acute Kidney  Injury for further 
guidance. 
Grade 2 
Hemoglobin < 10g/dL .
Grade 2 Platelets < 75,000/mm3or >750,000/mm3.
12-lead ECG demonstrating QTc 500; or a QRS interval 140msec or 50% 
increase from baseline; PR interval 300msec or 25% increase over baseline when 
baseline >[ADDRESS_854360], 
supi[INVESTIGATOR_050].  If confirmed to be abnormal and confirmed to be clinically  significant by  
[CONTACT_1697], dosing should be stopped and the blood pressure/pulse should be followed 

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 52periodicall y, as deemed appropriate b y the investigator, until the blood pressure/pulse rateare 
returned to within normal limits or deemed acceptable b y the investigator.
Vital sign abnormalities: 
Systolic blood pressure <90 mmHg or >160 mm Hg;
Diastolic blood pressure <50 mmHg or >100 mm Hg;
Pulse rate supi[INVESTIGATOR_050]/sitting <36 or >120 beats per minute (bpm); standing <36 or 
>140 bpm.
Other:
Subjects non- compliant with study  treatment .
3.4. Individual Stoppi[INVESTIGATOR_638751] -[ADDRESS_854361] withdrawn from this 
study for:
Adverse Events:
Serious infections, defined as an y infection (viral, bacterial, and fungal) requiring 
parenteral antimicrobial therap y or hospi[INVESTIGATOR_059] .
Other treatment emergent serious or severe AEs, after c onsultation with the [COMPANY_007] 
clinician.
Laboratory, Vital Sign, and ECG Abnormalities:
Individual stoppi[INVESTIGATOR_638752] (single repeat preferabl y 
performed within 24 hours of initial result) of the parameters outlined below . 

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 53Laboratory Variable Laboratory Value
Hem atology
Absolute Neutrophil Count <1000/mm3; <1.0 x109/L
Hem oglobin <10.0 g/dL; <6.2 mmol/L; <100 g/L
Platelet count <75,000/mm3; <75.0x 0x109/L
WBC <3000/mm3; <3.0x109/L
Lymphocytes <800/mm3; <0.8x109/L
Chemistry
AST >2.5x ULN
ALT >2.5x ULN
Creatinine (serum) >1.5x ULN
Total bilirubina>1.5x ULN
aTotal bilirubin 1.5xULN; subjects w ith a history of Gilbert's syndrome may have a direct bilirubin 
measured and w ould be eligible for this study provided the direct bilirubin is ULN.
Changes in liver function tests that meet Hy ’s Law criteria.
Note : An increase of  0.3mg/dL  (or 26.5mol/L) in serum creatinine relative to subjects’ 
own baseline measurement should trigger another assessment of SCr with in 24-hours from 
awareness.   See Potential Cases of Acute Kidney  Injury for further guidance.
12-lead ECG demonstrating QTc 500; or a QRS interval 140msec or 50% 
increase from baseline; PR interval 300msec or 25% increase ov er baseline when 
baseline >[ADDRESS_854362], supi[INVESTIGATOR_050].
  If 
confirmed to be abnormal, and confirm ed to be clinically  significant by  [CONTACT_1697] , dosing 
should be stopped and 
the blood pressure should be followed periodicall y, as deemed 
appropriate b y the investigator, until the blood pressure are returned to within normal limits 
or deemed acceptable by [CONTACT_093].
Diastolic: recurrent or persistent ( 24hrs) or s ymptomatic increase from baseline, in 
same posture, b y >20 mmHg.
Systolic: recurrent or persistent ( 24hrs) or s ymptomatic increase from baseline, in 
same posture, b y >30 mm Hg. 
Other:
Subjects non- compliant with study  treatment .

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 543.5.Discontinuation/End of Treatment Monitoring for Adverse Events, Laboratory, 
Vital Signs and ECG Abnormalities
Any subject meeting discontinuation criteria will be followed up every  [ADDRESS_854363]
is suitable for this protocol.
4.1. Inclusion Criteria: Healthy Subject Single/Multiple Ascending Dose Cohorts
Subject eligibility  should be reviewed and documented by  [CONTACT_4653]’s study team before subjects are included in the study .
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the 
study:
1.Health y female subjects of non- childbearing potential and/or male subjectsbetween 
the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant 
abnormalities identified by  a detailed medical history , full phy sical examination, 
including blood pressure and pulse rate measurement, 12- lead ECG and clinical 
laboratory  tests).
2.Female subjects of non -childbearing potential must meet at least 1 of the following 
criteria:
a.Achieved postmenopausal status, defined as follows: cessation of re gular menses 
for at least 12 consecutive months with no alternative pathological or 
physiological cause; and have a serum follicle -stimulating hormone (FSH) level 
confirming the post-menopausal state.
b.Have undergone a documented hy sterectomy  and/or bilater al oophorectomy .
c.Have medically  confirmed ovarian failure.
All other female subjects (including females with tubal ligations ) areconsidered to be 
of childbearing potential.
3.Body  Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg 
(110 lbs).

PF-[ADDRESS_854364] has been informed of all pertinent aspects of the study .
5.Subjects who are willing and able to comply with scheduled visits, treatment plan, 
laboratory  tests, and other study  procedures.
6.No evidence of active or latent or inadequately  treated infection with M ycobacterium 
tuberculosis (TB) as defined by  [CONTACT_716]:
a.negative Interferon Gamma Release Assay  (IGRA) (with the following acceptable 
assay s: QuantiF ERONR-TB Gold (QFT- G) test, T-SPOT TB , QuantiFERON -TB 
Gold I n-Tube test (QFT -GIT))performed during Screening or within [ADDRESS_854365] who is currently being treated for either latent or active TB infection is to be 
excluded.
7.Additional criterion for subjects to be enrolled in Japanese cohort onl y: Japanese 
subjects who have four Japanese biologic grandparents born in Japan.
4.2.Exclusion Criteria: Healthy Subject Single/Multiple Ascending Dose Cohorts 
Subjects presenting with any  of the following characteristics/conditions will not be included 
in the study :
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psy chiatric, neurologic, or 
allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at time of dosing).
2.Any condition possibly  affecting drug absorption (eg, gastrectomy ).
3.A positive ur ine drug screen.
4.History  of regular alcohol consumption exceeding 7 drinks/week for females or 
14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces 
(360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of s creening.
5. Treatment with an investigational drug within 30 days (or as determined by  [CONTACT_395097]) or [ADDRESS_854366] , 
whichever is longer .

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 566.Screening supi[INVESTIGATOR_9204] 140mm Hg (s ystolic) or  90mm Hg (diastolic), 
following at least [ADDRESS_854367].  If blood pressure (BP) is 140mm Hg 
(systolic) or  90 mm Hg (diastolic), the BP should be repeated two more times and 
the average of the three BP values should be used to determine the subject’s 
eligibility .
7. 12- lead ECG demonstrating QTc >450, or a QRS interval >120 msec at Screening.  If 
QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two 
more times and the average of the three QTc (or QRS) values should be used to 
determin
e the subject’s eligibility .
8.Subjects with ANY of the following abnormalities in clinical laboratory  tests at 
screening, as assessed b y the study -specific laboratory  and confirmed b y a single 
repeat, if deemed necessary :
Serum creatinine level above the up per limit of normal or an estimated 
Glomerular Filtration Rate (GFR) value 80mL/min, based on the 
Cockcroft -Gault calculation, at Screening (see Appen dix2).
Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transmi nase 
(SGOT) or alanine aminotransferase (ALT)/serum glutamic py ruvic transminase 
(SGPT) 
values more than 1.5 times the upper limit of normal.
Fasting glucose >110 mg/dL .
Total bilirubin 1.[ADDRESS_854368].
A white blood cell count below 4.5x103/mm3, including hi story  of benign ethnic 
neutropenia.  Subjects with borderline clinical laboratory  values outside the 
reference range may  be included in the study  if the investigator deems that the 
values are not clinically  significant.
Absolute neutrophil count of <2 x 109/L (<2000/mm3).
Hematocrit below 38% for males and 33% for females.  Subjects with borderline 
clinical laboratory  values outside the reference range may  be included in the study  
if the i nvestigator deems that the values are not clinically  significant.
Red blood cell and reticulocy tes outside the reference range at screening Subjects 
with borderline clinical laboratory  values outside the reference range may  be 
included in the study  if the Investigator deems that the values are not clinically  
significant.
Platelet counts below LLN .  Subjects with borderline clinical laboratory  values 
outside the reference range may  be included in the study  if the i nvestigator deems 
that the values are not clinically  significant.

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 579.Any medical history  of disease that has the po tential to cause a rise in total bilirubin 
over the upper limit of normal (ULN).  Subjects with borderline clinical laboratory  
values outside the reference range may  be included in the study  if the i nvestigator 
deems that the values are not clinically  significant.
Note: Subjects with a history  of Gilbert’s s yndrome may have a direct bilirubin 
measured and would be eligible for this study  provided the direct bilirubin is  ULN.
10.Pregnant female subjects ; breastfeeding female subjects; female subjects of 
childbearing potential.
11. Fertile m alesubjects who are unwilling or unable to use a highly  effective method of 
contraception as outlined in this protocol for the duration of the study and for at least 
28days after the last dose of investigational product.
12.Herba l supplements and and hormone replacement therapy  must be discontinued 
28days prior to the first dose of study  medication.  As an exception, 
acetaminophen/paracetamol may  be used at doses of 1g/day .  Limited use of 
non-prescription medications that are not believed to affect subject safety  or the 
overall results of the study  may  be permitted on a case -by-case basis following 
approval b y the sponsor . 
13.Use of prescription or nonprescription drugs and dietary  supplements within 7 days or 
5half-lives (which ever is longer) prior to the first dose of study  medication.   As an 
exception, acetaminophen/paracetamol may  be used at doses of 1g/day .  Limited 
use of nonprescription medications that are not believed to affect subject safety  or the
overall results of the study  may  be permitted on a case by  [CONTACT_638788] b y the sponsor . 
14.Blood donation (excluding plasma donations) of approximately  1pi[INVESTIGATOR_11731] (500 mL) or 
more within 56 days prior to dosing.
15.History  of sensitivity  to heparin or heparin -induce d thrombocy topenia. 
16.Unwilling or unable to comply  with the Lifestyle Requirements (Section
4.6)
described in this protocol.
17.Other severe acute or chronic medical or psychiatric condition including recent 
(within the past y ear) or active suicidal ideation or behavior or laboratory  abnormality  
that may  increase the risk associated with study
 participation or investigational 
product administration or may  interfere with t he interpretation of study  results and, in 
the judgment of the investigator, would make the subject inappropriate for entry  into 
this study .

PF-[ADDRESS_854369] a history  of any  lymphoproliferative disorder (such as Ep stein Barr Virus 
[EBV] -related lymphoproliferative disorder, as reported in some subjects on other 
immunosuppressive drugs), history  of lymphoma, leukemia, my eloproliferative 
disorders, multiple my eloma, or signs and sy mptoms suggestive of current ly mphati c 
disease.
21.Have a clinically  significant infection currentl y or within [ADDRESS_854370] dose of 
study  drug (eg, those requiring hospi[INVESTIGATOR_638753]), or a history  of chronic or recurrent infectio us disease.
22.Have or have had s ymptomatic herpes zoster or herpes simplex within 12 weeks, 
more than one epi[INVESTIGATOR_638754], or a history  (single epi[INVESTIGATOR_1865]) of 
disseminated zoster.
23.Are known to be infected with human immunodeficiency  virus (HIV) o r hepatitis B 
or C viruses. 
24.Subjects with a history  of cancer with the exception of adequately treated basal cell or 
squamous cell carcinoma of the skin.
25. Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within [ADDRESS_854371] undergone significant trauma or major surgery  within 4 weeks of Screening.
28.
Use of tobacco/nicotine containing products in excess of 5cigarettes/day .
29.Consumption of grapefruit or grapefruit juice or citrus fruits eg, Seville oranges, 
pomelos within [ADDRESS_854372] dose of study  medication until collection of 
the final pharmacokinetic blood sample.
30.Subjects who received (within 4weeks of first dose of PF -06826647) or were likel y 
to receive during the study  any of the medications listed in protocol Appendix 3.

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 594.3. Inclusion Criteria: Psoriasis Multiple Dose Cohorts
Subject eligibility  should be reviewed and documented by  [CONTACT_4653]’s st udy team before subjects are included in the study .
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the 
study :
1. F emale subjects of non -childbearing potential and/or m ale subjects with a diagnosis 
of plaque psori asis who are between the ages of [ADDRESS_854373] 1 of the following 
criteria:
a.Achieved postmenopausal status, defined as follows: cessation of regular menses 
for at least 12 consecutive months with no alternative pathological or 
physiological cause; and have a serum FSH level confirming the post menopausal 
state.
b.Have undergone a documented hy sterectomy  and/or bilateral oophorectomy .
c.Have medically  confirmed ovarian failure.
All o ther female subjects (including females with tubal ligations ) areconsidered to be 
of childbearing potential.
3.Body  Mass Index (BMI) of 17.5 to 37.5 kg/m2; and a total body weight >50 kg 
(110 lbs).
4.Evidence of a personally signed and dated informed consent document indicating that 
the subject has been informed of all pertinent aspects of the study .
5.Subjects who are willing and able to comply with scheduled visits, treatment plan, 
laboratory  tests, and other study  procedures.
6. Have a diagnosis of plaque psoria sis for at least [ADDRESS_854374] 15% of total BSA at Day -1 (prior to 
randomization in the study ).
8.Have a PASI score of 12 or greater at Day -1(prior to randomization in the study ).
9.Be a can didate for phototherapy  or systemic treatment of psoriasis (either naïve or 
history  of previous treatment) in the opi[INVESTIGATOR_871].
10. Must agree to avoid prolonged exposure to the sun and avoid other ultraviolet light 
sources during the stud y (eg,tanning beds).

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 6011.No evidence of active or latent or inadequately  treated infection with M ycobacterium 
tuberculosis (TB) as defined by  [CONTACT_716]:
a.negative Interferon Gamma Release Assay  (IGRA) (with the following acceptable 
assay s: QuantiFERONR-TB Gold ( QFT -G) test, T- SPOT TB , QuantiFERO N -TB 
Gold I n-Tube test (QFT -GIT))performed during Screening or within [ADDRESS_854375] has previously  receive d an adequate course of therapy  for either latent 
(9months of isoniazid in a locale where rates of primary  multi- drug resistant TB 
infection are <5%) or active TB infection, a QFT Gold test need to be obtained, but a 
chest radiograph or other appropriate image negative for active TB infection, must 
still be obtained if not done so within the prior [ADDRESS_854376] who is currently being treated for either latent or active TB infection is to 
be excluded.
4.4. Exclusion Criteria: Psoriasis Multiple Dose Cohort
Subjects presenting with any  of the following characteristics/conditions will not be included 
in the study :
1.Currently  have non- plaque forms of psoriasis, eg, ery throdermic, guttate, or pustular 
psoriasis.
2.Have current drug -induced psoriasis, eg, a new onset of psoriasis or an exacerbation 
of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or 
lithium.
3. If planned initiation of, or changes to, concomitant medication that could affect 
psoriasis (eg, beta blockers, calcium channel bl ockers, antimalarial drugs or lithium) 
are to occur within 2 weeks prior to randomization and/or during the study .
4.Subjects with ANY of the following abnormalities in clinical laboratory  tests at
screening, as assessed b y the study -specific laboratory  and confirmed b y a single 
repeat, if deemed necessary :
a.Hemoglobin:
If the hemoglobin level is greater than 5% below the lower limit of normal 
(LLN), subject is to be excluded;

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 61If the hemoglobin level is within 5% below the LLN, iron and folate levels are 
to be measured: if iron and/or folate levels are below the LLN, subject is to be 
excluded.
b. Absolute neutrophil count of <2 x 109/L (<2000/mm3).
c.Platelet count below the LLN .
d.Serum creatinine level above the upper limit of normal or an estimated 
Glomerular Filtr ation Rate (GFR) value 80mL/min, based on the 
Cockcroft -Gault calculation, at Screening (see Appendix 2).
e.Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transminase 
(SGOT) or alanine aminotransferase (ALT)/serum glutamic py ruvic transminase 
(SGPT) 
values more than 1.5 times the upper limit of normal.
f.Fasting glucose >140 mg/dL .
g.Total bilirubin 1.[ADDRESS_854377]; subjects with a history of Gilbert's syndrome may 
have a direct bilirubin measured and would be eligible for this study  provided the 
direct bilirubin is ULN.
5.Any psychiatric condition including recent or active suicidal ideation or behavior that 
meets an y of the following criteria:
Suicidal ideation associated with actual intent and a method or plan in the past
year: “Yes” answers on items 4 or 5 of the Columbia suicide severit y rating scale 
(C-SSRS) ( Appendix 9).
Previous history  of suicidal behaviors in the past 5 years: “Yes” answer (for 
events that occurred in the past 5 years) t o any of the suicidal behavior items of 
the C -SSRS.
Any lifetime history  of serious or recurrent suicidal behavior. 
Suicidal behaviors questionnaire –revised (SBQ -R) (Appendix 10) total score 8.
Clinically  significant depress ion: patient health questionnaire – 8 items (PHQ -8) 
(Appendix 11)when the total score 15.
The presence of any current major psychiatric disorder that is not explicitly 
permitted in the inclusion/exclusion criteria. 
In the op inion of the investigator or [COMPANY_007] (or designee) exclusion is required.

PF-[ADDRESS_854378] current or recent history  of severe, progressive, or uncontrolled renal, hepatic, 
hematological, gastrointestinal, metabolic, endocrine, pulmonary , cardiac, 
neurological or aller gic disease (including drug allergies, but excluding untreated, 
asymptomatic, seasonal allergies at time of dosing).
7.Will have vaccination with live virus, attenuated live virus, or an y live viral 
components within the [ADDRESS_854379] a history  of any  lymphoproliferative disorder (such as Epstein Barr Virus 
[EBV] -related lymphoproliferative disorder, as reported in some subjects on other 
immunosuppressive drugs), history  of lymphoma, leukemia, myeloproliferative 
disorders, multiple my eloma, or signs and sy mptoms suggestive of current ly mphatic 
disease.
10.Have a clinically  significant infection currentl y or within [ADDRESS_854380] dose of 
study  drug (eg, those requiring hospi[INVESTIGATOR_638755] y or 
opportunistic infections), or a history  of chronic or recurrent infectious disease.
11.Have or have had s ymptomatic herpes zoster or herpes simplex within 12 weeks, 
more than one epi[INVESTIGATOR_638754], or a h istory  (single epi[INVESTIGATOR_1865]) of 
disseminated zoster.
12.Any prior treatment with ly mphocy te depleting agents/therapi[INVESTIGATOR_014] (such as CamPath
[alemtuzab], alky lating agents [eg, cy clophosphamide or chlorambucil],total 
lymphoid irradiation, etc).
13.Have an y condition poss
ibly affecting oral drug absorption, gastrectom y, or clinically 
significant diabetic gastroenteropath y.
14.History  of regular alcohol consumption exceeding 7 drinks/week for females or 
14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces
(360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
15. 12- lead ECG demonstrating QTc >450, or a QRS interval >120 msec msec at 
Screening.  If QTc exceeds 450 msec or QRS exceeds 120 msec, the ECG should be 
repeated two more t imes and the average of the three QTc (or QRS) values should be 
used to determine the subject’s eligibility .

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 6316.Screening supi[INVESTIGATOR_9204] 160mm Hg (s ystolic) or 100mm Hg (diastolic), 
following at least [ADDRESS_854381].  If blood pressure (B P) is 160mm Hg 
(systolic) or  100 mm Hg (diastolic), the BP should be repeated two more times and 
the average of the three BP values should be used to determine the subject’s 
eligibility .
17.Herbal supplements and and hormone replacement therap y must be dis continued 
28days prior to the first dose of study  medication.  As an exception, 
acetaminophen/paracetamol may  be used at doses of 1g/day .  Limited use of 
non-prescription medications that are not believed to affect subject safety  or the 
overall results of the study  may  be permitted on a case -by-case basis following 
approval b y the sponsor.
18.Donated blood in excess of 500 mL (excluding plasma donations) within [ADDRESS_854382] dose of study  drug.
19.
Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within [ADDRESS_854383] undergone significant trauma or major surgery  within 4 weeks of Screening.
23.Are known to be infected with human immunodeficiency  virus (HIV) or hepatitis B 
or C viruses. 
24.Have participated in an y other studies with JAK inhibitors with in 3months prior to 
dosing.
25.In the opi[INVESTIGATOR_22747], will be uncooperative or unable to comply  
with study  procedures.
26. Have participated in other studies involving investigational drug(s) within 30 days or 
5half-lives (whichever is lo nger) prior to study  entry  and/or during study  
participation.
27.Other acute or chronic medical or ps ychiatric condition including recent (within the 
past y ear) or active suicidal ideation or behavior or laboratory  abnormality  that may  
increase the risk assoc iated with study  participation or investigational product 
administration or may  interfere with the interpretation of study  results and, in the 
judgment of the investigator, would make the subject inappropriate for entry  into this 
study .

PF-[ADDRESS_854384] of the study .
30.Pregnant female subjects ; breastfeeding female subjects; female subjects of 
childbearing potential.
31. Fertile m ales subjects who are unwilling or unable to use a highly  effective method of 
contraception as outlined in this protocol for the duration of the study and for at least 
28days after the last dose of investigational product.
32. Use of tobacco/nicotine containing products in excess of 5cigarettes/day .
33.A positive urine drug screen.
34. Consumption of grapefruit or grapefruit juice or citrus fruits eg, Seville oranges, 
pomelos within [ADDRESS_854385] dose of study  medication until collection of 
the final pharmacokinetic blood sample.
35.Require treatment with prohibite d concomitant medication(s) listed in Appendix 3or 
have received a prohibited concomitant medication in the [ADDRESS_854386] be on a stable regimen, which is defined as not starting a new drug or 
changing dosage within 2 weeks or 5 half-lives (whichever is longer) prior to first 
dose of study  drug.
36.Have previously  been treated with efalizuma b (Raptiva).
37.Have previously  been treated with secukinumab (Cosenty x) or ixekizumab (Taltz) .
38.Have previously  been treated with ustekinumab (Stelara).
39.Have received an y of the following treatment regimens specified in the timeframes 
outlined below:
Biolog ic therapi[INVESTIGATOR_109006] (including brodalumab) have discontinuation periods 
determined from approximately  5x half -life of the respective biologic .
Within [ADDRESS_854387] dose of study drug:
Any experimental therapy  for psoriasis
, psoriatic arthritis, or rheumatoid arthritis.

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 65Exception: Investigational biologics should be discussed with the [COMPANY_007] Medical 
Monitor (or designee) to confirm period of dis continuation required.
Apremilast (Otezla) .
Within [ADDRESS_854388] dose of study drug:
Adalimumab (Humira);
Certolizumab pegol (Cimzia);
Infliximab (Remicade);
Alefacept (Amevive).
Within [ADDRESS_854389] dose of study drug:
etanercept (Enbrel).
Systemic treatments other than biologics that could affect psoriasis (eg, oral or 
injectable corticosteroid s, retinoids, methotrexate, cy closporine, fumaric acid 
derivatives, sulfasalazine, hy droxycarbamide (h ydroxyurea), azathioprine).
Phototherapy  and psoralens (PUVA).
Other – intramuscular gold, herbal medications.
Within [ADDRESS_854390] dose of study drug:
Topi[INVESTIGATOR_488022] (eg, corticosteroids, tars, 
keratol ytics, anthralin, vitamin D analogs, and retinoids).  Treatments allowed are: 
non-medicated emollients for use over the whole body , low or least 
potent(Class 6 or 7) topi[INVESTIGATOR_488024], soles, face, 
andintertriginous areas only ; tar and salicy lic acid preparations for the scalp only , 
or shampoos free of corticosteroids for the scalp only .  More potent topi[INVESTIGATOR_28709] (Class 5-2) could be considered on an a s -needed basis on the face, scalp, 
and genital areas onl y after discussion with the Sponsor’s Medical Monitor.
Phototherapy  with UVB (narrowband or broadband).
4.5. Randomization Criteria
Subjects will be randomized into the study  provided they  have satisfied a ll subject eligibility  
criteria.
Health y subjects will be randomized (once) into the SAD period, at which time, they will 
receive treatment assignment (active PF -06826647 dose level or placebo) for both the SAD 
and MAD periods.  Subjects will receive the same blinded treatment assignment (ie ,the same 

PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 66dose level of active PF-06826647 or placebo) throughout in both the SAD (Period 1) and 
MAD (Period 2) periods. Optional BID cohort subjects may be directly randomized to the twice daily 10 day treatment regimen once confirmation of eligibility criteria occurs, without the need to participate in a single dose period. 
•The randomization ratio for the cohorts in  the healthy subject SAD/MAD segment
will be 3: 1 (PF-06826647:Placebo). 
•The randomization ratio for the planned psoriasis multiple dose cohorts will be 
2:1 (PF-06826647:Placebo). 
4.6. Lifestyle Requirements
The following guidelines are provided:
4.6.1. Meals and Dietary Requirements
•Administration of investigation product will be in fasted state in SAD period and 
under standard meal condition in MAD (QD and BID) period and in Psoriasis 
cohorts. Based on the emerging PK, and safety data, the meal condition requirement in SAD, MAD and Psoriasis cohorts may be adjusted.  
•Under any meal condition, subjects will not be allowed to eat or drink grapefruit or 
grapefruit-related citrus fruits (eg, Seville oranges, pomelos) from [ADDRESS_854391] dose of study medication until collection of the final pharmacokinetic blood sample.
•Except when the investigational product is dosed under high fat meal condition, the 
total daily nutritional composition should be approximately 55% carbohydrate, 
30% fat and 15% protein and the daily caloric intake per subject should not exceed approximately 3200 kcal while confined.
Dosing under fasted condition: 
•Subjects must abstain from all food and drink (except water) at least 8 hours prior to 
any safety laboratory evaluations (as indiated in the study Schedule of Activities ) and 
[ADDRESS_854392] administration.
•The investigational product should be administered with approximately 240 mL 
(8 fluid ounces) of ambient temperature water. Additional water may be allowed if 
needed to administer the entire dose.
•Water may be consumed without restriction beginning 1 hour after dosing.  
Non-caffeinated drinks (except grapefruit or grapefruit-related citrus fruit juices – see 
above) may be consumed with meals and the evening snack.
•Lunch will be provided approximately 4 hours after dosing.CCI
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 67Dinner will be provided approximatel y 9 to 10 hours after dosing.
An evening snack may  be permitted.
Dosing under standard meal condition:
Following a n overnight fast of at least 8hours, subjects should start breakfast approximatel y 
[ADDRESS_854393] and dinner (BID period only )will be consumed over approximately  
20minutes with study  drug administered within approximately  [ADDRESS_854394] meal on PK profile assessment 
days (Day s1 and 1 0) and are required to eat a minimum of approximately  80% of the meal
preceding dosing .  Subjects will be encouraged to eat the full standard meal and are required 
to eat a minimum of approximately  50% of the meal on all other dosing days.  Subjects 
should be encouraged to eat any snack that will precede dosing.  The study  treatment should 
be administered with approximately  240 mL (8fluid ounces) of ambient temperature water.
Additional water may  be allowed if required to administer the entire dose.  No food will be 
allowed for at least [ADDRESS_854395] -dose.
Water can be allowed as desired except for [ADDRESS_854396] 
administration.  There are no water restrictions prior to dosing for subjects dosed 
under fed conditions.  
Lunch will be provided approximately  4hours after dosing.
Dinner will be provided approximatel y 9 to 10 hours after dosing.
An eveni ng snack may  be permitted.
Dosing under high fat meal condition (if needed):
Following an overnight fast of at least 8hours , subjects should start a 
high-fat/high- calorie breakfast approximately  25minutes prior to administration of 
the investigational pr oduct.  The breakfast will be consumed over approximately  
20minutes with investigational product administered within approximatel y 5minutes
after completion of the meal.  Subjects will be encouraged to eat the full meal on 
Day 1 and are required to eat a minimum of approximately  80% of the meal. 
The study  treatment should be administered with approximately  240 mL 
(8fluid ounces) of ambient temperature water. Additional water may  be allowed 
if required to administer the entire dose.

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 68The breakfast will b e a high -calorie/high -fat test meal.  The following breakfast as 
a representative example of a high -fat, high -calorie meal: [ADDRESS_854397] with butter, 4 ounces of hash brown potatoes, 
8fluid ounces (240 mL) of whole milk.
Water can be allowed as desired except for [ADDRESS_854398] 
administration.  There are no water restrictions prior to dosing for subjects dosed 
under fed conditions. 
The investigational product should be administered with approximatel y 240 mL of 
ambient temperature water .
No food will be allowed for at least [ADDRESS_854399] -dose.
Lunch will be provided approximately  4hours after dosing.
Dinner will be provided approximatel y 9 to 10 hours after dosing.
An evening snack may  bepermitted.
4.6.2. Alcohol, Caffeine ,and Tobacco
Subjects will abstain from alcohol for [ADDRESS_854400] at the discretion of the investigator.
Subjects will abstain from caffeine -containing products for 24 hours prior to the start 
of dosing until collection of the final pharmacokinetic sample of each study period.
Subjects will limit the use of tobacco- or nicotine-containing products for 24 hours 
prior to dosing and during confinement in the research unit to not exceed 5 cigarettes 
a day .
4.6.3. Activity
[IP_ADDRESS]. Healthy Volunteer Single Ascending Dose Period
Subjects will be con fined to the procedure room after dosing on Day 1 during 
continuous cardiac monitoring, except to use the bathroom.  After this, if the 
equipment setup allows, subjects may  be ambulatory  during the ECG monitoring 
period, but should not engage in strenuous activities.  If equipment does not allow 
ambulation, appropriate accommodations will be made b y the study site to facilitate 
continuous monitoring (ie ,bedside urinals should be provided to accommodate 
subjects’ excretory  needs).

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page [IP_ADDRESS]. All Subjects 
Subjects wil l abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests.  Walking at a normal pace will be permitted.
Subjects must avoid prolonged ex posre to the sun and other ultravoilet light sour ces 
during this study (eg,tanning beds) .
4.6.4. Contraception
All fertile male subjects who are, in the opi[INVESTIGATOR_871], sexually  active and at risk
for pregnancy , with their partner(s), must agree to use a highly  effective method of 
contraception consistently and correctl y for the duration of the active treatment period and 
forat least [ADDRESS_854401].  The investigator or his/her 
designee, in consultation with t he subject, will confirm the subject has selected the most 
appropriate method of contraception for the individual subject and his female partner from 
the permitted list of contraception methods (see below) andwill confirm that the subject has 
been instruc ted in its consistent and correct use. At time points indicated in the 
Schedule of 
Activities, the investigator or designee will inform the subject of the need to use highly  
effective contraception consistently  and correctly  and d ocument the conversation and the 
subject’s affirmation in the subject’s chart (subjects need to affirm their consistent and 
correct use of at least 1 of the selected methods of contraception).  In addition , the 
investigator or designee will instruct the su bject to call immediately  if the selected 
contraception method is discontinued or if pregnancy  is known or suspected in the subject or 
partner .
Highly  effective methods of contraception are those that, alone or in combination, result in a 
failure rate of l ess than 1% per year when used consistently .
1.Established use of hormonal methods of contraception associated with inhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal), provided the subject or 
male subject’s female partner plans to remain on the same treatment throughout the 
entire study  and has been using that hormonal contraceptive for an adequate period of 
time to ensure effectiveness .
2.Correctly placed copper -containing intrauterine device (IUD). 
3. Male condom or female condom us ed WI TH a separate spermicide product (ie, foam, 
gel, film, cream, or suppository ).  For countries where spermicide is not available or 
condom plus spermicide is not accepted as highly  effective contraception, this option 
is not appropriate.
4.Male sterilization with absence of sperm in the postvasectomy  ejaculate.
5.Bilateral tubal ligation/bilateral salpi[INVESTIGATOR_8820] y or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in accordance with the device’s label).

PF-[ADDRESS_854402] agree to prevent potential transfer to and exposure of 
partner(s) to drug through ejaculate b y using a condom consistently  and correctl y, beginning 
with the first dose of investigational product and continuing for at least [ADDRESS_854403] 
dose of PF -06826647.
NOTE: Sexual abstinence, defined as completel y and persistently  refraining from all 
heterosexual intercourse (including during the entire period of risk associated with the study  
treatments) may  obviate the need for contraception O NLY if this is the preferred and usual 
lifesty le of the subject.
[IP_ADDRESS]. Females – Childbearing Potential
Females of childbearing potential will be excluded from this study . 
4.7.Sponsor ’sQualified Medical Personnel
The contact [CONTACT_1133]'s appropria tely qualified medical personnel for the 
study is documented in the study contact [CONTACT_505858] .
http://ecf.pfizer.com/sites/crops/team/C2501001/default.aspx
To facilitate access to appropriatel y qualified medical personnel on study -related medical 
questions or problems, subjects are provided with a contact [CONTACT_1137]. The contact [CONTACT_4662], 
at a minimum, protocol and investigational product identifiers, subject study  number s, 
contact [CONTACT_31039],and cont act details for a contact [CONTACT_153845] a medical 
question or problem originating from another healthcare professional not involved in the 
subject ’s participation in the study . The contact [CONTACT_638789] ; however, it should be used 
only in the event that the established communication pathway s between the investigator site 
and the study  team are not available. It is therefore intended to augment, but not replace ,the 
established communication pathway s between the investigat orsite and the study  team for 
advice on medical questions or problems that may arise during the stud y. For sites other than 
a [COMPANY_007] CRU, t he contact [CONTACT_74074] ,and if a 
subject calls that number ,he or she will be directed back to the investigator site.
5.STUDY TREATMENTS
For the purposes of this study , and per International Conference on Harmoni sation ( ICH)
guidelines, investigational product is defined as a pharmaceutical form of an active 
ingredient or placebo being tested or used as a reference /comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way  different from the approved form, or when used for an unapproved 
indication, or when used to gain further information about an approved use (I CH E6 1.3 3).
For this study , the investigational product (s) PF -[ADDRESS_854404] will receive the study treatment 
regimen assigned to the corresponding randomization number.  I t will also appear on the 
study  medication containers.
Randomization will occur for the SAD/MAD cohorts, and the Psoriasis cohorts . 
Health y subjects will be randomized (once) into the SAD period, at which time, they will 
receive treatment assignment (active PF -06826647 dose level or placebo) for both the SAD
and MAD periods.  Subjects will receive the same blinded treatment assignment (ie, the same 
dose level of active PF -
06826647 or placebo) throughout in both the SAD (Period 1) and 
MAD (Period 2) periods. 
5.2.Breaking the Blind
Thisstudy  will be subject and i nvestigator blinded , sponsor -open.   At the initiation of the 
study , the study  site will be instructed on the method for breaking the blind.  The method will 
bemanual.   Blinding codes should only be broken in emergency  situations for reasons of 
subject saf ety.  Whenever possible, the investigator or sub investigator should consult with a 
member of the stud y team prior to breaking the blind.  When the blinding code is broken, the 
reason must be full y documented and entered on the case report form.
Blood spec imens will be obtained from all subjects for pharmacokinetic analy sis to maintain 
the study  blind at the investigator site.  
For the SAD/MAD cohorts onl y the investigator 
site(s) and the stud y monitor(s) will be blinded to study  treatment.  A designated limited
number of s ponsor colleagues within the study  team will be unblinded to subject treatments 
in order to permit real- time interpretation of the safet y and PK data; and provide information 
necessary  to potentially  alter the dose -escalation sequence .  The stud y monitor will remain 
blinded to treatment until all monitoring for the study  has been completed.  Specimens from 
subjects randomized to placebo will not be routinely  analy zed.  To minimize the potential for 
bias, treatment randomization information will be kept confidential b y [COMPANY_007] personnel and 
will not be released to the investigator or investigator site personnel until the study  database 
has been locked.  If an investigator would like to know the treatment assignment of a subject 
in the case of emergencyor in the event of a safety concern, in which case, the process for 
breaking the blind must be followed. 
The study  will be double -blind (including site, investigator, subject) , sponsor -open, for the 
Psoriasis cohorts. To minimize the potential f or bias, treatment randomization information 
will be kept confidential and will not be released to the investigator or investigator site 
personnel until the study  database has been locked. A designated limited number of [COMPANY_007] 
personnel will be unblinded to individual psoriasis subject treatment assignment to permit 
interpretation of interim anal ysis results, safet y data ,or management of subject ’s safety . 

PF-[ADDRESS_854405] Supplies . 
5.4.1. Dosage Form and Packaging
PF-06826647 will be supplied by [CONTACT_177263] 5 mg, 25 mg, or 100 mg tablets, and will be 
administered to health y volunteers during the SAD/MAD periods and to psoriasis subjects.
All tablets will be supplied to the CRU in bulk.  Individual dosing containers forunit dosing 
may be supplied, if needed.
There is no [ADDRESS_854406] SAD cohort.  Materials for PF -06826647 spray  
dried dispersion suspension and placebo dosages will be provided by [CONTACT_638790] (CRU), for administration to 
healthy  subjects participating in the starting dose cohort (3mg) of the Single Ascending Dose 
portion of the protocol .
5.4.2. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performe d to make 
the investigational product read y for administration or dispensing to the subject/caregiver b y 
qualified staff.  Dispensing is defined as the provision of investigational product, 
concomitant treatments, and accompan ying information by  [CONTACT_22806](s) to a 
healthcare provider, subject, or caregiver in accordance with this protocol.  L ocal health 
authority  regulations or investigator site guidelines may  use alternative terms for these 
activities.
PF-[ADDRESS_854407] (EDR).  Prepared doses will 
be provided in unit dose containers an d labeled in accordance with [COMPANY_007] regulations and the 
investigator site’s labeling requirements.
PF-[ADDRESS_854408]. The 
tablets will be provided in unit dose containers and labeled in accordance with [COMPANY_007] 
regulations and the clinical site’s labeling requirements. 

PF-[ADDRESS_854409] 8hours, subjects will receive s tudy medication at 
approximatel y 08:00 hours (plus or minus 2 hours).   Investigator site personnel will 
administer study  medication to subjects.
For subjects undergoing BI D dosing, the second dose of study  medication will be 
administered approximately  12hours after the initial (morning) dose.  
Blinded PF -[ADDRESS_854410] 
will be provided for the tablet administration .
Administration instructions for the PF
-06826647 susp ension dose (3mg single dose cohort 
only)will be provided in the extemporaneous dispensing record .
In order to standardize the conditions on pharmacokinetic sampling day s, all subjects will be 
required to refrain from ly ing down (except when required for blood pressure, pulse rate, and 
ECG measurements) . Meal and dietary  requirements as described in Section 4.6.[ADDRESS_854411] be capable of measuring and documenting (for example, via a log), at a 
minimum, daily  minimum and maximum temperatures for all site storage locations (as 
applicable, including frozen, refrigerated, and/or room- temperature products).  This should 
be captured from the time of investigational product receipt throughout the study .  Even for 
continuous- monitoring sy stems, a l og or site procedure that ensures active evaluation for 
excursions should be available.  The intent is to ensure that the minimum and maximum 
temperature is checked each business day  to confirm that no excursion occurred since the last 

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 74evaluation and to pr ovide the site with the capability  to store or view the minimum/maximum 
temperature for all non- working day s upon return to normal operations.  The operation of the 
temperature -monitoring device and storage unit (for example, refrigerator), as applicable, 
should be regularl y inspected to ensure they  are maintained in working order. 
Any excursions from the product -label storage conditions should be reported to [COMPANY_007] upon 
discovery .  The site should actively  pursue options for returning the product to the storage 
conditions described in the labeling, as soon as possible.  Deviations from the storage 
requirements, including any actions taken, must be documented and reported to [COMPANY_007]. 
Once an excursion is identified, the investigational product must be quara ntined and not used 
until [COMPANY_007] provides permission to use the investigational product.  It will not be considered a 
protocol deviation if [COMPANY_007] approves the use of the investigational product after the 
temperature excursion.  Use of the investigational product prior to [COMPANY_007] approval will be 
considered a protocol deviation.  Specific details regarding information the site should report 
for each excursion will be provided to the site. 
5.7.Investigational Product Accountability
The investigat orsite must ma intain adequate records documenting the receipt, use, loss, or 
other disposition of the investigational product supplies.  All investigational product s will be 
accounted for using a drug accountabilit y form/record. 
5.7.1. Destruction of Investigational Product Supplies 
The sponsor or designee will provide guidance on the destruction of unused investigational 
product (eg, at the site).   If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with applicable 
environmental regulations, institutional policy , and any  special instructions provided by  
[CONTACT_4618] ,and all destruction must be adequatel y documented.
5.8.Concomitant Treatment (s)
Subjects will abstain from all concomitant treatm ents, except for the treatment of adverse 
events, as described in the Exclusion Criteria section and in Appendix 3ofthis protocol. 
All concomitant treatments taken during the study  mus t be recorded with indication, daily  
dose, and start and stop dates of administration.  All subjects will be questioned about 
concomitant treatment at clinic visit as indicated in the Schedule of Activities.
Treatments taken within [ADDRESS_854412] selection criteria for the study. The investigator (or an appropriate delegate at the investigator site) will obtain informed consent from each subject in accordance with the procedures described in the protocol. If the time between Screening and dosing for a healthy subject in the SAD period is anticipated to exceed 28 days as a result of unexpected delays (eg, delayed drug shipment), then subjects do not require re-screening if the Day -1 laboratory (including urine drug screen), ECG, vital sign results, contraception check and urine pregnancy test (if applicable), and review of prior/concomitant medications all confirm that the subject still meets the eligibility criteria, as outlined in Section [ADDRESS_854413] who qualified for this protocol but did not enroll from an earlier cohort 
may participate in a subsequent cohort without re-screening provided the Day -1 laboratory (including urine drug screen), ECG, vital sign results, contraception check and urine pregnancy test (if applicable) and review of prior/concomitant medications all confirm that the subject still meets the eligibility criteria outlined in Section [ADDRESS_854414] completed screening procedures but did not 
enroll due to scheduling related delays, site logistics, or Sponsor imposed delays (eg, due to protocol amendments or other), the screening window may be extended from 28 days as described above, to up to 45 days.
6.2. Treatment Period
For treatment period procedures, see Schedule of Activities and ASSESSMENTS section.
 
 
6.3. Follow-up/End of Study Procedures
For follow up and end of study procedures, see Schedule of Activities and ASSESSMENTS
section.
6.3.1. Follow-up Contact
[CONTACT_31051]-up contact [CONTACT_31052] [ADDRESS_854415] to capture any potential adverse events (see the Time Period for Collecting AE/SAE Information section) and to confirm 
CCI
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 76appropriate contraception usage (see the Contraception section).  Contact [CONTACT_168074] a phone call.
6.4.Subject Withdrawal /Early Termination
Subjects ma y withdraw from the study at an y time at their own request, or they may  be 
withdrawn at an y time at the discretion of the investigator or sponsor for safety (see also the 
Withdrawal From the Stud y Due to Adverse Events section) or behavioral reasons, or the 
inability  of the subject to comply  with the protocol -required schedule of study  visits or 
procedures at a given investigator site.  The earl y termination visit applies only to subjects 
who are randomized and then are prematurely  withdrawn from the study .
It may  be appropriate for the subject to return to the clinic for final safet y assessments to be 
scheduled as earl y as practically feasible following the decision to withdraw from the stud y.  
Subjects should be questioned regarding their reason for withdrawal.  At the earl y withdrawal 
visit, every  effort must be made to complete the following assessments:
Physical examination;
Supi[INVESTIGATOR_638756] e;
12-lead ECG measurement;
Blood and urine specimens for safety  laboratory ;
Blood sample for pharmacokinetic anal ysis*.
*
For subjects who discontinue earl y during the treatment period due to an adverse event, a 
final PK sample should be collected when possible.  Subjects discontinuing earl y for other 
reasons may not be asked to provide a final PK sample , depending on when in the study  
discontinuation occurs. For such cases, please contact [CONTACT_638791] .
Lack of completion of a ll or an y of the earl y termination procedures will not be viewed as 
protocol deviations so long as the subject’s safet y was preserved.
Subjects who withdraw from the study  may  be replaced at the discretion of the investigator 
upon consultation with the spo nsor (provided the nature of the safet y event does not preclude 
dose escalation and exposure stoppi[INVESTIGATOR_638757]).
Replacement of psoriasis subject(s) who discontinue earl y ma y occur at discretion of the
sponsor in order to ensure adequate number of subjects completing through Day 28. 

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 77Withdrawal of consent : 
Subjects who request to discontinue receipt of study  treatment will remain in the study  and 
must continue to be followed for protocol -specified follow -up procedures.  The only  
exception to th is is when a subject specificall y withdraws consent for an y further contact 
[CONTACT_310799].   
Subjects should notify  the investigator in writing of the decision to withdraw consent from 
future follow -up, whenever possible.   The withdrawal of consent should be explained in 
detail in the medical records by  [CONTACT_093], as to whether the withdrawal is only from 
further receipt of investigational product or also from study  procedur es and/or posttreatment 
study  follow -
up, and entered on the appropriate case report form ( CRF )page.   In the event 
that vital status (whether the subject is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordance with local law.
If the subject withdraws from the study  and also withdraws consent for disclosure of future 
information, no further evaluations should be performed and no additional data should be 
collect ed.  The sponsor may  retain and continue to use any  data collected before such 
withdrawal of consent.
Lost to f ollow -up: 
If a subject does not return for a scheduled visit, every  effort should be made to contact [CONTACT_1560].  The investigator or site staf f should attempt to contact [CONTACT_110280].  After 
2attempts, CRU staff may send a registered letter.  If no response is received from the 
subject, the subject will be considered lost to follow- up.  All attempts to contact [CONTACT_638792] r eceived during contact [CONTACT_155806]’s 
medical record.  In an y circumstance, every  effort should be made to document subject 
outcome, if possible.  The investigator should inquire about the reason for withdrawal, 
request that t he subject return all unused investigational product(s), request that the subject 
return for a final visit, if applicable, and follow up with the subject regarding any unresolved 
AEs.
All reasonable efforts must be made to locate subjects to determine and report their ongoing 
status.  This includes follow- up with persons authorized by  [CONTACT_74084].  All 
attempts should be documented in the subject’s medical records.   If it is determined that the 
subject has died, the site will use locally  perm issible methods to obtain the date and cause of 
death.
  If the investigator’s use of a third- party representative to assist in the follow -up 
portion of the study  has been included in the subject’s informed consent, then the investigator 
may use a sponsor -retained third- party representative to assist site staff with obtaining the 
subject’s contact [CONTACT_110284] -up portion of the study .  The site staff and representative will consult publicly  
available sources, such as public health registries and databases, in order to obtain updated 
contact [CONTACT_3031].   If,
after all attempts, the subject remains lost to follow- up, then the 
last-known- alive date as determined by  [CONTACT_638793]’s medical records.

PF-[ADDRESS_854416] information will be provided to the investigator site prior 
to initiation of the study .
7.1.Safety
7.1.1. Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the STUDY 
PROCEDURES section of this protocol.  Additional laboratory results may be reported on 
these samples as a result of the method of analy sis or the ty pe of analyzer used by  [CONTACT_332854] ; or as derived from calculated values.  These additional tests would not require 
additional collection of blood.  Unscheduled clinical labs may  be obtained at any  time during 
the study  to assess any  perceived safet y concerns.

PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 79Table 7. Laboratory Tests
Hematology Chemistry *Urinalysis Other
Hemoglobin
HematocritRBC countMCV
MCH
MCHCPlatelet countWBC countTotal neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)Basophils (Abs)Lymphocytes (Abs)Reticulocytes (%)BUN/urea and Creatinine
Glucose (fasting)CalciumSodium
Potassium
ChlorideTotal CO
2(Bicarbonate)
AST, ALTTotal BilirubinAlkaline phosphatase
Uric acid
AlbuminTotal proteinSerum Cystatin C Creatinine phosphokinase 
(for psoriasis subjects 
only)pH
Glucose (qualified)Protein (qualified)
Blood (qualified)
KetonesNitritesLeukocyte esteraseUrobilinogen
Urine bilirubin
Microscopy
aFSHb
Urine drug screeningc
FibrinogenLipi[INVESTIGATOR_805]: TC, TG, LDLc, HDLInterferon Gamma Release Assay (IGRA) (with the following acceptable assays: QuantiFERON
R-TB Gold (QFT-G) 
test, T-SPOT TB, 
QuantiFERON-TB Gold In-Tube test (QFT-GIT)
f
HIV, HepBsAg, HepBcAb , HCVAbf
 
 
PK
6β-hydroxy cortisol
  
 
Additional Testse
(Needed for Hy’s law)Other :
AST, ALT (repeat)
Total bilirubin (repeat)
Albumin (repeat)
Alkaline phosphatase (repeat)Direct bilirubinIndirect bilirubin
Creatine kinase
GGTPT/INRTotal bile acidsAcetaminophen drug and/or protein adduct 
levelsUrine for [ADDRESS_854417] 12 consecutive months. 
c. At Screening and pre-dose only (see Schedule of Activities ).  Minimum requirement for drug testing 
includes: cocaine, tetrahydrocannabinol (THC), opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_103856].CCI
CCI
CCI
CCI
CCI
C
C
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 80e. Additional testing for potential Hy's Law cases only.
f. Screening only.  All subjects will be screened for HBsAg and HBcAb; subjects who are HBsAg 
positive will be screen-failed.  Subjects who are HBsAg negative but HBcAb positive will be reflex-tested for HBsAb and, if HBsAb positive, may enroll; if HBsAb negative, they will be 
screen-failed.  Subjects who are positive for HCV Ab or HIV will be screen-failed.
 
*
.Urinalysis sample may also be used to assess additional markers of renal function.
This table lists all protocol laboratory tests included in the study.  For a detailed description of 
laboratory tests required for a given subject cohort with specific collection time points, please refer to the Schedule of Activities . 
•Minimum requirement for drug testing includes: cocaine, THC, opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], 
benzodiazepi[INVESTIGATOR_103856].
•Subjects may undergo random urine drug screening at the discretion of the 
investigator.  Drug screening conducted prior to dosing must be negative for subjects 
to receive study medication. 
7.1.2. Pregnancy Testing
All pregnancy tests used in this study, either urine or serum, must have a sensitivity of at 
least 25 mIU/mL and must be performed by a certified laboratory.  For female subjects of childbearing potential, [ADDRESS_854418]/study treatment(s) ([ADDRESS_854419]/study treatment administration).  Following a negative pregnancy test result at screening, appropriate contraception must be commenced and the second negative pregnancy test result will then be required at the baseline visit and within [ADDRESS_854420] day of the menstrual period (counting the first day of the menstrual period as Day 1) before the subject may receive the investigational product/study treatment.  In the absence of regular menstrual bleeding, the study candidate should have used [ADDRESS_854421] has not become pregnant during the study.  Pregnancy tests will also be done whenever 1 menstrual cycle is missed during the active treatment period and when potential pregnancy is otherwise suspected, and may be repeated if requested by [CONTACT_110453] (IRBs)/ethics committees (ECs) or if required by [CONTACT_427].  In the case of a positive confirmed pregnancy, the subject will be withdrawn from administration of investigational product and from the study.C
C
I
PF-[ADDRESS_854422]’s arm supported at the level of the 
heart and recorded to the nearest mm Hg after approximately  5minutes of rest.  The same 
arm (preferabl y the dominant arm) will be used throughout the study.  Subjects should be 
instructed not to speak during measurements. 
The same properl y sized and calibrated blood pressure cuff will be used to measure blood 
pressure each time.  The use of an automated device for measuring BP and pulse rate is 
acceptable, although, when don e manuall y, pulse rate will be measured in the brachial/radial 
artery  for at least 30 seconds.  When the timing of these measurements coincides with a 
blood collection, blood pressure and pulse rate should be obtained prior to the nominal time 
of the blood collection.
For current smokers participating in this study , vital sign assessment (blood pressure and 
pulse rate) should not occur within 1 hour of smoking. 
7.1.5. Temperature
Temperature will be measured orally.  No eating, drinking or smoking is allowed for 
15 minutes prior to the measurement.
7.1.6. Electrocardiogram 
Electrocardiograms (ECGs) should be collected at times specified in the Schedule of 
Activities section of this protocol.
All scheduled ECGs should be performed after the subje ct has rested quietly  for at least 
10minutes in a supi[INVESTIGATOR_2547]. 

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 82Triplicate 12 -lead ECGs will be obtained approximately  2-4 minutes apart; the average of the 
triplicate ECG measurements collected predose on Day 1will serve as each subject’s 
baseline Q Tc value.  When the timing of these measurements coincides with a blood 
collection, the ECG should be obtained prior to the nominal time of the blood collection, 
blood pressure and pulse rate. 
To ensure safet y of the subjects, a qualified individual at th e investigator site will make 
comparisons to baseline measurements.  Within a given study  period (i e,SAD, MAD), 
baseline measurements from the current period will be used for comparison.  If the QTc 
interval is increased b y 45msec from the baseline, or an absolute QTc value is 500msec 
for an y scheduled ECG, then 2 additional ECGs will be collected, approximately  2
-4minutes 
apart, to confirm the original measurement.  If either of the QTc values from these repeated 
ECGs remains above the threshold valu e (45msec from the baseline; or is 500msec), then 
a single ECG must be repeated at least hourl y until QTc values from 2 successive ECGs fall 
below the threshold value that triggered the repeat measurement. 
If the average of QTc values from the triplicate measurements remains above the threshold 
value (45msec from the baseline; or is 500msec), then a single ECG must be repeated at 
least hourly  until QTc values from 2 successive ECGs fall below the threshold value that 
triggered the repeat measuremen t.
If QTc values remain 500msec (or 45msec from the baseline) for greater than 4 hours (or 
sooner at the discretion of the investigator); or QTc intervals get progressively  longer, the 
subject should undergo continuous ECG monitoring.  A cardiologist s hould be consulted if 
QTc intervals do not return to less than 500 msec (or to <45 msec above the baseline) after 
8hours of monitoring (or sooner at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality.  It is important that leads are placed in the 
same positions each time in order to achieve precise ECG recordings.  If a machine -read QTc 
value is prolonged, as defined above, repeat measu rements may  not be necessary  if a 
qualified phy sician’s interpretation determines that the QTc values are in the acceptable 
range.
For current smokers participating in this study , ECG assessments should not occur within 
1 hour of smoking. 
7.1.7. Continuous Cardi ac Monitoring by [CONTACT_638794].
All abnormal rh ythms will be recorded and reviewed by  [CONTACT_638795].  The time, duration, and description of the clinicall y 
significant event will be recorded in the case report form (CRF).  I n addition, a printed record 
of the tracing(s) of the clinically  significant rhy thm(s) will be made and retained with other 
source documents.

PF-[ADDRESS_854423] radiograph performed as part of
Screening if the individual previously received an adequate course of therapy for either latent (9 months of isoniazid in a locale where rates of primary multi-drug resistant TB infection are <5%) or active TB infection, and if there is no record and no report of having one performed in the prior 3 months.
7.1.9. Interferon Gamma Release Assay (IGRA) Tests
Interferon Gamma Release Assay (IGRA) will be performed at screening.  The following 
acceptable IGRA assays include: Interferon Gamma Release Assay (IGRA) (with the following acceptable assays: QuantiFERON
R-TB Gold (QFT-G) test, QuantiFERON-TB 
Gold In-Tube test (QFT-GIT) and T-SPOT TB test).  A QFT-G test is recommended in subjects who have been previously vaccinated with BCG.
7.1.10. Urine Creatinine and 
 
 
  
 
 
 CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 84 
[IP_ADDRESS]. 24 Hour Urine Creatinine and  in Multiple Ascending Dose 
Period: Day -1 and Day 10
The same procedure outlined in Section [IP_ADDRESS] for urine collection in the single ascending 
dose period will be utilized in the multiple ascending dose period.  One aliquot of 10 mL(“urine blank”) from the 0-24 hour period will be obtained from the urine collection for creatinine measurement on Day -1. Also, two 1-mL aliquots will be transferred to 
appropriately-labeled tubes and stored at -70 °C within 2 hours of collection for  
After 24-hour collection on Day 10, two aliquots of 10 mL will be collected in appropriately 
labelled tubes for PK analysis and creatinine measurement. Also, two 1-mL aliquots will be 
transferred to appropriately-labeled tubes and stored at -70 °C within 2 hours of collection for 
On Day 10, urine will be collected from the BID period over 2 time intervals: 0-12 hours and 
12-24 hours.  The PK sample will be collected from the 0-12 hour interval. 
 
[IP_ADDRESS]. 24 Hour Creatinine Clearance Calculation
Creatinine clearance (mL/min) = (Creatinine (urine)/Creatinine(serum)) x (Volume Urine 
(mL)/Time (hours) x 60)
 
 
7.1.11. Serum Creatinine and Serum Cystatin-C
Serum creatinine is the best known standard test for monitoring renal function. However, 
serum creatinine based estimates of glomerular filtration rate (eGFR) may be affected by [CONTACT_153848], including chronic and acute illness.  Cystatin C is a test that can be used either as an adjunct to or a replacement for serum creatinine.  The most reliable estimates of GFR use both test results.
8
Cystatin C is a low molecular weight protein that is used as an alternative to serum creatinine for monitoring of renal function.  It seems to correlate more closely with GFR than does serum creatinine concentration and may be a more sensitive detector of early renal 
dysfunction.
9,10While use of cystatin C has been limited, its independence of demographic CCI
CCI
CCI
CCI
CCI
CCI
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 85factors (eg, race) has made it an interesting means of determining changes in renal function 
in clinical settings and it is included in the 2012 Kidney  Disease: Improving Global 
Outcomes (KDIGO) guidelines.   Estimate d GFR may  be calculated via the 2012 Chronic 
Kidney  Disease Epi[INVESTIGATOR_254097] (CKD -EPI)creatinine, cy statin C, or 
creatinine -Cystatin C equations
.11
Serum creatinine and serum cy statin C will be measured from the   serum chemistry  specified 
in the Schedule of Activities section of the protocol. Serum creatinine and cy statin C based 
eGFR will be calculated at baseline and end of treatment ( EOT) at a minimum (additional 
time points may  be assessed) . 
When a subject has an increase in serum creatinine of 0.3mg/dL  relative to the subject’s 
baseline, and after that increase has been confirmed by  a (single) repeat test obtained as soon 
as practically  feasible, but within 24hours of the initial result ,this willtrigger assessment of
serum cy statin -C in order to facilitate both cy statin C based and serum crea tinine based 
eGFR calculations.
7.1.12. Estimated Glomerular Filtration Rate
Serum creatinine and serum cy statin -C based estim ated GFR (eGFR) will be calculated at 
baseline and end of study treatment period at a minimum for all subjects, in order to facilitate 
calculation of eGFR at these time points.  When cystatin -C testing isperformed during the 
treatment period , corresponding serum creatinine and cy statin -C based eGFR will be 
determined to support assessment of renal function.
The respective 
estimated GFR (eGFR) values will be calculated using the 2 sets of equations 
developed b y the Chronic Kidney  Disease Epi[INVESTIGATOR_638758] (CKD -EPI), which 
utilize serum creatinine (SCr) and serum Cy statin C (S Cy statin C) respectively .7
(Appendix 4).
7.2.
Selection of IndexPlaques and Non- Lesional Skin for Skin Bio psies for Psoriasis 
Subjects
The index psoriatic plaque(s) to be used for skin biopsy should be selected pre -dose at the 
Day -1visit.
Index lesion sites may  be located on the torso (upper and mid back, chest), abdomen, 
buttocks, upper arms, and upper legs.  Index lesions may  not be located on the scalp, face, 
elbows, knees, lower legs, genital area and inguinal area, intertriginous areas and lower back.
Ideally, a single target plaque, approximately the size of the palm of the subject’s hand, 
should be ide ntified and the location and borders noted in the clinic chart; anatomical 
markers should be used as needed to describe the target plaque location.  A photograph of the 
site may  also be used.  The plaque should be of sufficient size that the presence of mu ltiple 
biopsy  sites will not interfere with clinical evaluation of the lesion; potential biopsy  sites 
should be pre -selected.  The plaque should also be large enough to perform the required 
number of biopsies specified in the protocol.   If a single index l esion meeting the above 
description cannot be found, two index plaques, located in the same area of the body , that are 

PF-[ADDRESS_854424] 3 to 5 cm in diameter should be identified and the locations noted in the clinic chart.  
The index plaque(s) must have a total score of at least [ADDRESS_854425] 3 cm from the target psoriatic plaque.  A biopsy of non-lesional skin will be obtained pre-dose at the Day -1visit only.
7.3. Skin Biopsies (Psoriasis Subjects only)
The index plaque(s) selected for biopsy will be outlined using a black permanent marker on 
plastic transparency film.  An area will be marked on the transparency film for identification and biopsy.  The film will be identified with the study number and subject’s identification number and retained with subject’s clinic/site source documents.
Punch biopsies of the lesional skin will be obtained at each time point as specified in the 
Schedule of Activities .  At the discretion of the investigator and the subject, two 4 mm 
biopsies will be obtained.  At Day -1, two 4 mm biopsies of lesional skin and two 4 mm biopsies of non-lesional skin will be obtained.
Biopsy samples will be prepared and shipped following instructions in a separate manual 
provided by [CONTACT_456].
Throughout the study period, the ‘punch’ biopsy instrument should be placed at least 3 mm 
from the target plaque’s edge as identified at the Day -[ADDRESS_854426] the width of the biopsy punch instrument apart.
 
 
Punch biopsies from the index psoriatic plaque(s) will be obtained pre-dose on Day -1, at 
Day [ADDRESS_854427] the investigator or other designated site staff if they experience bleeding, warmth, swelling, tenderness, or erythema at the biopsy site; an unscheduled visit may be required for clinical assessment.
7.4. Psoriasis Clinical and Histological Assessments
Clinical and histological psoriasis assessments that will be collected throughout the study are 
outlined in this section.  These measures will be evaluated by [CONTACT_255958], or qualified medical professional.  Detailed descriptions for the  
, , and Patient Global Assessment are 
provided in the Appendices. 
7.4.1. Psoriasis Area and Severity Index (PASI) (Psoriasis subjects only)
PASI should be collected at times specified in the Schedule of Activities section of this
protocol.
The Psoriasis Area and Severity Index quantifies the severity of a subject’s psoriasis based 
on both lesion severity and the percentage of body surface area affected.
Lesion severity: the basic characteristics of psoriatic lesions – erythema, induration and 
scaling – provide a means for assessing the severity of lesions.  Assessment of these three main signs is performed separately for four areas of the body: head, upper limbs, trunk, and lower limbs.  Average erythema, induration and scaling are rated for each body area according to a 5-point scale: 0, no involvement; 1, slight; 2, moderate; 3, marked; 4, very marked.
 
 
Calculating PASI
In each area, the sum of the severity rating scores for erythema, induration and scaling is 
multiplied by [CONTACT_153850], multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4).  The sum of the numbers obtained for each of the four body areas is the PASI.
1
PASI = 0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) +
0.3At(Et + It + St) + 0.4Al(El + Il + Sl)
where A = area of involvement score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; 
t = trunk; l = lower limbs
The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores 
representing increasing severity of psoriasis.  The PASI score will be used for the primary analysis.CCI
CCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 887.4.2. Linear-method Psoriasis Area and Severity Index (L-PASI)
A second method of calculating PASI will also be performed.  A linear-scaling method will 
be applied to the Psoriasis Area and Severity Index calculation, adapting the classic calculation by [CONTACT_638796] a 7-point scale. 
The linear-scaling method will be calculated from the study database; investigator sites will 
only perform the classic PASI calculation during the study.  The L-PASI score will be used for a sensitivity analysis.
L-PASI Calculation
L-PASI = 0.1(6xBh)x(Eh + Ih + Sh) + 0.2(6Bu)x(Eu + Iu + Su) +
0.3(6xBt)x(Et + It + St) + 0.4(6xBl)x(El + Il + Sl)
where B = percentage area of involvement; E = erythema; I =induration; S = scaling; h = head; u = upper 
limbs; t = trunk; l = lower limbs
 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 89 
 
 
 
 
 
 
 
 
 
 
7.4.6. Target Lesion and Regional Photography (Psoriasis subjects only)
Standardized digital photographs of target lesions and surrounding region photography will 
be taken at selected study sites using a professional quality digital camera.  These photographs are for illustrative purposes only. 
Target Lesion Photography : Two target lesions will be selected at the Day -1 visit.  
Anything extraneous to each lesion and its surrounding area are to be removed from the photographic field.  The camera/lens will be set at the appropriate magnification.  A close-up attachment scale attached to the camera system will help ensure that photographs are all taken at the same magnification and from the same set distance.  Photographs will be taken in duplicate with lighting, framing, and exposure held constant.CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 90Regional Photography : Regional photographs of each target lesion and surrounding area 
will also be taken.  Once the camera/lens is set at the appropriate magnification, proper focusing technique will help ensure that photographs are all taken from the same set distance from the camera.  Photographs will be taken in duplicate with lighting, framing, and exposure held constant.
Digital study images will be captured on memory cards.  The contents of those cards will be 
uploaded to Canfield Scientific, Inc. using Canfield’s secure, compliant website.  All study images received will be monitored and archived in a fully validated, 21 Code of Federal Regulations (CFR) Part 11 Food and Drug Administration (FDA) compliant system.  A copy of each subject's Day -[ADDRESS_854428] file in order to confirm the location/field of view to be photographed at the end of treatment.  Photography will be performed at Da y -1, Day 7, Day 14, and Day 28, as well as 
at the follow-up visits occurring at Day 42 and Day 56/Early Termination and Day 84.  Additional instructions related to target lesion and Regional Photography can be located in the study manual. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 91 
 
 
7.6. Pharmacokinetics
7.6.1. Plasma for Analysis of PF-06826647
During all study periods, blood samples (4 mL) to provide approximately 1.2-1.[ADDRESS_854429] nominal time relative to dosing.  However, samples obtained within 10% of the nominal time (eg, within 6 minutes of a 60 minute sample) from dosing will not be captured as a protocol deviation, as long as the exact time of the sample collection is noted on the source document and data collection tool (eg, CRF/DCT).
•Samples will be centrifuged at approximately 1700 x g for about 10 minutes at 4 °C.  The 
plasma will be stored in appropriately la beled screw capped polypropylene tube at 
approximately -20 °C within 1 hour of collection. 
•Samples will be analyzed using a validated analytical method in compliance with 
[COMPANY_007] standard operating procedures.
•Details regarding the collection, processing, storage and shippi[INVESTIGATOR_638759].
•The PK samples must be processed and shipped as indicated to maintain sample 
integrity.  Any deviations from the PK processing steps, including any actions taken, 
must
be documented and reported to the sponsor.  On a case-by-case basis, the 
sponsor may make a determination as to whether sample integrity has been compromised.  Any sample deemed outside of established stability, or of questionable integrity, will be considered a protocol deviation.
•  
 
 
 CCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 927.6.2. Urine for Analysis of PF-06826647
Urine will be collected as outlined in the Schedule of Activities . 
Urine will be stored at approximately 4 °C during each collection period.  At the end of each 
24 hour urine collection period, the urine will be mixed thoroughly and total volume will be 
measured and recorded.  A 7-8 mL aliquot will be withdrawn for measurement of drug 
concentrations and will be stored frozen at approximately -20 °C within 1 hour of the end of 
the collection interval.  The urine blank for PK will be obtained from the 24-hour collection on Day -1 (0-24 hr) for subjects undergoing QD or BID dosing.  On Day 10, urine will be collected for the BID cohort over 2 time intervals: 0-[ADDRESS_854430] operating procedures.
As part of understanding the pharmacokinetics of the study drug, samples may be used for 
 identification and/or evaluation of the bioanalytical method.  These data will be 
used for internal exploratory purposes and will not be included in the clinical report. 
7.6.3. Shipment of Pharmacokinetic Samples
The shipment address and assay lab contact [CONTACT_36544].
 
 
 
 
 CCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 94 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
  
 CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 96  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 97 
 
 
7.10. Blood Volume
The total blood sampling volume for individual subjects in this study is approximately 
552.8 mL for the SAD and MAD cohorts and approximately 475 mL for the Psoriasis cohort.  The actual collection times of blood sampling may change, but the total blood volume collected will not increase.  Additional blood samples may be taken for safety assessments at times specified by [CONTACT_4618], provided the total volume taken during the study does not exceed 550 mL during any period of 30 consecutive days.
Table 8. Blood Volume: Single Ascending Dose Period
Sample TypeSample 
Volume 
(mL)Number of Sampling Times
Screening Treatment 
PeriodFollow-up 
PeriodTotal Volume 
(mL)
Interferon Gamma Release Assay 
(IGRA)3 1 0 0 3
HIV, HepBsAg, HepBcAg, 
HCVAb8.5 1 0 0 8.5
FSH 2 1 0 0 2
Blood Safety Labs (hematology & 
chemistry)14.5 1 3 1 72.5
Fibrinogen 2.7 0 1 1 5.4
Lipid Panel 0 1 2 1 0
 
PK Blood Sampling 4 0 12 1 52
TOTAL 183.9CCI
C
CI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 98Table 9. Blood Volume: Multiple Ascending Dose Period
Sample Type Sample 
Volume 
(mL)Number of Sampling Times
Screening Treatment 
PeriodFollow-up 
PeriodTotal Volume 
(mL)
Blood Safety Labs (hematology 
& chemistry)14.5 0 7 1 116
Fibrinogen 2.7 0 2 0 5.4
Lipid Panel 0 0 4 1 0
 
PK Blood Sampling 4 0 24 1 100
TOTAL 368.9C
CI
C
C
CCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 99Table 10. Blood Volume: Psoriasis Multiple Dose Period
Sample TypeSample 
Volume 
(mL)Number of Sampling Times
Screening Treatmen
t PeriodFollow-up 
PeriodTotal Volume 
(mL)
Interferon Gamma Release Assay (IGRA)31 0 0 3
HIV, HepBsAg, HepBcAg, 
HCVAb8.5 1 0 0 8.5
FSH 21 0 0 2
Blood Safety Labs (hematology 
& chemistry)14.5 1 9 3 188.5
Lipid Panel 01 5 1 0
 
PK Blood Sampling 401 4 1 6 0
TOTAL 475.0
Total volumes for the tables above do not include discarded blood from pre-draws used to 
remove fluid from flushed catheters, if applicable. 
7.11. Assessment of Suicidal Ideation and Behavior
 C
CI
CCI
CCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 100 
 
 
 
 
7.11.2. Patient Health Questionnaire – 8 items (PHQ-8)
Patient health questionnaire – 8 items ( Appendix 11 ) is a patient-report questionnaire consists 
of [ADDRESS_854431] depression level. 
At Screening Visit, if PHQ-8 total score ≥15, the subject will not be included in the study.
7.11.3. Suicidal Behaviors Questionnaire-revised (SBQ-R)
Suicidal behaviors questionnaire- revised ( Appendix 10 ) is a patient-report questionnaire 
consists of 4 items to assess suicidal ideation, suicide attempts, threat of suicidal behavior, and likelihood of suicidal behavior.
At Screening Visit, if SBQ-R total score ≥8, the subject will not be included in the study.
7.12. Triggered Requirements 
7.12.1. Potential Cases of Acute Kidney Injury
Abnormal values in serum creatinine (SCr) concurrent with decline in eGFR that meet the 
criteria described below in the absence of other causes of kidney injury, are considered potential cases of acute kidney injury and should be considered important medical events.  
An increase of ≥0.3 mg/dL (or ≥26.5μmol/L) in serum creatinine relative to subjects’ own 
baseline measurement should trigger another assessment of SCr to confirm, within 24-hours 
from awareness.
If the second (repeat) result is still of ≥0.3 mg/dL (or ≥26.5μmol/L) relative to subject 
baseline, assessment of serum Cystatin C (S Cystatin C) should be referenced.  Based on these measurements, estimated GFR using serum creatinine (2009 CKD-EPI [CONTACT_67889]
7) and 
serum cystatin C (2012 CKD-EPI [CONTACT_67889]7) will be determined and reviewed, preferably 
within 72 hours and not later than 96 hours from the confirmed (repeat) elevated serum creatinine result.CCI
PF-[ADDRESS_854432] demonstrates CONCOMITANT sCr- based AND S Cy statin C -based 
eGFR decline of 30%compared to the subject’s baseline eGFR, then the subject should not 
be further dosed and adequate, immediate, supportive measures including immediate 
evaluation by a nephrologist (preferably within 24 hours) with appropriate 
management and treatment as clinicall y indicated.  Results should be repeated as indicated 
by [CONTACT_638797] a minimum until the eGFR returns to baseline 15% or the 
renal parameters are deemed to be stable b y the nephrologist and/or PI.
If the subject cannot be seen by a nephrologist within 24 hours (as described above), 
then the subject should be sent to a local emergency room for evaluation and treatment 
as clinically indicated.
Subjects should return to the investigational site and be evaluated as soon as possible, 
preferably within 24-48- hours from a wareness of the abnormal eGFR result.  This 
evaluation should include laboratory  tests, detailed history , and ph ysical assessment.  I n 
addition to evaluating eGFR as calculated b ySCrand S Cystatin C,laboratory  tests should 
include: serum blood- urea-nitrogen, serum creatine kinase, serum electrol ytes (including at a 
minimum potassium, sodium, phosphate/phosphorus, calcium), in addition to urinary  
dipstick, urine microscopic examination, and urinary indices.  All cases confirmed on repeat 
testing as meetin g the eGFR criteria for acute -kidney -injury , with no other cause(s) of 
laboratory  abnormalities identified should be considered as potential cases of drug -induced 
kidney  injury  irrespective of availability of all the results of the investigations performed to 
determine etiolog y of the abnormal SCr.  If 2healthy  subjects in a given cohort are noted to 
have 2 consecutive decreases from baseline in eGFR of -30%, based on both sCr AND 
SCystatin C,an assessment of whether the finding may be considered adver se drug reaction 
should be undertaken.
This requirement applies to all subjects, all cohorts.  
7.13. Rater Qualifications 
Investigators participating in this study  should be experienced in the conduct of psoriasis
clinical trials and have prior training and ex perience in the required protocol -specific
psoriasis subject clinical evaluations. The same rater should evaluate the same subject(s)
whenever possible.
8.ADVERSE EVENT REPORT ING
8.1.Requirements
The table below summarizes the requirements for recording safet y events on the CRF and for 
reporting safety  events on the Clinical Trial (CT) Serious Adverse Event (SAE) Report Form 
to [COMPANY_007] Safety .  These requirements are delineated for 3 types of events: (1) SAEs; 
(2)non-serious adverse events (AEs); and (3) exposur e to the investigational product under 
study  during pregnancy  or breastfeeding, and occupational exposure. 

PF-[ADDRESS_854433] under 
study  during pregnancy  or 
breastfeeding, and 
occupational exposureAll (regardless of whether 
associated with an AE), 
except occupational 
exposureExposure during pregnancy , 
exposure via breastfeeding, 
occupational exposure 
(regardless of whether 
associated with an AE)
All observed or volunteered events regardless of tre atment group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
paragraphs.
Events listed in the table above that require reporting to [COMPANY_007] Safety  on the CT SAE Report 
Form within [ADDRESS_854434] be made immediately , irrespective of the extent of available 
event information.  This time frame also applies to additional new (follow -up) information on 
previously  forwarded reports.  I n the rare situation that the investigator does not become 
immediately  aware of the occurrence of an event, the investigator must report the event 
within 24 hours after learning of it a nd document the time of his/her first awareness of the 
event.
For each event, the investigator must pursue and obtain adequate information both to 
determine the outcome and to assess whether it meets the criteria for classification as an SAE 
(see the Serious Adverse Eve ntssection below).  In addition, the investigator may  be 
requested b y [COMPANY_007] Safety to obtain specific follow -up information in an expedited fashion.  
This information is more detailed than that recorded on the CRF.  In general, this will include 
a description of the event in sufficient detail to allow for a complete medical assessment of 
the case and independent determination of possible causalit y.  An y information relevant to 
the event, such as concomitant medicati ons and illnesses, must be provided.  I n the case of a 
subject death, a summary of available autopsy  findings must be submitted as soon as possible 
to [COMPANY_007] Safety .  An y pertinent additional information must be reported on the CT SAE 
Report Form; addition
al source documents (eg, medical records, CRF, laboratory data) are to 
be sent to [COMPANY_007] Safet y ONLY upon request.

PF-[ADDRESS_854435] 
in the determination of case seriousness, further information may  be requested from the 
investigator to provide clarity  and understanding of the event in the context of the clinical 
study .
8.1.1. Additional Details on Recor ding Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  I t 
should be noted that the CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same 
data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.
8.1.2. Eliciting Adv erse Event Information
The investigator is to record on the CRF all directly  observed AEs and all AEs spontaneously  
reported b y the stud y subject .  In addition, each study  subject will be questioned about the 
occurrence of AEs in a non -leading manner.
8.1.3. With
drawal From the Study Due to Adverse Events (see also the Subject 
Withdrawal /Early Termination section)
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted bel ow, and recorded on the CRF. 
When a subject withdraws from the study  because of an SAE, the SAE must be recorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with the 
Requirements section above.
8.1.4. Time Period for Collecting AE/SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each subject begins from the time the subject provides informed consent, which 
is obtained before the subje ct’s participation in the study  (ie, before undergoing any  
study -related procedure and/or receiving investigational product), through and including a 
minimum of 28 calendar days; except as indicated below after the last administration of the 
investigationa l product.
For subjects who are screen failures, the active collection period ends when scree n failure 
status is determined.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a subject during the active collection period are reported to [COMPANY_007] 
Safety  on the CT SAE Report Form.

PF-[ADDRESS_854436] after the active collection period has ended are reported to [COMPANY_007] 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable pos sibility  of being related to investigational 
product must be reported to [COMPANY_007] Safety .
Follow up by  [CONTACT_74095] a level acceptable to the investigator, and 
[COMPANY_007] concurs with that assessment.
[IP_ADDRESS]. Recording Non -serious AEs and SAEs on the CRF
During the active collection period, both non -serious AEs and SAEs are recorded on the 
CRF.
Follow -up by  [CONTACT_47610] a level acceptable to the investigator, and [COMPANY_007] concurs with that assessment.
8.1.5. Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
non-serious); the inve stigator must record the causal relationship on the CRF, and report such 
an assessment in accordance with the SAE reporting requirements, if applicable.  An 
investigator’s causalit y assessment is the determination of whether there exists a reasonable 
possi bility  that the investigational product caused or contributed to an AE; generall y the facts 
(evidence) or arguments to suggest a causal relationship should be provided.  If the 
investigator does not know whether or not the investigational product caused th e event, then 
the event will be handled as “related to investigational product” for reporting purposes, as 
defined b y the sponsor.  If the investigator's causality
 assessment is “unknown but not 
related” to investigational product, this should be clearl y documented on study  records. 
In addition, if the investigator determines that an SAE is associated with study  procedures, 
the investigator must record this causal relationship in the source documents and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, including suspected unexpected serious adverse reactions, will be carried out 
in accordance wi th applicable local regulations.
8.2.Definitions
8.2.1. Adverse Events
An AE is an y untoward medical occurrence in a study subject administered a product or 
medical device; the event need not necessaril y have a causal relationship with the treatment 
or usage.  Exampl es of AEs include, but are not limited to: 

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 105Abnormal test findings;
Clinically  significant signs and sy mptoms;
Changes in physical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease ;
Drug abuse;
Drug dependency .
Additional ly, AEs may  include signs and s ymptoms resulting from:
Drug overdose;
Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy  (EDP);
Exposure via breastfeeding;
Medication error;
Occupational exposure.
8.2.2. Abnormal Test Findi ngs
Abnormal objective test findings should be recorded as AEs when an y of the following 
conditions are met: 
Test result is associated with accompan ying symptoms; and/or
Test result requires additional diagnostic testing or medical/surgical intervention; 
and/or
Test result leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional concomitant 
drug treatment, or other therap y; and/or

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 106Test result is considered to be an AE b y the investigator or sponsor.
Merel y repeating an abnormal test, in the absence of an y of the above conditions, does not 
constitute an AE.  An y abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Eve nts
A serious adverse event is any  untoward medical occurrence at any  dose that:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient hospi[INVESTIGATOR_1081];
Results in persistent or signi ficant disability /incapacity  (substantial disruption of the 
ability  to conduct normal life functions);
Results in congenital anomaly /birth defect.
Or that is considered to be:
An important medical event.
Medical and scientific judgment is exercised in dete rmining whether an event is an important 
medical event.  An important medical event may  not be immediately  life-threatening and/or 
result in death or hospi[INVESTIGATOR_059].  However, if it is determined that the event may  jeopardize 
the subject or may  require in tervention to prevent one of the other AE outcomes, the 
important medical event should be reported as serious.
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that d o not result in hospi[INVESTIGATOR_059]; 
or development of drug dependency  or drug abuse.
8.2.4. Hospi[INVESTIGATOR_47575] y initial admission (even less than 24 hours) in a hospi[INVESTIGATOR_31009] , or any  prolongation of an exist ing admission.  Admission also 
includes transfer within the hospi[INVESTIGATOR_4591]/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 
tuberculosis unit).  An emergency  room visit does not necessaril y constitute a hospi[INVESTIGATOR_059]; 
however, the event leading to the emergency  room visit is assessed for medical importance.

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 107Hospi[INVESTIGATOR_4592]:
Rehabilitation facilities;
Hospi[INVESTIGATOR_4593];
Respi[INVESTIGATOR_4594] (eg, caregiver relief);
Skilled nursing facilities;
Nursing homes;
Same -day surgeries (as outpatient/same -day/ambulatory  procedures).
Hospi[INVESTIGATOR_4595] a precipi[INVESTIGATOR_74039].  Examples include: 
Admission for treatment of a preexisting condition not associated with the 
development of a new AE or with a worsening of the preexisting condition (eg, for 
workup of a persistent pretreatment laboratory  abnormality );
Social admission 
(eg, subject has no place to sleep);
Administrative admission (eg, for yearly physical examination);
Protocol -specified admission during a study  (eg, for a procedure required by  [CONTACT_8896]);
Optional admission not associated with a precipi[INVESTIGATOR_638760] (eg, for elective 
cosmetic surgery );
Hospi[INVESTIGATOR_4597] a medical AE;
Preplanned treatments or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subjec t.
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , should not 
be reported as SAEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an SAE.  For example, an acute 
appendicitis that begins during the reporting period should be reported if the SAE 
requirements are met, and the resulting appendectomy  should be recorded as treatment of the 
AE.

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 1088.3.Severity Assessment
If required on the AE page of the CRF, the inve stigator will use the adjectives MILD, 
MODERATE, or SEVERE to describe the maximum intensity  of the AE.  For purposes of 
consistency , these intensity  grades are defined as follows:
MILD Does not interfere with subject's usual function.
MODERATE Interfere s to some extent with subject's usual function.
SEVERE Interferes significantl y with subject's usual function.
Note the distinction between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SAE.  For example, a headache may be severe (interferes significantly with 
the subject's usual function) but would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.
8.4.Special Situations
8.4.1. Potential Cases of Drug- Induced Liver Injury
Humans exposed to a dru g who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a harbinger of a more 
serious potential outcome.  These subjects fail to adapt and therefore are "susceptible" to 
progressive and serious liver injury , commonly  referred to as drug- induced liver injury  
(DILI).  Subjects who experience a transaminase elevation above 3 times the up per limit of 
normal (× ULN) should be monitored more frequently  to determine if they are an “adaptor” 
or are “susceptible.”
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bi lirubin (TBili) elevations (>2 × ULN) b y several 
days or weeks.  The increase in TBili ty pi[INVESTIGATOR_1306] y occurs while AST/ALT is/are still elevated 
above 3 × ULN (ie, AST/AL T and TBili values will be elevated within the same lab sample).  
In rare instances, b y the time TBili elevations are detected, AST/ALT values might have 
decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case d epends on the subject’s 
individual baseline values and underl ying conditions.  Subjects who present with the 
following laboratory  abnormalities should be evaluated further as potential DILI (Hy ’s law) 
cases to definitivel y determine the etiology of the abn ormal laboratory  values:

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 109Subjects with AST/AL T and TBili baseline values within the normal range who 
subsequently  present with AST OR ALT values >3 × ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available .
For subjects with baseline AST ORALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT basel ine values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 × ULN; or >8 × ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × U LN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The subject should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_854437] and AL T and TBili, laboratory  tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma -glutamyl 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphatase and acetaminophen drug and/or protein adduct levels.  
Consideration should also be given to drawing a separate tube of clotted blood and an 
anticoagulated tube of blood for f urther testing, as needed, for further contemporaneous 
analyses at the time of the recognized initial abnormalities to determine etiology .  A detailed 
history , including relevant information, such as review of ethanol, acetaminophen (either b y 
itself or as a coformulated product in prescription or over
-the-counter medications), 
recreational drug, supplement (herbal) use and consumption, family  history , sexual history , 
travel history , history  of contact [CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  
of liver or allergic disease, and potential occupational exposure to chemicals, should be 
collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg, biliary  tract) may  be warranted. 
All cases demonstrated on r
epeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 110A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
8.4.2. Exposure to the Investigational Product During Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding an d 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.
[IP_ADDRESS]. Exposure During Pregnancy
For both unapproved/unlicensed products and for marketed products, an exposure during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure would be a case involving direct contact 
[CONTACT_4490] a [COMPANY_007] product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been exposed to chemotherapeutic products).
A male has been e xposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed 
during his partner’s pregnancy .
If a subject or subject’s partner becomes or is found to be pregnant duri ng the subject’s 
treatment with the investigational product, the investigator must report this information to 
[COMPANY_007] Safety  on the CT SAE Report Form and an EDP supplemental form, regardless of 
whether an SAE has occurred.  In addition, the investigator must submit information 
regarding environmental exposure to a [COMPANY_007] product in a pregnant woman (eg, a subject 
reports that she is pregnant and has been exposed to a cy totoxic product by [CONTACT_31061][INVESTIGATOR_4598]) to [COMPANY_007] Safety  using the EDP supplemental form.  This must be done irrespective 
of whether an AE has occurred and within 24 hours of awareness of the exposure.  The 
information submitted should include the anticipated date of delivery  (see below for 
information related to termination of pregnancy ).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrity  of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrity  of the terminated fetus should be assessed by  [CONTACT_4692] (unless 

PF-[ADDRESS_854438] findings are conclusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregna ncy meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to [COMPANY_007] Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_854439] 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the investigational produc t. 
Additional information regarding the EDP may  be requested by  [CONTACT_456].  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposur e, the 
investigator will provide the subject with the Pregnant Partner Release of Information Form 
to deliver to his partner.  The investigator must document in the source documents that the 
subject was given the Pregnant Partner Release of Information For m to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to [COMPANY_007] Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Re port Form.  An exposure during breastfeeding report is not created when a [COMPANY_007] 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated w ith such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwis e) gets in unplanned direct contact [CONTACT_8898], which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to [COMPANY_007] Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of w hether there is an associated 
SAE.  Since the information does not pertain to a subject enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.

PF-[ADDRESS_854440] SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
Medication errors All (regardless of whether 
associated with an AE) Only  if associated with an 
SAE 
[IP_ADDRESS]. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong subject, or at the wrong t ime, or at the wrong dosage strength.
Medication errors include :
Medication errors involving subject exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the par ticipating subject.
Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and non -serious, are recor ded on an AE page of the 
CRF. 
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_854441] SAE Report 
Form only when associated with an SAE .
9. DATA ANALYSIS/STATIS TICAL METHODS
Detailed methodolog y for summary  and statistical anal yses of the data collected in this study  
are outlined here and further detailed in a Statistical Anal ysis Plan (SAP), which will be 
maintained by  [CONTACT_456].  The Statistical Anal ysis Plan may  modify  what is outlined in the 
protocol where appropriate; however, an y major modifications of the endpoint definitions or 
their anal yses will also be reflected in a protocol amendment.

PF-[ADDRESS_854442] Single Ascending and Multiple Dose 
A sample size of 8 subjects in each SAD and MAD cohort (with 6 active and 2 placebo) with 
approximatel y 48 subjects (assuming 6 cohorts) and [ADDRESS_854443] cohort is not based on a ny statistical considerations, and may  
enroll up to 8 subjects in order to support characterization of the PF -06826647 PK profile in 
Japanese subjects. The sample size was based on the clinical consideration to provide safet y 
and tolerability  information and pharmacological considerations and on the need to minimize 
exposure to healthy  subjects at each dose level.  No formal inferential statistics will be 
applied to the safet y, pharmacod ynamic or pharmacokinetic data.
9.1.2. Psoriasis Multiple Dose 
A sample size of approximately 42subjects total is planned for thetwo psoriasis cohort (s).  
Psoriasis subjects will be randomized 
in each Psoriasis cohort to receive either active
PF-06826647 ( or placebo ) with a planned randomization ratio of 2 :1(PF-06826647 :Placebo )
foreach cohort .  The between -subject standard deviation of absolute PASI  change from 
baseline to Day 28 (obtained from Sponsor data on file ) is a ssume d to be 8. The true 
difference between PF-06826647 and placebo is assumed to -7.8 (derived from the 
meta -analysis of the T ofacitinib data).   Based on these assumptions the sample size is 
calculated to be 14 subjects per arm to provide approximately  80.7 % power. This calculation 
assumes a one -sided alpha of 5%. The initial estimate of the total number of completers for 
the psoriasis cohort will be 42 with 21 (14 active +7placebo ) in each cohort. Based on the 
results from the planned interim anal ysis(described below in Section 9.7) PF-06826647 dose 
level or regimen may  be adjusted for subsequent psoriasis subjects/cohorts enrolled after the 
interim analy sis
. 
9.2.Efficacy Analysis
All subjects who receive at least one dose of randomized study  medication, and have a 
baseline and at least one post- baseline measurement (after takin g randomized study  
medication) will be included in the efficacy  data analy ses for the psoriasis cohorts .
9.2.1. Analysis of Secondary Endpoints 
The change from baseline in PASI  score at Day 28in the psoriasis multiple dose segme nt is a
secondary  endpoint. The treatment effect for each of the test dose groups is the treatment 
difference in the mean change from baseline of PASI  score at Day 28between the test dose 
and the placebo.  The estimates for treatment effect will be obtai ned by  [CONTACT_6486] a repeated 
measures linear model to the PASI  change from baseline score.  The model will include 
treatment (active doses and placebo), week and treatment -by-week interaction as fixed 
effects and baseline PASI score as a covariate. Estimates and 90% confidence intervals for 
treatment effect will be presented .

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 1149.3. Pharmacokinetic Analysis
9.3.1. Single and Multiple Dose Periods 
The PK data set will include data from all subjects receiving active drug and having any  
measurable concentration of study  drug .  Complete details will be provided in the study ’s 
SAP.
The following PK parameters will be calculated for PF-06826647 (if possible) from the 
plasma concentration -time data using standard noncompartmental methods:
Matrix Param eter Definition Method of Det ermination
PlasmaAUC last Concentration -time profile from time zero 
to the time of the last
quantifiable concentration (C last)Linear/Log trapezoidal method
AUC Area under the plasma
concentration -time profile over the dosing 
interval Linear/Log trap ezoidal method
AUC infaArea under the plasma concentration -time 
profile from time zero extrapolated to 
infinite timeAUC last+ (C last*/k el),
where Clast* is the predicted plasma 
concentration at the last quantifiable 
time point estimated from the 
log-linear regression analysis
Cmax Maximum plasma concentration Observed directly from data
Cmin Lowest concentration observed during 
dosing interval, ; if measured at end of 
dosing interval, equivalent to C troughObserved directly from data
Cav Average concentration at steady state Cav= AUC,ss/
Tmax Time for C max Observed directly from data as time 
of first occurrence
t1/2aTerminal elimination half -life Log e(2)/k el,
where kel is the terminal phase rate 
constant calculated by a linear 
regression of the log -linear 
concentration -time curve.  Only 
those data points judged to describe 
the terminal log -linear decline w ill 
be used in the regression
CL/FaApparent clearance Dose/AUC inffor SD 
Dose/AUC for MD
Vz/FaApparent volume of distribution Dose/(AUC inf. kel) for SD 
Dose/(AUC . kel) for MD
Rac Observed accumulation ratio bas ed on 
AUCAUC(ss)/AUC(sd)
Rac, Cmax Observed accumulation ratio based on C max Cmax(ss)/ C max(sd)
PTR Peak to Trough ratio Cmax,ss/C min,ss 
MRT Mean residence time AUMC inf/AUC inf, 
where AUMC infis the area under 
the first moment curve from time
zero to infinity.
Cmax(dn) Dose normalized C max Cmax/Dose

PF-[ADDRESS_854444](dn) Dose normalized AUC last AUC last/Dose
AUC inf(dn)aDose normalized AUC inf AUC inf/Dose
UrineAeτ Cumulative amount of drug recovered 
unchanged in urine from 0 to dose interval 
(τ) hours postdoseSum of [urine concentration * 
sample volume] for each collection 
interval 
Aeτ% Percent of dose recovered unchanged in 
urine from 0 to dose interval ( τ) hours 
postdoseAeτ/Dose*100
CLr Renal clearance Aeτ/AUCτ
aIf data permit
The PK parameters will be summarized descriptively by [CONTACT_2715], regimen and study population 
(healthy subject and psoriasis subject) in accordance with [COMPANY_007] data standards.  Summary statistics will also include the geometric mean and coefficient of variation for all parameters except T
max.
Dose normalized (to 1 mg) AUC and C maxvalues of PF-[ADDRESS_854445] 
dose (using a logarithmic scale if dose range is greater than 10-fold) for single- and multiple dose phases, and will include individual subject values and the geometric means for each dose.  These plots will be used to help understand the relationship between the plasma PK parameters and dose.  Additional PK analyses may be performed if deemed appropriate.
Urine amounts of PF-[ADDRESS_854446] model with treatment 
(Dose levels) and period as a fixed effect and subjects within a treatment as a random effect. Estimates of the adjusted mean differences (Test-Reference) and corresponding 90% confidence intervals will be obtained from the model. The adjusted mean differences and 90% confidence for the differences will be exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% confidence intervals for the ratios. Further details will be provided in statistical analysis plan (SAP).
 
 
 CCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 116 
 
 
 
 
 
 
 
 
 
 
 
 
9.6. Safety Analysis – Primary
Adverse events, ECGs, blood pressure, pulse rate, and safety laboratory data will be 
reviewed and summarized on an ongoing basis during the study to evaluate the safety of subjects.  Any clinical laboratory, ECG, BP, and PR abnormalities of potential clinical concern will be described.  Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate.
Medical history and physical examination and neurologic examination information and 
continuous cardiac monitoring collected during the course of the study will not be captured for inclusion into the study database, unless otherwise noted.  However, any untoward findings identified on physical and/or neurologic examinations or on telemetry monitoring 
conducted after the administration of the first dose of study medication will be captured as an 
adverse event, if those findings meet the definition of an adverse event.  Data collected at Screening that is used for inclusion/exclusion criteria, such as laboratory data, ECGs and vital signs will be considered source data, and will not be captured for inclusion into the study database, unless otherwise noted.  Demographic data collected at Screening will be included in the study database.CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 117Data relevant to the assessment of suicidality will be mapped to the Columbia-Classification 
Algorithm of Suicide Assessment (C-CASA) codes.  Baseline and post-baseline  data (mapped to C-CASA scores) will be summarized descriptively by [CONTACT_638798]-baseline visit.  The safety analyses will be carried out in the safety population, detailed analyses will be described in the SAP.
9.6.1. Electrocardiogram Analysis
Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval, PR 
interval and QRS interval will be summarized by [CONTACT_22841].
The number (%) of subjects with maximum post dose QTc values and maximum increases 
from baseline in the following categories will be tabulated by [CONTACT_3148]: 
Safety QTc
Borderline (msec) Prolonged (msec)
Absolute Value ≥450 - <480 ≥480
Absolute Change 30-<60 ≥60
In addition, the number of subjects with corrected and uncorrected QT values ≥[ADDRESS_854447] dose (for example, triplicate 
ECGs), the mean of the replicate measurements will be used to represent a single observation 
at that time point.  If any of the three individual ECG tracings has a QTc value ≥500 msec, 
but the mean of the triplicates is not ≥[ADDRESS_854448]’s individual tracing 
will be described in a safety section of the study report in order to place the ≥500 msec value 
in appropriate clinical context.  However, values from individual tracings within triplicate 
measurements that are ≥500 msec will not be included in the categorical analysis unless the 
average from the triplicate measurements is also ≥[ADDRESS_854449] dose from the average of the pre-dose triplicate values on Day 1.
In addition, an attempt will be made to explore and characterize the relationship between 
plasma concentration and QT interval length using a PK/PD modeling approach.  If a PK/PD relationship is found, the impact of subject factors (covariates) on the relationship may be examined. 
9.7. Interim Analysis
An interim analysis of the change from baseline at Day 28 in PASI score (psoriasis key 
secondary endpoint) will be conducted for the first psoriasis cohort (400 mg dose cohort). The analysis will be performed when 21 psoriasis subjects from the 400 mg cohort complete through study Day 28. Outcomes from this interim analysis may inform dose selection decisions/adjustments for later psoriasis subject cohorts to be enrolled in the study. The interim analysis is not planned to impact the conduct of the initial 400 mg psoriasis cohort. The analysis is planned to be performed after dosing of the full 400 mg psoriasis cohort CCI
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 118(n=21 subjects completing through study  Day28). Any decisions or dose adjustments that 
are taken, will be applied to the subsequent psoriasis cohort.
A designated limited number of 
Sponsor colleagues will review the interim analy sis results to support any  dose related 
decisions. For the healthy  SAD/MAD cohorts, this is asponsor -open stud y,and the sponsor 
may conduct unblinded reviews of the data during the course of the study  for the purpose of 
safet y assessment, facilitating d ose-escalation decisions, facilitating PK/PD modeling, and/or 
to support clinical development.  Unblinded results will be reviewed b y a designated limited
number of s ponsor colleagues within the study  team.
The psoriasis multiple dose cohorts are double-blind with respect to i nvestigator andsubject . 
The psoriasis multiple dose cohorts will be s ponsor -open (unblinded interim analy sis results 
will be reviewed b y a designated limited number of sponsor colleagues). In addition to the 
planned interim anal ysis from the 400 mg psoriasis cohort, t he sponsor may  analy ze selected 
clinical endpoints at the end of the Psoriais treatment period (Day 28)before the follow -up 
period is completed for all cohorts.  F or the purpose of safety assessment , select individuals
from sponsor may  conduct unblinded reviews of individual subject safet y data if needed to 
ensure proper management of subject safet y. If needed, a designated limited number of 
sponsor colleagues may  conduct unblinded reviews of the data during the course of the stud y 
to facilitate PK/PD modeling.
Refer to the stud y’s Data Blinding Plan and/or Statistical Analysis Plan for specific details 
including delineation of study  team members who will be involved in these unblinded 
reviews as well as steps to be ins tituted ahead of initiation of any  unblinded review to ensure 
study  integrit y is maintained.
9.8.Data Monitoring Committee 
This study  will not use a n external data monitoring committee (DMC ).
10.QUALITY CONTROL AND QUALITY ASSURANCE
[COMPANY_007] or its agent will cond uct periodic monitoring visits during study  conduct for studies 
conducted at non- [COMPANY_007] investigator sites,to ensure that the protocol and Good Clinical 
Practices ( GCPs) are being followed.  The monitors may  review source documents to 
confirm that the data recorded on CRFs [/DCT s]are accurate.  T he investigator and institution 
will allow [COMPANY_007] monitors/auditors or its agents and appropriate regulatory  authorities direct 
access to source documents to perform this verification.  This verification may  also o ccur 
after stud y completion.
During study  conduct and/or after study  completion, t
he investigator site may  be subject to 
review b y the IRB/EC , and/or to quality  assurance audits performed by  [CONTACT_4618], or companies 
working with or on behalf of [COMPANY_007], and/or to inspection by [CONTACT_8901].
The investigator(s) will notify  [COMPANY_007] or its agents immediately  of any  regulatory  inspection 
notification in relation to the study . Furthermore, the investigator will cooperate with [COMPANY_007] 
or its agent s to prepare the investigator site for the inspection and will allow [COMPANY_007] or its 
agent, whenever feasible, to be present during the inspection. The investigator site and 

PF-[ADDRESS_854450]’s medical records.  The investigator will promptly  provide copi[INVESTIGATOR_74040].  Before response submission to the regulatory 
authorities, the investigator will provide [COMPANY_007] or its agents with an opportunity  to review 
and comment on responses to any  such findings.
For studies conducted at non -[COMPANY_007] investigator sites, it is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possib le audits or 
inspections and that sufficient time is devoted to the process. 
11.DATA HANDLING AND RE CORD KEEPI[INVESTIGATOR_1645]
11.1. Case Report Forms/ Data Collection Tools/ Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a p aper form or 
an electronic data record or both, depending on the data collection method used in this study .
A CRF is required and should be completed for each included subject.  The completed 
original CRFs are the sole propert y of [COMPANY_007] and should not be made available in any  form to 
third parties, except for authorized representatives of [COMPANY_007] or appropriate regulatory  
authorities, without written permission from [COMPANY_007].
The investigator has ultimate responsibility  for the collection and reporting of all clinical, 
safet y,and laboratory  data entered on the CRFs and any  other data collection forms (source 
documents) and ensuring that they are accurate, authentic/original, attributable, complete, 
consistent, legible, timely  (contemporaneous), enduring ,and available when required.  The 
CRFs must be signed by  [CONTACT_110292].  An y corrections to entries made in the CRFs orsource 
documents must be dated, initialed ,and ex plained (if necessary ) and should not obscure the 
original entry .
In most cases the source documents are the hospi[INVESTIGATOR_110258]'s chart.  I n these cases, 
data collected on the CRFs must match those charts. 
In some cases, the CRF may  also serve as t he source document.  In these cases, a document 
should be available at the investigat orsite and at [COMPANY_007] that clearl y identifies those data that 
will be recorded on the CRF, and for which the CRF will stand as the source document.
11.2. Record Retention
To en able evaluations and/or inspections/ audits from regulatory  authorities or [COMPANY_007], the 
investigator agrees to keep records, including the identity  of all participating subjects 
(sufficient information to link records, e g,CRFs and hospi[INVESTIGATOR_1097]), all ori ginal signed 
informed consent [/assent ]documents , copi[INVESTIGATOR_4600], safety  reporting forms, source 
documents, detailed records of treatment disposition, and adequate documentation of relevant 
correspondence (e g,letters, meeting minutes, and telephone ca ll reports).  The records should 
be retained b y the investigator according to the ICHguidelines, according to local 
regulations, or as specified in the clinical study  agreement (CSA) , whichever is longer.

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 120If the investigator becomes unable for an y reason to continue to retain study records for the 
required period (e g,retirement, relocation), [COMPANY_007] should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to [COMPANY_007], such as another 
investigator, another institution, or to an independent third part y arranged by [CONTACT_4618]. 
Investigator records must be kept for a minimum of [ADDRESS_854451] obtain Pfi zer's written permission before disposing of an y records, 
even if retention requirements have been met.
12.ETHICS
12.1. Institutional Review Board/Ethics Committee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, informed consent[ /assent ]documents , and other relevant documents, 
eg,recruitment advertisements, if applicable, from the I RB/EC.  All correspondence with the 
IRB/EC should be retained in the investigator file .  Copi[INVESTIGATOR_1309] I RB/EC approvals should be 
forwarded to [COMPANY_007].
The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  theIRB/EC and [COMPANY_007] in writing immediately after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with the protocol, legal and regulatory  
requirements, andthe general principles set forth in the I nternational Ethic al Guidelines for 
Biomedical Research Involving Human Subjects (Council for International Organizations of 
Medical Sciences 2002), ICH G uideline for Good C linical Practice , and the Declaration of 
Helsinki .
12.3. Subject Information and Consent
All parties will e nsure protection of subject personal data and will not include subject names 
or other identifiable data in any reports, publications, or other disclosures, except where 
required b y laws. 
When study  data are compi[INVESTIGATOR_638761], subject 
names, address es, and other identifiable data will be replaced b ynumerical code sbased on a 
numbering sy stem provided by  [CONTACT_47617] -identify  study subjects .The investigator
site will maintain a confidential list of subjects who participated in the study, linking each 
subject’ snumerical code to his or her actual identity .  In case of data transfer, [COMPANY_007] will 
maintain high standards of confidentialit y and protection of subjects’ personal data consistent 
with applicable p rivacy  laws .

PF-[ADDRESS_854452] be reviewed and approved by  [CONTACT_4618] , approved by  [CONTACT_1201]/EC
before use, and available for inspection.
The investigator must ensure that each study  subject is fully  informed about the nature and 
objectives of the stud y and possible risks associated with participation.
The investigator, or a person designated b y the investigator, will obtain written informed 
consent from each subject before an y study -specific activity  is performed.  The invest igator 
will retain the original of each subject's signed consent document.
12.4. Reporting of S
afety Issues and S erious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any  area of the world , or if the investigator is aware of any  new 
information that 
might influence the evaluation of the benefits and risks of the investigational 
product, [COMPANY_007] should be informed immediately. 
In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study subjects against an y immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
13.DEFINITION OF END OF TRIAL
13.1. End of Trial in the [LOCATION_002]
Last subject last visit ( LSLV)is defined as the date the investigator reviews the last subject’s 
final safet y data and determines that no further evaluation is required for the subject to 
complete the trial.
14.SPONSOR DISCONTINUAT ION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opi[INVESTIGATOR_1100]/EC, or investigational product safety  problems, or at the 
discretion of [COMPANY_007].  In addition, [COMPANY_007] re tains the right to discontinue development of 
PF-[ADDRESS_854453] all participating subjects and the hospi[INVESTIGATOR_161656] 
(if applicable) within [ADDRESS_854454] extent possible.

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page [ZIP_CODE].PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by [CONTACT_638799].clinicaltrials.gov (ClinicalTrials.gov) , the European Clinical Trials 
Database (EudraCT), and/or 
www.pfizer.com, and other public registries in accordance with 
applicable loc al laws/regulations.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial US B asic Results on www.clinicaltrials.gov for [COMPANY_007]- sponsored 
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
[COMPANY_007] product , regardless of the geographical location in which the study  is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary completion date (PCD) 
for studies in adult populations or within [ADDRESS_854455]
[COMPANY_007] posts European Union ( EU)Basic Results on EudraCT for all [COMPANY_007] -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 y ear of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which any  data that could be used 
to identify  individual patients have been removed) on www.pfizer.com for [COMPANY_007]- sponsored 
interventional studies at the same time the US Basic Results document is posted to 
www.clinicaltrials.gov .
15.2. Publications by [CONTACT_110294] (PI)of the results of the study  base d on information collected or 
generated b y thePI, whether or not the results are favorable to the [COMPANY_007] product.  However, 
to ensure against inadvertent disclosure of confidential information or unprotected 
inventions, the i nvestigator will provide Pfize r an opportunity  to review any  proposed 

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 123publication or other t ype of disclosure of the results of the study  (collectively , “publication”)
before it is submitted or otherwise disclosed.
The i nvestigator will provide any publication to [COMPANY_007] at least [ADDRESS_854456] to the other 
requirements of this section .
For all publicatio ns relating to the study , the institution will comply  with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscr ipts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship,
established by  [CONTACT_4717].
Publication of study  results is also provided for in the C SAbetween [COMPANY_007] and the 
institution.  I n this section entitled Publications by  [CONTACT_4718], the defined terms shall have 
the meanings given to them in the C SA.
If there is an y conflict between the CSA and an y a
ttachments to it, the terms of the CSA 
control.  If there is an y conflict between this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of study  subjects, and the CSA will control as to all other 
issues.

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page [ZIP_CODE].REFERENCES
1. Fredriksson T, Pettersson U. Severe psoriasis –oral therap y with a new retinoid. 
Dermatologica 1978; 157 (4):238-44.
2. Long CC, Finlay  AY, Averill RW. The rule of hand: 4 hand areas = 2FTU = 1g. Arch 
Dermatol 1992; 128 (8) :1129-30.
3. Finlay  AY, Khan GK. Dermatology  Life Quality  Index (DLQI) – a simple practical 
measure for routine clinical use. Clin Exp Dermatol 1994; 19 (3) :210 -6.
4. Mazzotti E, Pi[INVESTIGATOR_22642] A, Sampogna F, et al.  Sensitivity  of the Dermatolog y Life Quality  
Index to clinical change in patients with psoriasis. Br J Dermatol 2003; 149 (2) :[ADDRESS_854457] : input and output integration. J Immunol . 
2007;178:2623- 9.
6. O'Sullivan LA, Liongue C, Lewis RS, et al. Cy tokine receptor signaling through the 
Jak-Stat-Socs pathway  in disease. Mol Immunol. 2007;44:2497 - 506.
7. Zhu Y, Ye X, Zhu B, et al. Comparisons between the 2012 New CKD -EPI (Chronic 
Kidney Disease Epi[INVESTIGATOR_8849]) Equations and Other Four Approved 
Equations. PL oS ONE 9(1): e84688. doi: 10.1371/journal.pone.0084688 .
8. Hoek FJ, Kemperman FAW, Krediet RT. A comparison between cy statin C, plasma
creatin ine and the Cockcroft and Gault formula for the estimation of glomerular
filtration rate. Nephrology  Dial ysis Transplantation 2003; 18(10): 2024 -31.
9. Newman DJ, Thakkar H, Edwards RG, et al. Serum cy statin C measured by  [CONTACT_638800] : A more sensiti ve marker of changes in GFR than serum creatinine.   
Kidney  International 1995; 47(1): 312
-8.
10. Dharnidharka VR, Kwon c, Stevens G. Serum cy statin C is superior to serum creatinine
as a marker of kidney function: A meta -analysis. American Journal of Kidney  Diseases
2002; 40(2): 221 -6.
11. Inker LA, Schmid CH, Tighiouart H, et al. Estimating Glomerular Filtration Rate from
Serum Creatinine and C ystatin C. New England Journal of Medicine 2012; 367(1):[ADDRESS_854458] of abbreviations that may be used in the protocol.
Abbreviation Term
AE adverse event
Abs Absolute
Ae12/24 amount of unchanged drug excreted into urine from time 0 to 
12 hours or 0-24 hours, respectively
Ae12/24% percentage of dose excreted unchanged into urine from [ADDRESS_854459] quantifiable concentration
AUC tau area under the concentration-time curve over the the dosing interval tau 
BA Bioavailability
BBS Biospecimen Banking System
BCG bacille Calmette-Guérin 
BE Bioequivalence
BID Bis in die (twice a day)
BMI body mass index
BP blood pressure
BPM beats per minute
BU business unit
BUN blood urea nitrogen
Cav average concentration
C-CASA Columbia-Classification Algorithm of Suicide Assessment
CD Crohn’s disease
CDS core data sheetCCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 126Abbreviation Term
Ceff efficacious concentration
CFR Code of Federal Regulations
CHO Chinese hamster ovary
CI confidence interval
CK creatine kinase
CKD Chronic Kidney Disease
CKD-EPI [INVESTIGATOR_638762]/F Apparent total clearance of the drug from plasma after oral 
administration
CL r renal clearance
Cmax peak or maximum observed concentration
Cmin Minimum plasma drug concentration
CO 2 carbon dioxide (bicarbonate)
CRF case report form
CRP C-reactive protein
CRU Clinical Research Unit
CSA clinical study agreement
CSF cerebrospi[INVESTIGATOR_638763]-drug interaction
DILI drug-induced liver injury
DMC data monitoring committee
DNA deoxyribonucleic acid
EC ethics committee
ECG Electrocardiogram
EDMC external data monitoring committee 
EDP exposure during pregnancy
EDR Extemporaneous Dispensing RecordCCI
CCI
CCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 127Abbreviation Term
EDTA edetic acid (ethylenediaminetetraacetic acid)
eGFR estimated glomerular filtration rate
EOT end of treatment
EPO erythropoietin
ET early termination
EU European Union
EIU exposure in utero
ESoE Early signal of efficacy
ERB external review board
EudraCT European Clinical Trials Database
FDA Food and Drug Administration ([LOCATION_002])
FDAAA Food and Drug Administration Amendments Act ([LOCATION_002])
FFPE formalin-fixed paraffin-embedded 
FIH first in human
FISH Fluorescence in situ hybridization
FSH follicle-stimulating hormone
GCP Good Clinical Practice
GFR glomerular filtration rate
GGT gamma-glutamyl transferase
GLDH glutamate dehydrogenase
GLP Good laboratory practice
GM-CSF Granulocyte-Macrophage Colony Stimulating Factor
GBP1 Guanylate binding protein [ADDRESS_854460] Hematocrit
HCV Hepatitis C virus
HCVAb hepatitis C antibody
HDL-C high density lipoprotein cholesterol
HED human equivalent dose
HEP human hepatocytes
HepBcAb hepatitis B core antibody
HepBsAg hepatitis B surface antigen
hERG human ether a-go-go gene
HGB hemoglobinCCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 128Abbreviation Term
HIV human immunodeficiency virus
HLM human liver microsomes
HSV herpes simplex virus
HVs healthy volunteers
HWB Human whole blood
IB investigator’s brochure
ICH International Conference on Harmonisation
IC50 50% inhibitory concentration
ID Identification
IEC independent ethics committee
IFN type I interferon
IGRA interferon gamma release assay
IND investigational new drug application
INR international normalized ratio
IL interleukin
IOBU-SDMC Internal Oncology Business Unit -Safety Data Monitoring 
Committee 
IP Investigational product
IR Immediate release
IRB institutional review board
IRC internal review committee
IUD intrauterine device
IUS Intrauterine system
IV intravenous
JAK Janus kinase
KDIGO Kidney Disease: Improving Global Outcomes
KDR kinase insert domain receptor
K2EDTA dipotassium ethylene diamine tetraacetic acid
LDLC low density lipoprotein cholesterol
LFT liver function test
LLN lower limit of normal
L-PASI Linear method Psoriasis Area and Severity Index
LPD local product documentCCI
CCI
CCI
CCI
PF-[ADDRESS_854461] visit 
MAD multiple ascending dose
MATE multidrug and toxin extrusion protein
MCH Mean corpuscular hemoglobin
MCHC Mean corpuscular hemoglobin concentration
MCV Mean corpuscular volume
MDR1 multidrug resistant protein 1
MedDRA medical Dictionary for Regulatory Activities
mRNA messenger riboneuclic acid
MTD maximum tolerated dose
MRP multidrug resistance-associated protein
MRT mean residence time
NAPAC Neuropsychiatric and Abuse Potential Advisory Council
N/A not applicable
NK Natural Killer cell
NOAEL no observed adverse effect level
NOEL no observed effect level
NRS Numeric Rating Scale
NTCP sodium/taurocholate co-transporting polypeptide
OATP organic anion transporting polypeptide
OBU Oncology Business Unit
OCT organic cation transporter
OEB5 occupational exposure banding [ADDRESS_854462] operating procedure
SRSD single reference study document
ss steady state
STAT Signal Transducer and Activator of Transcription
T1/[ADDRESS_854463] upper limit of normal
US [LOCATION_002]
USP18 ubiquitin specific peptidase 18
USPI [INVESTIGATOR_638764] A
UVB ultraviolet B
VEGFR2 vascular endothelial growth factor receptor 2
Vss Apparent volume of distribution at steady stateCCI
CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 131Abbreviation Term
Vz/F apparent oral volume of distribution
WBC white blood cellCCI
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 132Appendix 2.Cockcroft -Gault Calculation
The Cockcroft -Gault formula may  be used to calculate an Estimated Creatinine Clearance, 
which in turn estimates Glomerular filtration rate (GFR)
Est. Creatinine Clearance (mL /min) = ([140 -Age(years)] xWeight(kg) x Factora)
(72xSerum Creatinine [mg/dL ])
aFactor is equal to 0.[ADDRESS_854464]. John’s wort
Telaprevi r Rifabutin
Danoprevir Phenobarbital
Elvitegravir
Saquinavir Semagacestat
Lopi[INVESTIGATOR_638765] r
Grapefruit Juice Modafanil
Conivaptan Etravirine
Nefazodone Lersivirine
Nelfinavir
Saquinavir
Idelalisib
Boceprevir
Erythrom ycin
Fluconazole
Atazanavir
Darunavir
Diltiazem
Dronedarone
Crizotinib
Aprepi[INVESTIGATOR_638766]-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 135Appendix 4.Estimated Glomerular Filtration Rate
The estimated GFR (eGFR) will be calculated usi ng the 2 sets of equations developed b y the 
Chronic Kidney  Disease Epi[INVESTIGATOR_8849] (CKD -EPI), which utilize serum 
creatinine (SCr) and serum Cy statin C (S Cy statin C) respectivel y.7
CKD- EPI 2009Scr
Iffemale and SCr is  0.7mg/dL :
GFR (mL /min/1.73 m2) = 144 x (Scr/0.7)–0.329 x 0.993age (x 1.159, if black)
If female and SCr is >0.7 mg/dL :
GFR (mL /min/1.73 m2) = 144 x (Scr/0.7) –1.209x 0.993age(x 1.159, if black)
If male and SCr is  0.9mg/dL :
GFR ( mL/min/1.73 m2) = 141 x (Scr/0.9) –0.411x 0.993age(x 1.159, if black)
If male and SCr is >0.9 mg/dL :
GFR (mL /min/1.73 m2) = 141 x (Scr/0.9) –1.209x 0.993age(x 1.159, if black)
CKD- EPI 2012cys
If female and Scy s is 0.8mg/L :
GFR (mL /min/1.73 m2) = 1 33 x ( Scys /0.8) –0.499x 0.996age x 0.932
If female and Scysis >0.8 mg/L :
GFR (mL /min/1.73 m2) = 133 x ( Scys /0.8) –1.328x 0.996age x 0.932
If male and 
Scysis 0.8mg/L :
GFR (mL /min/1.73 m2) = 133 x ( Scys /0.8) –0.499x 0.996age
If male and Scy sis >0.8 mg/L :
GFR (mL /min/1.73 m2) = 133 x ( Scys /0.8) –1.328x 0.996age

PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 136CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 137CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 138
CCI
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 139Appendix 8. Patient Global Assessment of Psoriasis
Clear (no psoriasis)Almost ClearMildModerateSevere
Clear (no psoriasis)Almost ClearMildModerateSevereOverall, how would you describe your psoriasis right now ?
Choose only ONE response.
My psoriasis is:

PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 140CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 141CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 142CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 143CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 144CCI
PF-06826647
C2501001
Final Protocol Amendment 3, 05April 2018
Page 145CCI
PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 146Appendix 10.Suicidal Behaviors Questionnaire -Revised (SBQ- R)

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 147

PF-06826647
C250100 1
Final Protocol Amendment 3,05April 2018
Page 148Appendix 11. Patient Health Questionnaire – 8 items (PHQ - 8)
